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ADDENDA TO MD THESIS 
THE EFFECT OF OESTROGEN AND THE MENOPAUSE 
ON THE FEMALE LOWER URINARY TRACT 
Andrew Hextall 2000 
Chapter 3 
Page 56 Table 3.3. Third line should read `urethral sphincter incompetence'. 
Page 57 Line 14. Should read `producing a mechanical rise in urethral pressure'. 
Chapter 9 
Page 178 Line 3. Should read `There was an almost identical number of premenopausal'. 
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Page 243 Table 12.7. Cure rate for urge incontinence in the women given oestradiol 
should read 56%. 
Page 256 Line 18. Should read `was that 561/o'. 
Page 259 Line 6. Should read `and this severely impairs the possible'. 
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Fluctuations in the level of oestrogen and progesterone during the menstrual cycle and 
in pregnancy are thought to influence female lower urinary tract function. Furthermore, 
the menopause and subsequent oestrogen deficiency have been implicated in the 
aetiology of a number of urogenital problems. 
The aims of this thesis are to examine the influence of sex steroids on female 
lower urinary tract symptoms and the results of urodynamic investigation. In addition, 
as oestrogen deficiency has been associated with the development of the "urge 
syndrome", I propose to test the hypothesis that postmenopausal women with this 
condition will respond to treatment with oestradiol implants. 
The first section provides a review of normal and abnormal bladder and urethral 
function in women, along with the investigations necessary to make an accurate 
diagnosis. The effects of oestrogen, the menstrual cycle and the menopause are then 
outlined. There follows a detailed examination of the evidence linking oestrogen 
deficiency with the development of lower urinary tract dysfunction and infection. As 
young women with eating disorders provided a model for the changes occurring 
postmenopausally, the pathophysiology of this condition is also given. 
The second section describes the studies performed in this thesis and the results 
of each investigation are discussed. In the first study the effect of the menstrual cycle 
on urinary symptoms and videocystourethrography are determined. The second study 
assesses the prevalence of urinary symptoms in young oestrogen deficient women with 
eating disorders. The relationship between the menopause and bacteriuria in 
community dwelling women is analysed in the third study. Finally, in the fourth study a 
double blind, placebo controlled trial on the effects of 25mg oestradiol implants on the 
"urge syndrome" is reported. 
In the third section the relevance of the study findings are discussed, final 
conclusions are made and suggestions given for future work. 
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26 
1.1. INTRODUCTION 
The work contained in this thesis was carried out in the urogynaecology department of 
King's College Hospital between September 1996 and February 1999. 
Situated in Southeast London, King's College Hospital is a teaching centre 
which primarily serves the needs of Lambeth, Southwark and Lewisham Health 
Authority. The local population of just under 3 million people is one of the most 
deprived in England with high levels of premature death, mental illness and infectious 
diseases including 111V and AIDS. The latest estimated age distribution of the subjects 
living in the local catchment area is shown in Figure 1.1. The hospital, which became a 
NHS Trust in April 1993, has 900 beds and employs 4000 staff with an annual budget 
of approximately £185 million. In 1998 over 460 000 patients were treated. The 
women's health directorate is one of the biggest departments and offers specialist 
services in urogynaecology, colposcopy, oncology, menopause, gynaecological 
ultrasound scanning, fertility and family planning. 
1.2. DEPARTMENT OF UROGYNAECOLOGY 
The department of urogynaecology was established in 1979 by Professor Linda 
Cardozo. Referrals are received from local general practitioners, district nurses and 
continence advisors, and consultant gynaecologists and urologists working at King's 
College Hospital and the surrounding district general hospitals. In addition, the unit 
works as a tertiary referral centre with difficult or complex cases frequently sent from 
throughout the United Kingdom and abroad. Professor Cardozo is at present the only 
consultant in the unit but she is assisted by a subspecialty trainee in urogynaecology, 
three research registrars (of which I was one), a urogynaecology nurse specialist and an 
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the department for 5 sessions each week. The district continence advisors also see 
women in the clinics run by the department and follow patients up in the community 
when necessary. In addition to the above staff, at any one time the department is 
usually host to one visiting registrar from overseas. 
The full complement of urogynaecological investigation techniques is available 
including uroflowmetry, cystometry, videocystourethrography, ambulatory 
urodynamics, urethral pressure profilometry and electromyography. The unit has a 
special interest in ultrasound of the lower urinary tract and there is access to Magnetic 
Resonance Imaging (MRI). Referrals are made directly to the consultant who then 
allocates them to the appropriate clinic. All women are asked to complete a frequency 
volume chart, and a generic (SF36) and disease specific (King's health) quality of life 
questionnaire when they are sent their appointment. The majority of patients are 
initially seen in the "urodynamics clinic" which is held in the X-ray department five 
times each week, and is run by the registrars. In 1998 a total of 1377 women were 
referred for investigation in this clinic and 102 patients seen for follow up urodynamics 
after treatment (Figure 1.2). Elderly or disabled women are seen in the UCARE clinic 
(Urodynamic Clinic for the Assessment and Review of the Elderly) which was 
established in 1992 and is co-ordinated by the urogynaecology nurse specialist and 
district continence advisors. Particularly complex cases and tertiary referrals are given 
a "Job Lot" appointment; they are first seen in the consultant outpatient clinic in the 
morning and then have urodynamic investigations performed the same afternoon. 
Ambulatory urodynamic investigation is arranged subsequently when necessary. 
Follow-up after treatment usually takes place in the outpatients department 
where both urogyanecological and general gynaecological clinics are held on a weekly 
basis. Close links have been developed with the urologists working at King's College 
29 
Hospital who attend fortnightly urodynamic review sessions at which complex cases are 
discussed. Other cases of interest are also considered at the pelvic surgeons meeting, 
which is held jointly with the urologists and colorectal surgeons every two months. 
King's College Hospital with its urban and suburban catchment area and multi- 
racial population provided an ideal setting for the studies undertaken in this thesis. The 
large number of patients and great variety of lower urinary tract disorders seen in the 
department of urogynaecology provided me not only with a large study population, but 
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CHAPTER 2 
EMBRYOLOGY, ANATOMY, 
PHYSIOLOGY AND PHARMACOLOGY OF 
THE FEMALE LOWER URINARY TRACT 
32 
2.1. INTRODUCTION 
The female lower urinary tract comprises the urinary bladder and urethra. The 
following chapter gives an outline of its embryology, anatomy, physiology and 
pharmacology. A detailed review of the hormonal influences on the bladder, urethra 
and continence mechanism is given in Chapter six. 
2.2. EMBRYOLOGY 
The female lower urinary and genital tracts have a common embryological origin, with 
both arising from the primitive urogenital sinus. The developing embryo is initially 
formed from three layers: endoderm, mesoderm and ectoderm. Approximately 15 days 
following fertilisation, cells differentiate from the primitive streak and migrate from the 
ectoderm and endoderm layers. This intermediate layer forms the intra-embryonic 
mesoderm, from which the pronephric, mesonephric and metanephric systems are 
derived, the latter two forming the definitive kidney and ureter. At the caudal end of the 
female embryo, the mesoderm fails to form and the ectoderm and endoderm persist as a 
bilaminar region forming the cloacal membrane. Mesoderm adjacent to the cloacal 
membrane produces bilateral elevations, the cloacal folds. During the fourth to seventh 
weeks of development a wedge of tissue known as the urorectal septum grows caudally 
between the allantois and hindgut (Figure 2.1. ), until it reaches the cloacal membrane, 
thereby separating the cloaca into an anterior urogenital sinus and posterior anorectum. 
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Three portions of the primitive urogenital sinus can be distinguished (Sadler 1995): 
1. The upper part forms the urinary bladder, which is initially connected with the 
allantois. The allantois becomes obliterated forming the urachus, a thick fibrous 
cord which connects the apex of the bladder with the umbilicus. 
2. The narrow pelvic part of the urogenital sinus, which in the male gives rise to 
the prostatic and membranous urethra. 
3. The definitive urogenital sinus which is considerably flattened from side to side 
and is separated by the urogenital membrane. 
During division of the cloaca the caudal portions of the mesonephric ducts 
become absorbed into the urinary bladder, forming the trigone. The ureters, initially out 
buddings of the mesonephric duct, enter the bladder separately (Gyllensten 1949) and 
move cranially as a result of ascent of the kidneys (Figure 2.1. ). As a consequence, the 
trigonal mucosa is mesodermal in origin whereas the remainder of the bladder and 
urethra is derived from the urogenital sinus and is therefore endodermal in origin 
(Frazer 1935). The mesodermal lining of the trigone is subsequently replaced by 
endodermal epithelium, so that the bladder becomes completely lined with epithelium 
of endodermal origin. 
Within the urogenital sinus there are four different embryological muscular 
promordia (detrusor muscle, trigonal muscle, urethral smooth muscle and urethral 
striated muscle) which develop into the female bladder and urethra (Droes 1974). The 
detrusor muscle is present by the twelfth week and surrounds the entire bladder. The 
three layers of the trigone develop between the sixteenth and twenty-fourth week. 
Urethral smooth muscle is present by the twelfth week but the urethral striated muscle 
does not develop until 16 weeks. Although the bladder and urethra appear to form a 
35 
continuous mass on gross inspection there are important differences from one region to 
another which can be explained by their different embryological origins. 
At about 17-19 days after fertilisation, the mesodermal borders of the cloacal 
membrane thicken laterally to form the urethral folds and cranially to form the genital 
tubercle. In the female these structures continue to develop into the labia and clitoris. 
The urorectal septum becomes the perineal body in adult life. 
2.3. ANATOMY 
The bladder is mainly composed of detrusor smooth muscle fibres which can stretch to 
almost four times their resting length without increasing linear tension (Gosling et al 
1999). In contrast to muscle in the gut distinct inner longitudinal and outer circular 
layers are not formed. Instead smooth muscle bundles act as inter-digitating slings 
(Bro-Rasmussen & Halborg Sorensen 1965) which functionally constrict as a single 
syncytial mass (Gosling & Dixon 1975). The bladder therefore is capable of storing 
increasing amounts of urine at low pressure for prolonged periods until emptying can be 
initiated at a convenient time. The bladder is covered by an adventitia and serosa over 
its dome, and is lined by a submucosa and transitional cell epithelium. 
Within the lower aspect of the bladder is a triangular area known as the trigone, 
which is formed between the two ureteral orifices and the internal urinary meatus. At 
the base of the triangle is the interureteric ridge. The trigone contains a specialised 
group of smooth muscle fibres which arise from a separate embryological primordium. 
Above they are continuous with the smooth muscle of the ureters (Woodburne 1965) 
and continue below down into the urethra. The smooth muscle fibres of the trigone are 
smaller than those of the detrusor and have a greater density of surrounding connective 
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tissue. The mucosa in this region frequently undergoes squamous metaplasia and 
therefore differs from the transitional cell epithelium found in the rest of the bladder. 
At the bladder neck the arrangement of the smooth muscle provides sphincteric 
closure of the urethra. Sympathetic denervation or damage to this area results in the 
bladder neck remaining open at rest (Stamey & Kaufman 1975). The highest 
intraluminal pressure is found in the proximal urethra where there is an inner 
longitudinal arrangement of muscle fibres, formed by a direct continuation of the fibres 
from the bladder, and a sleeve of outer circular muscle. In addition to this smooth 
muscle, striated muscle fibres surround 20-80% of the urethra forming the external 
rhabdosphincter. In its upper 2/3, the sphincter fibres lie in a primarily circular 
orientation. Distally they leave the urethra to encircle the vaginal wall as the 
urethrovaginal sphincter or extend along the inferior ramus above the urogenital 
diaphragm as the compressor urethrae. This muscle is composed largely of slow twitch 
muscle fibres which help to maintain its constant tone (Gosling et al 1981) and probably 
account for 1/3 of its resting closure pressure (Rud et al 1980). In addition, voluntary 
activation during times of raised intraabdominal pressure, compresses the urethra and 
increases urethral closure pressure. 
The female adult urethra extends a distance of 3-4cm from the internal urethral 
meatus of the bladder to the external urethral meatus and has a mucosal lining of non- 
keratinizing squamous epithelium similar to that of the lower vagina (Carlile et al 
1987). Throughout its length it is approximately 6mm in diameter. After an intramural 
portion 15% of its length, the urethra runs anterior-inferiorly (in the standing position), 
lying behind the symphysis pubis before traversing the urogenital diaphragm to reach 
the perineum. The distal 20% of the urethra is not involved in the continence 
mechanism (DeLancey 1986). Within the urethral wall is a well developed vascular 
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plexus (Berkow 1953) which has several types of specialised arteriovenous anastomosis 
allowing rapid changes in perfusion. Occlusion of arterial flow into these venous 
reservoirs influences urethral closure pressure and it is therefore thought that these 
vessels contribute to continence (Rud et al 1980). Interspersed within the muscle and 
submucosa of the urethra is a considerable quantity of both collagenous and elastin 
connective tissue. 
The lower urinary tract is controlled by a complex interplay between the central 
and peripheral nervous systems and local regulatory factors (Andersson 1993). This is 
shown diagrammatically in Figure 2.2.. Contraction of the detrusor smooth muscle and 
relaxation of the outflow tract result from activation of parasympathetic neurones 
located in the sacral parasympathetic nucleus (SPN) at the level of S2-S4 (De Groat et 
al 1981). The axons pass through the pelvic nerve and synapse with postganglionic 
nerves in either the pelvic plexus, in ganglia on the surface of the bladder (vesical 
ganglia) or within the walls of the bladder and urethra (intramural ganglia) (Lincoln & 
Burnstock 1993). The sympathetic innervation of the bladder and urethra arises mainly 
from the thoraco-lumbar region T10-L2 of the spinal cord. The axons travel mainly in 
the hypogastric nerve but also pass through the paravertebral chain and enter the pelvic 
nerve. The predominant effects of the sympathetic innervation of the lower urinary tract 
are inhibition of the parasympathetic pathways at spinal and ganglion levels. 
Bladder sensation is transmitted via several different nervous sources. 
Proprioception is relayed by myelinated AS fibres and long latency unmyelinated C 
fibres in parasympathetic afferents travelling in the pelvic nerve to sacral segments S2- 
4. The AS fibres respond to passive distension and active contraction, therefore 



















Figure 2.2.: Diagrammatic representation of the innervation of the lower 
urinary tract. 
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high mechanical threshold and respond mainly to chemical irritation of the bladder 
mucosa or cold (Habler et al 1990, Fall et al 1990). Somatosensory perception of fluid 
in the urethra and the external urethra sphincter is transferred through the pudendal 
nerve to sacral segments S2-S4 (Lincoln & Burnstock 1993). Abnormal sensation can 
be produced by a number of conditions including systemic illnesses such as diabetes 
mellitus and neurological disease of both the spinal cord and brain. 
The continence mechanism can be separated anatomically and functionally into 
two units. The intrinsic continence mechanism consists of structures which lie within 
the vesical neck and are not specifically activated by contraction of voluntary muscles. 
The extrinsic continence mechanism usually refers to a group of structures which 
respond when an individual is instructed to stop their urine stream. This is primarily 
achieved by a constriction of the urethral lumen by the striated urogenital sphincter and 
an elevation of the bladder neck by contraction of the levator ani muscles. 
The position and mobility of the bladder and urethra are determined by the 
fascia and muscles of the pelvic floor and their connection to the bony pelvis. The 
pelvic floor consists of several components. The upper layer is provided by endopelvic 
fascia which attach and suspend the pelvic organs to the pelvic side walls (DeLancey 
1992). The part of the fascia which attaches to the uterus is known as the parametrium 
and composed of the cardinal and uterosacral ligaments. These structures consist of 
blood vessels, nerves and fibrous connective tissue. The structural layer that supports 
the bladder, also known as pubocervical fascia, is composed of the anterior vaginal wall 
and its attachment through the endopelvic fascia to the pelvic wall. Below the 
endopelvic fascia is the levator ani, which consists of the pubococcygeus and 
iliococcygeus muscles. The levator ani is attached at each end to the pubic bones and 
forms aU shaped sling of muscle passing behind the rectum in the midline. The 
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urethra, vagina and rectum pass through an opening in the levator ani known as the 
urogenital hiatus. Laterally, the iliococcygeus arises from a fibrous band on the pelvic 
sidewall known as the arcus tendinous levator ani. The levator ani forms a relatively 
horizontal sheet of muscle at the entrance to the pelvis on which the pelvic organs rest. 
In addition, via its attachment to the vagina the levator ani elevates and supports the 
urethra when there is an increase in intra-abdominal pressure. Close to the midline, the 
pubourethral ligaments also firmly attach the anterior aspect of the urethra to the 
posterior-inferior surface of the symphysis pubis. The interaction between the pelvic 
floor muscles and supportive ligaments is of crucial importance both to continence and 
the prevention of pelvic organ prolapse. 
2.4. PHYSIOLOGY 
The main role of the bladder is for the collection and expulsion of urine. At birth the 
bladder stores and discharges urine in a rhythmic manner which is independent of 
central cortical control. During the first five years of life this pattern comes under 
voluntary regulation, particularly during a period of adult supervision and biofeedback 
known as "toilet" or "potty" training. Similar methods are used in the treatment of 
incontinence (Chapter three). 
2.4.1. The storage phase of the bladder cycle. 
The majority of the normal bladder cycle is spent storing urine at increasing volumes 
with a continuously low intravesical pressure which gradually results in central 
awareness. This is not purely a passive mechanism: the reflex contraction of the 
urethral rhabdosphincter is reinforced and there is reciprocal inhibition of bladder 
parasympathetic stimulation. This relaxation is in part enabled by a spinal reflex 
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pathway triggered by vesical afferent activity in the pelvic nerves, which initiates 
sympathetic firing from the lumbar region of the spinal cord (De Groat et al 1999). 
Normal adult bladder function is characterised by quiescence of the 
parasympathetic efferent pathways and absence of involuntary bladder contractions 
during the filling phase. In addition, the pressure in the bladder remains low during 
filling because of the almost infinite compliance of the bladder until capacity is 
increased. This is largely achieved by the arrangement of detrusor muscle fibres, reflex 
inhibitory pathways and the absence of connective tissue restriction, particularly by 
collagen. Disturbance of any of these mechanisms can result in increases in intravesical 
pressure at lower bladder volumes than would normally be expected with the bladder 
then being described as hypertonic. Increases in intravesical pressure may lead to 
incontinence particularly if the urethral sphincter is compromised. 
The bladder continues to fill with urine at a rate of 0.5-5 ml/minute, unless 
emptied, until it reaches its capacity (Hilton 1992). The absolute capacity of the bladder 
is determined by the vesicoelastic properties of the bladder, the physical limits of 
smooth muscle strength and the resistance of the outflow. However, in normal women 
the absolute capacity is rarely reached because the woman voids when the bladder has 
filled to its functional capacity. The functional capacity of the bladder is 
characteristically between 400-600m1(Cardozo et al 1993a) and depends upon bladder 
sensation, stability, compliance and voluntary voiding patterns. 
2.4.2. The emptying phase of the bladder cycle 
Micturition in women is incompletely understood but several key events are known to 
occur and these are co-ordinated by the pontine micturition centre (PMC) in the 
brainstem. The PMC receives information from afferent neurones in the bladder and 
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from the cerebral cortex and hypothalamus, and also controls the descending pathways 
of the micturition reflex. At a socially convenient time, following central initiation and 
then activation of the sacral parasympathetic nucleus, there is co-ordinated release of 
acetylcholine from the parasympathetic post-ganglionic nerve terminals in the bladder 
(De Groat et al 1993). There follows a depolarisation of smooth muscle cells with an 
inward flow of calcium. Actin/myosin activation leads to a sustained contraction of the 
detrusor smooth muscle fibres which provides the power for urinary evacuation. The 
urethra normally opens during this first phase of normal voiding, but it is unclear if this 
is an active or passive phenomenon secondary to an increase in intravesical pressure. In 
some women gravity alone may lead to expulsion of urine, with the patient simply 
having to relax the rhabdosphincter and pelvic floor. In others manual suprapubic 
pressure or voluntary straining may be necessary to enhance bladder emptying if there is 
diminished intrinsic detrusor function. 
Urinary flow is determined using uroflowmetry with additional information 
gained by the simultaneous recording of intravesical and intra-abdominal pressures 
during pressure flow studies (Chapter four). When normal, the flow appears as an 
abrupt rise in the flow rate followed by a gradual return to zero, with the residual 
volume of urine in the bladder typically less than 50m1 (Cardozo et al 1993a). Some 
women retain a large residual volume of urine which has the effect of reducing the 
functional bladder capacity. For example, a woman who has an absolute bladder 
capacity of 600ml and post-micturition residual of 500m1 may only have a functional 
capacity of 100ml. 
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2.5. PHARMACOLOGY 
There are several regions of the lower urinary tract and micturition reflex pathways 
which are potential sites for drugs aimed for the control of bladder and urethral 
function. The main classes of therapeutic agents which may be useful for the treatment 
of lower urinary tract dysfunction are discussed below. 
2.5.1. Central Targets 
The supraspinal micturition reflex is under GABAergic tonic inhibitory control (De 
Groat et al 1993). GABA (y-amino butyric acid) receptor agonists such as baclofen 
have been used to treat women with idiopathic detrusor instability (Taylor & Bates 
1979) and detrusor hyperreflexia secondary to lesions of the spinal cord (Wein 1995). 
However, at present more effective agents are used as first line therapy. 
The role of serotonin in the control of the lower urinary tract is complex and 
poorly understood but probably involves modulation of parasympathetic, sympathetic 
and somatic efferent pathways. Drugs which interfere with serotonin or serotonin 
receptors have not been systematically investigated or widely used for the treatment of 
urinary complaints (McMurray & Brading 1998). 
The role of noradrenaline and dopamine in the central control of the lower 
urinary tract has also not been clearly determined. While stimulation or blockade of 
central receptors to these transmitters may have the potential to influence micturition 
and bladder disorders, the therapeutic benefits of such agents have not been established. 
2.5.2. Peripheral targets 
The preganglionic neurotransmission of the parasympathetic system is predominantly 
mediated by acetylcholine acting on nicotinic receptors, although transmission can be 
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modulated by adrenergic, muscarinic, purinergic and peptidergic presynaptic receptors 
(De Groat et al 1981). The postganglionic neurones in the pelvic nerve mediate the 
excitatory input to the human detrusor smooth muscle by releasing acetylcholine acting 
on muscarinic receptors which are found throughout the bladder. The preganglionic 
sympathetic transmission is similar to the parasympathetic system. Some preganglionic 
terminals synapse with the postganglionic cells in the paravertebral ganglia, while 
others synapse closer to the pelvic organs. Short postganglionic neurones innervate the 
target organs with their effect primarily mediated via the release of noradrenaline. The 
bladder neck and urethra have a dense distribution of alpha-adrenergic receptors and the 
bladder dome contains beta-adrenergic receptors. 
Both normal bladder contractions and contractions in hyperactive bladders are 
predominantly mediated by acetylcholine acting on muscarinic receptors (Andersson 
1993). Muscarinic receptor antagonists are currently the most important drugs for the 
treatment of bladder overactivity. Five muscarinic receptor subtypes (M1-M5) have 
been identified (Eglen et al 1996, Caulfield & Birdsall 1998). The human detrusor has a 
predominance of M3 receptors (Yamaguchi et al 1994, Wang et al 1995, Kondo et al 
1995). Since excitatory neurotransmission is entirely cholinergic in nature (McMurray 
& Brading 1998), and the receptors present on bladder smooth muscle cell membranes 
responsible for mediating contractile activity are of the muscarinic subtype, 
antimuscarinics in low concentrations have been used to increase bladder capacity and 
block unstable contractions. All antimuscarinic preparations used in the treatment of 
urinary incontinence are reversible, competitive antagonists of acetylcholine. Non 
selective antimuscarinic agents such as oxybutynin are limited by their systemic 
anticholinergic side effects such as dry mouth, blurred vision and constipation. 
45 
Recently the selective antimuscarinic agent tolterodine has been introduced which has a 
much more favourable side effect profile. This is considered further in Chapter three. 
Although adrenergic innervation in the human detrusor is sparse, a number of 
adrenoreceptor subtypes have been shown to exist, with a possible predominance of 
relaxation mediating ß-adrenoreceptors (Andersson 1993). Application of ß- 
adrenoreceptor agonists, such as Isoprenaline, to human detrusor muscle produces an 
inhibitory effect which causes smooth muscle relaxation. No differences have been 
shown in ß-adrenoreceptor density between normal and hyperactive bladders (Restorick 
& Mundy 1989). However, it is possible that an atypical ß-adrenoreceptor subtype is 
present in the bladder of some women, suggesting the possibility of developing new 
selective therapeutic agents. Unfortunately, the use of current ß-adrenoreceptor 
agonists and antagonists for lower urinary tract disorders is limited by their systemic 
actions and side effects. 
The normal human detrusor responds to noradrenaline by relaxing, probably via 
effects on both a and ß-adrenoreceptors. However, the circularly orientated smooth 
muscle within the female urethra is under excitatory control by adrenergic fibres which 
act on smooth muscle cell membranes (Andersson 1993). Women with stress 
incontinence have been treated with a-adrenergic agents such as phenylpropanolamine, 
which may act by increasing intracellular calcium levels, causing a contraction of the 
urethral musculature and therefore an increase in urethral pressure. 
Calcium channels are important local regulators of cell function. Of the six sub- 
classes of calcium channel currently known, only the L-type has been demonstrated 
within the smooth muscle of the bladder (Turner & Brading 1997). Upon membrane 
depolarisation, an influx of calcium ions into muscle cells can directly initiate a 
contraction (Ganitkevich & Isenberg 1995). Regulation of the intracellular calcium 
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concentration in the smooth muscle of the bladder is therefore a potential way to 
modulate a bladder contraction. However, very few clinical trials have investigated 
their use on lower urinary tract disorders. Although calcium channel antagonists have 
been shown to increase bladder capacity and reduce unstable contractions in women 
with detrusor overactivity (Rud et al 1979) they are very rarely used in clinical practice 
for this indication. 
A number of different prostaglandin are synthesised within the bladder muscle 
(Andersson 1993) but they are not thought to be important mediators of bladder 
contraction during micturition. Although the exact mechanism of action of 
prostaglandins in detrusor muscle has not been studied extensively, it is possible that 
they contribute to its tone and spontaneous rhythmic activity (McMurray & Brading 
1998). Prostaglandins may have an important physiological role by sensitisation of 
sensory nerves, and they have been implicated in the pathophysiology of a number of 
bladder disorders. Some women with cystitis may have an exaggerated prostanoid 
production leading to intense activation of sensory nerves (Maggi 1992). 
Unfortunately, side effects from prostaglandin synthesis inhibitors include nausea, 
headache and gastrointestinal symptoms which limit their use in clinical practice. 
Oestrogen receptors have been isolated in the trigone of the bladder, urethra and 
muscles of the pelvic floor. The action of the sex hormones oestrogen and progesterone 
on the lower urinary tract, and the use of oestrogen replacement therapy to treat urinary 
complaints, is discussed in detail in Chapter six. 
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CHAPTER 3 




Treatment of female urinary symptoms including incontinence is perhaps the least 
glamorous but most rewarding division of obstetrics and gynaecology. Until the last 25 
years few women admitted to suffering from incontinence and even fewer sought 
medical help. In a large study of patients seen after tertiary referral, Norton and 
colleagues (1988) found that 60% of subjects had delayed seeking treatment for more 
than one year from the time their symptoms became severe. Half of these patients said 
that this was because they were too embarrassed to discuss the problem with their 
doctor, and 17% said that they thought the problem was normal for their age. 
Unfortunately, many gynaecologists in the past have been reluctant to treat these "wet 
women" partly because incontinence is not a life threatening condition, but also because 
the causes were poorly understood. This often led to inappropriate and unsuccessful 
therapy. 
Today more women are prepared to seek help but frequently on presentation 
they are embarrassed, depressed and often desperate (Wyman et al 1987). Normal daily 
activities which many women take for granted, such as going to a dance or playing with 
their children, may be severely affected with some patients becoming housebound for 
fear of leaking urine (Jameson 1983). Women with the symptoms of urgency and urge 
incontinence may be particularly severely affected because of the unpredictability and 
severity of their urinary leakage. This may lead to poor self-esteem with many women 
looking dishelved when they first present. The change in their appearance following 
treatment can be remarkable. Many come back for review wearing new clothes and 
make up with a new vigour for life. 
The financial burden of incontinence in the United Kingdom is unknown but in 
1986 the direct cost of continence pads and appliances was over £50 million with a 
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further £18 million spent on prescription items (Sanderson 1991). The costs of 
investigation and treatment are also substantial. Studies based on health care systems in 
the USA (Hu 1990) and Sweden (Ekelund et al 1993) estimate that urinary incontinence 
costs about 2% of national health care budgets or the equivalent to £1.4 billion pounds 
per year. There may also be the additional costs of residential care, as incontinence may 
also be an important factor when considering whether or not to institutionalise an 
elderly person (Sanford 1975, Ekelund et a! 1987). 
In this chapter I shall review the epidemiology, pathophysiology and treatment 
of the most common causes of urinary symptoms in adult women. The role of 
oestrogen, the menopause and oestrogen deficiency in the aetiology of urinary 
complaints is considered in detail in Chapter six. 
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3.2. LOWER URINARY TRACT SYMPTOMS 
Women with urogenital dysfunction may present with a variety of lower urinary tract 
complaints. The urinary symptoms described in this thesis are defined as follows: 
Frequency Going to the toilet very often. 
Nocturia Getting up at night to pass urine. 
Urgency A strong and difficult to control desire to pass urine. 
Urge incontinence Urinary leakage associated with a strong desire to pass 
urine. 
Stress incontinence Urinary leakage with physical activity 
(e. g. ) coughing, sneezing, running. 
It is unusual for a woman to have only one complaint and common for a patient to have 
a variety of different problems. There is considerable overlap in the symptomatology 
associated with different conditions and therefore further investigation is almost always 
required to determine the underlying pathology. This is considered further in Chapter 
four. 
3.3. EPIDEMIOLOGY 
The International Continence Society (ICS) has defined urinary incontinence as "a 
condition where involuntary loss of urine is a social or hygienic problem and is 
objectively demonstrable" (Bates et al 1979). Estimates of prevalence vary according to 
the different populations studied, methods used for investigation and definitions used. 
The exact number of women with incontinence based on the ICS criteria is unknown. 
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Several large studies have evaluated the prevalence of urinary symptoms and urinary 
incontinence in community dwelling women in the last 20 years. 
Thomas and colleagues (1980) surveyed the London boroughs and health 
districts of Brent and Harrow and asked for the number of notifications of people with 
incontinence each year. A postal questionnaire was also sent to all patients aged over 5 
years on the lists of 12 general practitioners. Although the notified prevalence of 
incontinence in women aged less than 65 years was only 2.5% of the population, the 
results of the patient survey suggested that 25.1% of women had regular or occasional 
urinary leakage. Incontinence was reported less commonly by nulliparous than parous 
women, with those women having four or more babies most likely to report regular 
incontinence. Less than one third of patients with severe incontinence in this study 
were receiving medical help for their condition. 
Jolleys (1988) surveyed 937 women attending a rural general practice and 
achieved an 89% response rate to her questionnaire. Of those women who took part in 
the study, 343 women (41%) complained of "inappropriate urinary leakage. " The 
prevalence of urinary incontinence was again higher in parous women, but there was no 
recognisable association with the type of delivery. 
O'Brien and associates (1991) studied 7300 adults randomly selected from one 
urban and one rural general practice in Somerset. Validated responses from a 
questionnaire showed that 4.4% of men and 16.4% of women had urinary incontinence, 
defined as "two or more leaks in any month. " Only half of the people who were 
diagnosed as being incontinent took up the offer of treatment and it is possible that the 
diagnostic criteria used was too strict with many patients not having a social or hygienic 
problem as defined by the ICS definition of incontinence. It is clear from this and other 
reports (Wyman et al 1987, Norton 1990) that the severity of symptoms does not always 
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correlate with the psychosocial impact perceived by the individual sufferer. In addition, 
patients with frequency and urgency may be bothered as much by their symptoms as 
those with daily incontinence. 
Several reports have suggested that the prevalence of incontinence increases 
with age. In an American study performed in the state of Michigan (Diokno et al 1986) 
trained interviewers visited the homes of 1955 senior citizens aged 60 or more. Any 
respondent who reported "losing urine of any volume with a minimum frequency of 6 
days within the last 12 months" was considered to be incontinent. There was a 
significantly greater prevalence of incontinence in women compared to men (38% v 
19%), with 9.0% of the incontinent female population complaining of urge 
incontinence, 27% stress incontinence and 56% mixed urinary leakage. The remaining 
patients with incontinence were unclassified. The frequency of voiding was 
significantly increased among subjects with incontinence compared to those who were 
asymptomatic (P<0.001). Of the women studied, 11% complained of difficulty 
emptying the bladder and 18% had problems with pain, burning or stinging during 
micturition. In an analysis of a MORI poll Brocklehurst (1993) also found that the 
prevalence of incontinence increased in each decade of life. However, only 12% of the 
incontinent women over the age of 60 in this study thought that their age was the cause 
of their problem. 
A report providing the average prevalence of incontinence from all the available 
data has been produced by the Royal College of Physicians (1995). This is shown in 
Table 3.1.. 
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Population Age (years) % Incontinent 
Women living at home 15-44 5-7 
45-64 8-15 
65 and over 10-20 
Men living at home 15-64 3 
65 and over 7-10 
Both sexes together in 
institutions 
9 Residential homes 25 
" Nursing homes 40 
" Hospital (elderly and 50-70 
elderly mentally infirm) 
Table 3.1.: Percentage of the population with urinary incontinence. Figures are 
based on an average of data from epidemiological studies (Royal College of 
Physicians 1995). 
At present a very large Medical Research Council (MRC) funded prospective 
study is taking place in the University of Leicester which will hopefully provide a better 




3.4. AETIOLOGY OF LOWER URINARY TRACT SYMPTOMS 
There are a number of different conditions which may cause urinary symptoms and 
incontinence in women (Table 3.2. ). The two most common problems, genuine stress 
incontinence and detrusor instability, are considered below along with an overview of 
the main causes of irritative urinary symptoms. It is important that an accurate 
diagnosis is made before therapy is instituted because the treatment of each condition 
may be completely different. This is particularly the case when surgery is being 
contemplated, as the results may be irreversible. 
" Genuine stress incontinence 
" Detrusor instability 
9 Overflow incontinence 
" Fistulae 
9 Urethral diverticulum 
" Congenital anomalies (e. g. ) ectopic ureter 
" Functional (e. g. ) immobility secondary to arthritis 
" Temporary (e. g. ) constipation, urinary tract infection 
Table 3.2.: Causes of female urinary tract symptoms and incontinence. 
3.4.1. Genuine stress incontinence 
The symptom of stress incontinence may occur in women with a variety of different 
lower urinary tract pathologies. However, it is only after urodynamic investigation that 
genuine stress incontinence (GSI) may be diagnosed with accuracy. This condition is 
defined as "the involuntary loss of urine when the intravesical pressure exceeds the 
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maximum urethral closure pressure in the absence of detrusor activity" (Abrams et al 
1990). While incontinence associated with coughing or exercise is the predominant 
symptom in women with GSI, patients may also complain of frequency, urgency and a 
variety of other problems. 
The aetiology of GSI is complex and incompletely understood. A number of 
different pathological processes have been implicated (Table 3.3. ) including intrinsic 
deficiency of the urethral sphincter, bladder neck hyper-mobility, reduced pressure 
transmission to the proximal urethra, changes in collagen and the development of a 
neuropathy. The role of the menopause and oestrogen deficiency in the development of 
GSI is considered in Chapter six. 
" Raised intra-abdominal pressure 
(e. g. ) Pulmonary disease, constipation, pelvic masses 
" Urethral sphincter incontinence 
(e. g. ) Damaged intrinsic sphincteric mechanism, hyper-mobility, denervation 
. Decreased or absent urethral pressure transmission 
" Trauma 
(e. g. ) Surgery, childbirth 
. Bladder overdistension 
(e. g. ) infrequent voiding, neuropathic overflow incontinence 
" Congenital abnormalities 
(e. g. ) short urethra 
Collagen deficiency 
. Oestrogen deficiency and the menopause 
Table 3.3.: Factors implicated in the aetiology of genuine stress incontinence. 
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3.4.1.1. Conservative management of genuine stress incontinence 
Conservative (non-surgical) treatment of genuine stress incontinence should be 
considered in all women presenting with GSI. However, it is particularly useful for 
young women who have not completed their family and those unfit for surgery. Simple 
behavioural changes such as avoidance of precipitating factors and regular toileting to 
keep the bladder relatively empty can be useful first line measures. Women with 
incontinence should also be advised to limit their fluid intake to 1500m1 per 24 hours. 
The mainstay of conservative treatment for GSI is pelvic floor physiotherapy 
which was first introduced by the American gynaecologist Arnold Kegel (1948). Pelvic 
floor exercises (PFE) appear to work by a number of different mechanisms. Strength 
training may increase muscular volume and structural support to the bladder and urethra 
during rises in intra-abdominal pressure (Bo 1995a). During a pelvic floor muscle 
contraction the urethra may also be pressed against the posterior aspect of the 
symphysis pubis, producing a mechanical rise in urethra pressure (DeLancey 1988). 
Furthermore, as up to 30% of women with stress incontinence are unable to contract 
their pelvic floor correctly at presentation (Bo et at 1988), some patients may simply 
need to be re-taught the "knack" of squeezing the appropriate muscles at the correct 
time (Miller et at 1998). Cure rates varying as widely as 21-84% have been reported 
(Kegel 1948, Bernstein 1997, Bo et al 1999). Success appears to depend upon the type 
and severity of incontinence treated, the instruction and follow-up given, the 
compliance of the patient and the outcome measures used. However, it is clear that 
PFE's are more effective if patients are given a structured programme to follow, rather 
than simply being given verbal instruction and left to perform the treatment 
unsupervised at home (Henalla et al 1989, Bo et al 1990, Lagro-Janssen et al 1991a). 
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The success of PFE's may be further enhanced by the use of biofeedback 
(Burgin et al 1986). This technique allows patients to receive visual or audio feedback 
relating to contraction of their pelvic floor. The most commonly used device in clinical 
practice is a perineometer, which may give women an improved concept of a pelvic 
floor contraction and provide an effective stimulus to encourage greater and continued 
effort. 
Vaginal weighted cones were introduced by Plevnik (1985). After an 
explanation of their function, the user is instructed to place the lightest cone into the 
vagina. Contraction of the pelvic floor is then necessary to hold the cone in place 
during walking or coughing. Cones of gradually increasing weight are used depending 
upon the ability of the patient to retain the device in the vagina. A recent randomised 
controlled study of conservative treatments for GSI has indicated that only 7.5% of 
women felt they no longer had an incontinence problem after using vaginal cones for 
six months, and there was no difference in pelvic muscle strength compared to the 
control group at the end of the study period (Bo et al 1999). Unfortunately, as well as a 
lack of efficacy cones may produce prolonged isometric contractions of the pelvic floor 
muscles and muscle injuries due to overuse (Bo 1995b). 
Electrical stimulation of the pelvic floor is a widely used treatment for GSI and 
may be used alone or in combination with PFE's. The most effective and popular form 
at present is functional electrical stimulation using a vaginal electrode. Sand and 
colleagues performed a prospective, randomised, double blind trial of 35 women using 
an active stimulator and 17 controls using a sham device (Sand et al 1995). Pad testing 
showed that stress incontinence was improved by at least 50% in 62% of patients using 
an active device compared with only 19% using sham devices (P<0.01). Interestingly, a 
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recent meta-analysis has shown that electrical stimulation is as effective as pelvic floor 
exercises for the treatment of GSI (Berghmans 1998). 
Oestrogen supplementation has also been used as a conservative treatment of 
genuine stress incontinence. This is considered further in Chapter six. 
3.4.1.2. Surgical management of genuine stress incontinence 
Surgery is the mainstay of treatment for women with severe genuine stress incontinence 
and those who have failed to improve satisfactorily with conservative measures. Over 
100 different surgical procedures have been described which indicates that none have 
achieved 100% success rates without complications. The choice of operation is 
influenced by the clinical features and the results of urodynamic investigations. The 
results of a major review of surgery for GSI (Jarvis 1994) are shown in Table 3.4.. 
PROCEDURE SUBJECTIVE CURE OBJECTIVE CURE 
Bladder buttress 80.9 72.0 
Colposuspension 89.6 84.3 
Bladder neck suspension 77.6 70.0 
Sling procedures 82.4 85.3 
Injectables 56.4 60.2 
Table 3.4.: Results of surgery for genuine stress incontinence. Values given are 
percentages. Adapted from Jarvis (1994). 
It is clear from this review and other work recently published (Black & Downs 1996) 
that procedures performed through a suprapubic approach, such as a colposuspension, 
have a longer lasting cure rate than those performed vaginally. However, they also have 
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a higher complication rate and may not be suitable for elderly women who are frail or 
unfit for surgery. In this case less invasive procedures such as periurethral injection of 
collagen or macroplastique (Khullar et al 1997, Monga et a] 1999), or insertion of a 
tension free vaginal tape may be more appropriate (Ulmsten et al 1999). 
3.4.2. Detrusor instability 
Detrusor instability (DI) is defined by the International Continence Society as "a 
condition in which the detrusor is shown to contract, either spontaneously or on 
provocation, during bladder filling whilst the subject is attempting to inhibit 
micturition" (Abrams et al 1990). In the presence of underlying neurological disease 
the term "detrusor hyper-refexia" is used. The most common presenting symptoms are 
frequency and urgency of micturition, which occur in 80% of patients (Cardozo & 
Stanton 1980). However, women may present with a variety of different complaints 
including those listed below: 
" Frequency 
" Nocturia 
" Urgency / Urge incontinence 
" Stress Incontinence 
" Nocturnal enuresis 
" Coital incontinence 
The severity and unpredictability of symptoms frequently makes detrusor 
instability a very distressing condition for the patient with a significant impact on 
quality of life. In women with DI there is often no obvious underlying cause. However, 
there are several theoretical reasons why unstable bladder contractions may occur. In 
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infancy during "potty training" conscious inhibition of the voiding reflex is acquired. It 
is possible that in some patients DI may be a consequence of poorly learnt bladder 
control as a child. Indeed, there is a strong association between nocturnal enuresis in 
childhood and DI presenting in adult life (Whiteside & Arnold 1975). DI may occur in 
association with bladder outflow obstruction secondary to benign prostatic hypertrophy 
in men. While primary bladder outflow obstruction in women is relatively rare, a 
similar situation may occur following colposuspension. Approximately 15% of women 
develop de novo DI following retropubic bladder neck surgery (Cardozo & Stanton 
1979). The finding in this study by Cardozo and Stanton that the incidence of DI is 
increased aller multiple continence procedures suggests that bladder dissection and 
consequent denervation is an important underlying pathophysiological cause of this 
problem 
In women with detrusor hyper-refexia the complex neurological pathways 
controlling micturition are disrupted, allowing abnormal uninhibited detrusor 
contractions to occur. It is possible that women with idiopathic DI an underlying 
neurological deficit is also present but less obvious. It has been postulated that damage 
to central inhibitory pathways or sensitisation of peripheral afferent terminals in the 
bladder may unmask primitive voiding reflexes that trigger bladder overactivity (De 
Groat 1997). Others have suggested that there may be a myogenic basis for DI 
(Brading 1997). Partial dencrvation of the dctrusor may be responsible for altering the 
properties of smooth muscle, leading to both an increased excitability and ability of 
activity to spread between cells, resulting in co-ordinated myogenic contractions of the 
whole detrusor. 
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It is important to remember that DI is only one of a number of causes of 
irritative bladder symptoms and it can only be diagnosed on cystometry. This is 
considered in detail in Chapter four. 
3.4.2.1. Conservative management of Detrusor Instability 
The mainstay of treatment for detrusor instability is bladder retraining and medication. 
Bladder neck surgery is rarely indicated and can in fact have disastrous effects with a 
deterioration of the patient's condition. 
Behavioural therapy in the form of retraining or "bladder drill" is a logical 
treatment for Dl in view of the loss of bladder control, which was acquired during 
infancy. Treatment is aimed at both unlearning an abnormal voiding pattern and 
relearning a more appropriate one. Bladder drill was first described as "bladder 
discipline" by Jeffcoate and Francis (1966). Several studies since then have shown 
impressive subjective, and sometimes objective, results. Many have used a regime 
similar to that described by Jarvis (1981), who found the efficacy of bladder drill to be 
superior to that of drug therapy. This is still used today and described below: 
1) Exclude pathology (e. g. ) infection, bladder stone. 
Admit to hospital - the treatment can also be performed as an outpatient. 
2) Explain rationale to patient. 
3) instruct to void c%vry 1'/2 hours during the day. The patient must not void 
between these times; she must wait or be incontinent. 
4) Increase voiding interval by 1/2 hour when initial goal achieved, and continue 
with 2 hourly voiding etc. 
S) Give encouragement. 
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Frewen (1982) reported that 86% of 150 women with frequency and urgency were 
symptomatically cured following 3 months of bladder drill. However, Holmes and 
colleagues (1983) found that 43% of patients had relapsed 3 years after this form of 
therapy. This was regardless of whether the bladder had been shown to be stable on 
urodynamics following treatment. Bladder drill is now frequently performed on an 
outpatient basis, often in combination with drug therapy. Limitation of fluid intake to 
1500ml/24 hours, and avoidance of tea, coffee and alcohol can also be beneficial. 
Maximal electrical stimulation can be used for both the treatment of genuine 
stress incontinence and detrusor instability. Pudendal nerve stimulation, using either a 
vaginal or anal electrode, has been shown to result in inhibition of the detrusor and 
relaxation of the bladder. Wise and co-workers (1992) performed a comparative trial of 
maximal electrical stimulation and oxybutynin. In both groups there was a significant 
reduction in urinary symptoms using a visual analogue scale, and a reduction in 
frequency using a urinary diary. however, electrical stimulation appeared to be more 
acceptable to the women in the study. This form of treatment is currently mainly 
performed by continence advisors, specialist nurses and physiotherapists often in 
combination with other therapies. 
Drug therapy is probably the most frequently used treatment for DI. Until 
recently oxybutynin hydrochloride (a compound with antimuscarinic, spasmolytic and 
local anaesthetic properties) has been the medication of first choice. The first double 
blind, placebo controlled study of30 patients was reported in 1980 (Moisey et al 1980). 
Of the patients treated with oxybutynin, 60% were symptomatically improved compared 
to 8% of those on placebo. Unfortunately, oxybutynins use is limited by a lack of 
specificity and anticholincrgic side effects of dry mouth, blurred vision and 
constipation. As many of these symptoms are caused by a metabolite of oxybutynin, 
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produced in the liver following oral therapy, other routes of administration (such as 
vaginal, rectal and intra-vesical therapy) have been tried with varying degrees of 
success. Other anticholincrgic medications such as probantheline and imipramine have 
also been proven to be useful treatments for DI but unfortunately they have a similar 
side effect profile to oxybutynin. 
Several subpopulations of muscarinic receptors have been identiat 1. at least 
five different subtypes (M1-MS) have been cloned. Receptor studies w wn that 
there is a predominance of M3 receptors in the human dctrusor compared to other 
subtypes (Anders-, -n 1997). Tolterodine is a new potent competitive muscarinic 
receptor antag t developed for the treatment of the overactive bladder. This 
compound was selected for development with the objective of achieving separation of 
the antimuscarinic effects on the bladder and salivary glands. A number of studies have 
compared the efficacy of toltcrodine with oxybutynin. It has been demonstrated that the 
two compounds are cquipotent at bladder muscarinic (M3) receptors. However, 
radioligand binding data show that tolterodine has 8 times less potency than oxybutynin 
at the muscarinic receptors in the parotid gland. 
Appell (1997) has recently published a pooled analysis of the safety, efficacy, 
and tolerability of toltcrodinc in 4 randomised 12. week studies of patients with an 
overactive bladder. It was shown that tolterodine significantly reduced the number of 
incontinent episodes and increased the volume voided/micturition compared to placebo. 
In addition, adverse events were tolerated significantly better than those due to 
oxybutynin. 
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3.4.2.2. Surgical management of dctrusor instability 
Many different surgical techniques have been used to treat DI but few have produced 
effective long-term results and all are associated with significant complications. 
Vaginal denervation (Ingelman-Sundbcrg 1978), bladder transection (Turner-Warwick 
& Ashken 1976), bladder distension (Dunn et al 1974), subtrigonal injection of phenol 
(Ewing et al 1982) and other procedures have all been introduced enthusiastically at 
varying times but few are in regular use today. 
For those women with extremely severe DI refractory to all other therapies an 
augmentation "clam" cystoplasty or urinary diversion may be appropriate. 
3.4.3. Frequency and urgency 
The urinary symptoms of frequency and urgency (also known as irritative symptoms) 
may occur in women of all ages but they arc particularly common following the 
menopause. There arc many pathological causes of these complaints (Table 3.5. ) which 
may occur alone or in combination with other problems such as nocturia, dysuria or 
incontinence. Treatment primarily depends upon the aetiology of the patient's 
symptoms, which is almost always diagnosed by investigation (Chapter four). 
Women who drink excessively can be helped to modify their intake provided a 
metabolic cause for their thirst such as diabetes mellitus is excluded. A 
frcqucncy/ volume chart can sometimes be useful to indicate to the patient their 
abnormal drinking habits and bladder retraining can also be helpful. Urinary tract 
infection should be treated with antibiotics, based on the urine culture and sensitivity 
results. When the standard urine culture is negative it is sometimes worth examining 
the urine for fastidious organisms including Mycoplasma hominis and Ureaplasma 
Urcalyticum (Boos et al 1997). 
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Patients with GSI or DI should be treated as described earlier. Women with 
impaired bladder emptying arc usually treated with a combination of double voiding, 
cholinergic medication and sometimes intermittent or indwelling catheterisation 
depending upon the severity of their condition. Women with chronic inflammation of 
the bladder mucosa (chronic cystitis) are often difficult to treat satisfactorily. Pain is the 
presenting complaint in 70% of patients (Koziol 1994) but usually women have a 
number of different symptoms which often vary in their intensity. Urinary tract 
infection may previously have been diagnosed but often urine culture is negative. 
Clinical examination is often unrewarding but sensory urgency is usually diagnosed on 
cystometry. Cystoscopy with bladder base biopsy must be undertaken to confirm the 
diagnosis. Some women with severe bladder inflammation may be diagnosed as having 
interstitial cystitis, the aetiology of which is poorly understood (Toots-Hobson & 
Cardozo 1996). I iowevver, treatment is usually as per other causes of this condition. In 
view of the possible underlying infective process, regardless of the results of urine 
culture, long-term antibiotics arc often prescribed. Norfoxacin 400mg daily for three 
months is currently the most effective and has few side effects. Alternatively, a bladder 
antiseptic such as hexamine hippurate may be used. Other treatments such as 
anticholinergic or anti-inflammatory medication, local anaesthetics, dimethylsulphone 
(DMSO) and bladder distension have all been tried with varying degrees of success. 
The number of treatment options available provides an indication that few are effective 
in treating this condition which frequently runs a chronic and relapsing course. 
The role of oestrogen in the pathophysiology and treatment of irritative bladder 
symptoms is discussed fully in Chapter six. 
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" Psvchosocial 




(e. g. ) Urinary tract infection 
Detrusor instability (detrusor h)per"reflexia) 
Genuine stress incontinence 
Impaired bladder emptying 
Small capacity bladder 
Chronic cystitis (interstitial cystitis) 
Urethral syndrome 
Intravesical pathology (stones, papilloma, tumour) 
Tuberculosis 
" Gvnaecoloical 
(e. g. ) Pregnancy 
Prolapse 
Pelvic mass (Fibroids, ovarian tumour) 
0 Sexaal 
(e. g. ) Coitus 
Sexually transmitted disease 
" Medical 
(e. g. ) Diuretic therapy 
Congestive cardiac failure 
Impaired renal function 
Neurological disease 
. Endocrine 
(e. g. ) Diabetes mellitus 
Diabetes insipidus 
. Oestrogen deficiency and the menopause 
Table3.5..: Common causes of female urinary frequency and urgency. 
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CHAPTER 4 




When assessing a woman who presents with lower urinary tract symptoms it is important to 
take an accurate history and perform a detailed examination. However, it is now widely 
accepted that there is a poor correlation between a patient's symptomatology and the 
underlying pathophysiology (Bates et al 1970, Cardozo & Stanton 1980, Jarvis et al 1980, 
Lagro-Janssen ct al 1991b). If therapeutic decisions are based on symptoms alone then 
more than 25% of patients may be treated with inappropriate and potentially harmful 
therapy. In this chapter the investigations used for the evaluation of women with lower 
urinary tract symptoms are outlined. 
4.2. BASIC / OFFICE INVESTIGATIONS 
4.2.1. Mid-stream urine (\1SU) sample. 
Urinary tract infection (UTI) may cause or exacerbate urinary symptoms. The results of 
urodynamic investigations will also be invalidated if tests are performed when the patient 
has a UT!. A mid-stream sample of urine must therefore be taken from all women 
presenting with urinary symptoms. A detailed account of urine culture and the role of 
urinary tract infection in postmenopausal women is given in Chapter eight. 
4.2.2. Frequency-volume charts 
While a clinical interview may provide some information on the voiding habits of a patient 
the impression of symptom severity obtained is largely subjective and to some extent 
retrospective in nature. Patients tend to exaggerate their urinary symptoms when giving a 
history (Wyman et al 1988) and their recall of incontinent episodes may not be reliable. 
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The frequency volume chart (also known as a urinary diary) provides an objective 
assessment of a patient's fluid input and urine output. An example of the chart used in this 
thesis is shown in the Appendix. The instructions given to the patients are shown on the 
reverse side. As well as the number of voids and incontinence episodes, the mean volume 
voided over a 24 hour period can also be calculated. Frequency volume charts have the 
advantage of assessing symptom severity in the individual's own environment under 
normal conditions. 
Self monitoring techniques may themselves modify the behaviour they are 
measuring (Verbrugge 1980). however, reported micturition frequency and the number of 
incontinent episodes have been found to be highly reproducible on test-retest analysis 
(Wyman et al 1988, Iarsson & Victor 1988). There is some controversy regarding the 
optimum duration that the charts should be completed for. A balance needs to be reached 
between asking the patient to complete a diary for a long time period, which may possibly 
increase its reliability, and the inconvenience of doing so. Current practice is to ask the 
patient to complete the chart for at least 5 days. Wyman and colleagues (1988) compared 
the results obtained in each weck of a two week diary. There was a strong correlation 
between the two weeks, suggesting that it is acceptable for the patient to complete a diary 
for seven rather than 14 days. Larsson and Victor (1988) studied 151 asymptomatic 
women aged 19-81 )-cars who agreed to complete a frequency volume chart over a 48 hour 
period. The voiding characteristics of the women in this study are shown in Table 4.1.. 
Only 8% had a micturition frequency of eight times or more in 24 hours with a tendency for 
the number of nocturnal micturitions to increase with age. Unfortunately, in symptomatic 
women it is not possible to reliably distinguish patients with genuine stress incontinence 
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from those with othcr urodynamic diagnoses using frequency volume charts alone (Barnick 
1997). 
PARAMETER MEAN SD RANGE 
Frequency / 24h 5.8 1.41 3-11 
Mean volume voided (ml) 250 79 90-610 
Largest single volume voided (ml) 460 174 200-1250 
Table 4.1.: Normal frequency / volume chart data. Adapted from Larsson and Victor 
(1988). Note the large standard deviation and range of the largest single volume 
voided which limits the usefulness of this parameter. 
4.2.3. Pad test 
A simple way of measuring the quantity of urine lost due to incontinence is to compare the 
difference in weight of a perineal pad before and after its use. This is usually done with a 
standardised volume of fluid in the bladder over a predetermined time period. The 
technique is particularly useful in a research setting to objectively study the effectiveness of 
treatments for stress incontinence. However, it was not an appropriate tool for the studies 
in this thesis and therefore it is not considered further. 
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43. SYMPTOM QUESTIONNAIRES AND QUALITY OF LIFE INSTRUMENTS 
Obtaining details of a patient's urinary symptoms and their severity can be done in a 
number of different ways. Taking a history is the most commonly used method in clinical 
practice but the information obtained is largely subjective and open to significant bias. 
Changes in specific symptoms in response to treatment may also be difficult to determine 
particularly if the patient is seen by a number of different clinicians over a long time period. 
This technique is therefore not considered a reliable way to obtain information in a research 
setting. Self completed questionnaires also need to be used cautiously as they rely on the 
patient's full comprehension of the terms used. 
Direct questioning using a structured questionnaire has the advantage that 
information is collected in a systematic and consistent way. Questionnaires of this type are 
often used in conjunction with visual analogue scores (VAS). The format of the VAS used 
in this thesis utilises a straight line 10cm long (Appendix). One end (0cm) represents the 
complete absence of a particular symptom and the other end (10cm) the maximum severity 
of that complaint. The patient is asked to mark on the line their perception of the severity 
of each symptom and a numerical value is determined by measuring the distance in 
centimetres of the mark from the 0cm position (Altman 1991). One of the main 
disadvantages of this system is that few women mark directly on the 0cm position to 
indicate that this symptom is absent, and therefore a falsely high score may be obtained. 
However, VAS arc easily understood by most patients, quick to complete and provide a 
simple objective way to assess both symptom severity and the changes that may occur 
following treatment. 
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It is now widely acknowledged that the impact of urinary symptoms cannot be fully 
described by measures of disease status such as simple questionnaires or the results of 
complex investigations (Kelleher et al 1995, Muldoon et al 1998). Indeed, a poor 
correlation has been found between the subjective degree of bother that symptoms cause 
and objective measures of the degree of urinary incontinence (Wyman et al 1987, 
Ryhammer ct al 1995). Psychosocial factors such as the impact on normal functioning, 
social and personal relationships, emotional wellbeing and satisfaction with everyday life 
also need to be taken into account. Quality of life (QoL) instruments have therefore been 
developed to measure the abstract concept of an individual's perceived level of physical, 
psychological and social wellbeing (Kelleher ct al 1995). There are two main types of QoL 
questionnaire, each containing a number of sections (also known as domains) which focus 
on particular aspects of health. 
Firstly, generic questionnaires (e. g. ) Short Form 36, Nottingham Health Profile and 
the Sickness Impact Profile which measure general health status. These measures have 
been developed to assess overall function and are useful for evaluating the health of 
different populations. Ilowever, they are relatively insensitive measures of the effect 
urinary symptoms on QoL and its improvement after treatment (Kelleher et at 1997). For 
example, there is no strong correlation between stress incontinence and generic QoL, 
although there does appear to be some correlation for urge incontinence (Ilunskaar & 
Vinsncs 1991, Grimby ct al 1993). 
Secondly, disease specific questionnaires (e. g. ) Incontinence Impact Questionnaire 
and King's Health Questionnaire which assess the impact of particular conditions on QoL. 
This type of measure offers greater sensitivity for evaluation of the severity of specific 
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conditions and is therefore more applicable to use in clinical trials. In this thesis the King's 
Health Questionnaire (Kelleher et al 1997) was used to assess the impact of urinary 
symptoms on QoL. The questionnaire and scoring system (Appendix) were generated after 
seven different pilot versions had been tested on over 500 women. There are 30 questions 
divided into eight sections as follows: 
1. General health perceptions. 
2. Urinary symptoms. 
3. Role limitations. 
4. Physical / social limitations. 
5. Personal relationships. 
6. Emotions. 
7. Sleep-energy disturbance. 
8. Incontincncc impact. 
The King's Health Questionnaire has been shown to be a valid and reliable 
instrument sensitive to changes in lower urinary tract symptonatology and useful for 
evaluating treatment outcome. Women of all ages and intellectual ability find it easy to 
understand and urger with over 97% of the women tested by Kelleher (1997) completing 
it correctly. 
QoL is an abstract and highly subjective concept influenced by personal and cultural 
values, goals, age, life cxpcctancy and a broad range of different experiences (Kelleher et al 
1997). While duration of symptoms and quantity of urine lost do not appear to 
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significantly effect QoL scores (W)man et at 1990) the underlying cause of a patients 
urinary complaint is a major factor in predicting the extent of QoL impairment. Detrusor 
instability has a greater overall impact on almost all domains of QoL than genuine stress 
incontinence, presumably because the condition is less predictable in nature and the women 
have less control over their bladder symptoms (Wyman et at 1987, Kelleher et at 1997). 
The main exception to this is the finding that women with genuine stress incontinence have 
higher scores in the domain of incontinence impact. 
4.4. URODYNAMIC INVESTIGATIONS 
4.4.1. Uroilowmctry 
Uroflowmetry is the simple and non-invasive measurement of urine flow. To obtain a 
representative record of flow parameters the woman is asked to void in private when her 
bladder is comfortably full. Several types of flowmeter can be used but the commonest are 
those with either a strain gauge weighing transducer placed under a receptacle into which 
the patient voids or devices with a disk which rotates at a speed dependant upon the flow of 
urine (Cutner 1997). The signals produced are electronically converted and smoothed to 
give visual representation of a patient's urinary flow. A normal flow pattern is shown in 
Figure 4.1.. The maximum flow rate and volume voided are recorded and an estimation of 
the postmicturition residual determined either by catheterisation or using ultrasound. 
In most circumstances in adults a voided volume of less than 150 ml cannot be 
interpreted reliably while flow rates obtained above 500 ml may also be low, perhaps due to 
decompensation as the bladder capacity is reached (Abrams et al 1983). The normal flow 








Time to +1 Time (s) 
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Flow time 
Figure 4.1.: Normal uroflowmctry study with ICS recommended 
descriptive terminology. 
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prolonged void, reduced flow rate and evidence of abdominal straining then it is 
possible that she may have voiding difficulties, particularly if these findings are 
accompanied by a post-micturition residual of more than 50ml. However, it is usually 
necessary to repeat the assessment at least once as some women may develop this 
pattern of voiding if they are embarrassed by the test itself and find it difficult to pass 
urine in unusual surroundings. 
A reduced flow rate simply gives an indication that a woman may have a 
voidiz g problem. However, it gives no information as to whether this is due to an 
impaired detrusor contraction or bladder outflow obstruction. Uroflowmetry is 
therefore often considered in conjunction with a pressure flow study obtained during 
voiding cystometry as described below. 
4.4.2. Cystomctry 
Measurements of bladder pressure and urine flow have been made for several decades 
but with advances in electronic technology and equipment urodynamic investigation has 
assumed greater importance. The aim of cystometry is to reproduce the patient's 
symptoms and give a pathophysiological explanation of her problem. The 
cystomctrogram (CMG) is used to measure several features of bladder behaviour 
including sensation, capacity, compliance, contractility and urethral function. The 
collection of this information has been standardised by the International Continence 
Society (ICS) (Abrams et al 1990). 
Several steps are involved in performing a cystometrogram (CMG): 
1. Insertion of pressure transducers and filling catheter. 
2. Filling cystometry. 
3. Voiding cystometry. 
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In general, the patient should not be taking medication which may affect bladder 
function (particularly anticholinergics) as this may alter the results of the 
cystometrogram and as stated earlier there must be no evidence of urinary tract infection 
4.4.2.1. Insertion of pressure transducers and filling catheter 
Pressure measurements are made by external transducers connected to the patient by 
either solid state transducer catheters or fluid filled catheters (the later are used at 
King's College Hospital). To assess these different components of bladder behaviour 
the following measurements are required: 
1. Intravesical pressure (pves) which is the total pressure in the bladder. 
2. Intraabdominal pressure (pabd) which is taken to be the pressure surrounding the 
bladder. 
3. Detrusor pressure (pdet) which is the component of intravesical pressure created 
by active and passive forces in the bladder wall. It is calculated automatically by 
most urodynamic equipment using the equation: Pdet = pves - pabd 
Almost all units pass a pressure catheter transurethrally into the bladder to 
measure pves and a rectal catheter to measure pabd. A filling catheter is also inserted 
into the bladder at the same time. Urethral catheters do slightly distort the normal 
anatomy (Tessier & Schick 1990), and therefore suprapubic catheters have been 
suggested as a superior alternative (Rollema et al 1990). However, they are more 
painful and difficult to insert and probably associated with higher morbidity than 
pressure catheters inserted transurethrally. It is currently thought that fine fluid filled 
pressure catheters (4.5F) have little clinically significant effect on bladder outlet 
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mechanics, and the larger diameter catheters (12F) which are used for filling the bladder 
are removed before a patient is asked to void at the end of the study. 
To reliably determine detrusor pressure all systems must be zeroed at 
atmospheric pressure and air bubbles must be thoroughly flushed out of the lines prior 
to commencing recording. At the beginning of the study the patient is asked to cough, 
thereby causing a rise in intra-abdominal pressure which is demonstrated by a rise in 
both intravesical and rectal pressure. The rise in pves and pabd should be identical and 
therefore the electronically subtracted pdet will remain flat. To ensure that the pressure 
in the bladder and rectum continues to be recorded satisfactorily during filling checks 
are made at regular intervals, usually by asking the patient to cough after every 100m1 
of fluid has been infused. Similarly, after completing the voiding CMG, before removal 
of the pressure transducers, it is essential to ensure that they have not been dislodged 
during the void and are still recording pressure changes reliably by asking the patient to 
cough once more. 
4.4.2.2. Filling cystometry 
In most units the bladder is filled with fluid which has been stored at room temperature. 
For simple cystometry normal saline is generally used but for those patients where the 
bladder needs to be imaged X-ray contrast (Isopaque) is given instead. This later 
technique is then called videocystourethrography (VCU). In its report the ICS has 
defined bladder filling as fast (>100 ml per minute), medium (10-100 ml per minute) 
and slow (up to 10 ml per minute). It should be noted that even the ICS slow fill rate is 
unphysiological and much quicker than could be expected normally, except under 
extreme diuretic conditions. 
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In this thesis all patients underwent VCU in the X-ray department using a 
standardised technique. After insertion of the filling catheter and pressure lines, and 
measurement of the urinary residual, the bladder was filled with Isopaque at 100 ml per 
minute (using a computer controlled pump) with the woman in the supine position. The 
woman was asked to indicate when she first had a desire to pass urine, and the pressure 
and volume of fluid in the bladder were recorded. Although subjective in nature this 
first sensation to pass urine can then be described as normal, early/reduced if the 
volume in the bladder is less than normal or increased/absent if above the normal range. 
This later finding may be associated with a bladder of large capacity, chronic urinary 
retention or neurological disease although commonly it is idiopathic. Bladder filling 
was continued until the woman had developed a strong desire to void or 500 ml of 
contrast had been infused. The pressure and volume were again noted and recorded as 
the maximum bladder capacity. While it may be possible to fill the bladder beyond a 
volume of 500m1, this may result in unnecessary discomfort for the patient and produce 
artefacts secondary to overfilling. The normal ranges for filling cystometry are shown 
in Table 4.2.. 
PARAMETER RANGE 
Postmicturition residual 0-50m1 
First sensation to void 150-250m1 
Maximum bladder capacity 400-600m1 
Table 4.2.: Normal ranges for filling cystometry. Adapted from Benness (1997). 
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During the filling phase the pressure in the bladder is constantly recorded. In the 
normal physiological state the bladder is a low pressure storage unit and as described in 
Chapter two, the pressure does not normally rise until its absolute capacity is reached. 
This is described as normal compliance and the bladder is regarded as being stable. 
Rapid filling of the bladder during cystometry may produce a rise in detrusor pressure 
which is termed low compliance. In the urogynaecology unit at King's College 
Hospital this is diagnosed when the pressure at the end of filling is greater than 
15cmH2O. As the compliance of the bladder is a function of the change in pressure for 
a change in volume it is important clinically to consider the volume in the bladder when 
the pressure rises above this level. If this finding occurs with less than 350m1 in the 
bladder it is felt to be clinically significant, while small rises at the end of filling may 
simply be regarded as an artefact of the test, particularly if the patient has a large 
bladder capacity. This area is controversial and there is disagreement between different 
units as to its measurement and interpretation. In our unit the pressure at the end of 
filling is considered the most significant. However, sometimes the pressure in a low 
compliant bladder falls a few seconds after filling is stopped, and although the pressure 
is then lower it is still above the normal range. This second measurement is recorded in 
some other centres. 
Causes of reduced bladder compliance include detrusor muscle hypertrophy, 
which may be associated with detrusor instability or bladder outflow obstruction, 
particularly in men in association with prostatic hypertrophy. In women this is most 
commonly seen after surgery for stress incontinence. Hypertrophied muscle is less 
elastic than normal detrusor smooth muscle and also synthesises more collagen, 
resulting in an increase in stiffness. Ageing may also result in partial replacement of 
bladder smooth muscle with collagen. Women with low bladder compliance have an 
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increased incidence of detrusor instability on ambulatory monitoring, suggesting that in 
some women the underlying pathology may be similar if not the same. A schematic 
diagram of a normal cystometrogram and one showing low compliance is shown in 
Figure 4.2.. 
At the end of filling, the filling catheter is removed and the X-ray table rotated 
so that the bladder can be imaged with the patient standing. A series of provocative 
manoeuvres are then performed. This initially takes the form of one, three and then five 
coughs while the bladder is imaged to see if any incontinence occurs. Women who leak 
with the first cough are graded as having severe incontinence, those during a series of 
three coughs moderate leakage and women who only leak at the end of five coughs mild 
incontinence. The grading of incontinence may be changed depending upon the actual 
quantity of urine lost and is not solely dependent upon the timing in relation to the 
provocative tests. If the patient's main complaint is of incontinence and there is no 
demonstrable leakage after coughing, other provocative manoeuvres such as star jumps, 
hand washing and listening to running water may also be necessary to demonstrate 
objective evidence of urinary leakage. It is vital that the detrusor pressure at the time a 
patient is incontinent is noted as this is of prime importance when trying to determine if 
the patient has underlying detrusor instability or genuine stress incontinence as the main 
cause of their problem. 
Detrusor instability (DI) is characterised by involuntary bladder contractions 
which occur during the filling phase. These may be spontaneous or provoked and 
cannot be completely suppressed by the patient. Any associated leakage of urine is 
called urge incontinence. Provocation may include rapid filling, alterations in posture 
or movement such as standing, tap running and coughing. Detrusor instability results in 
phasic contractions, which should be contrasted with altered compliance where the 
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detrusor pressure rises gradually (Figure 4.2. ). There is at present no accepted method 
for quantification of detrusor contractions and it is unclear what the effects of posture 
and filling speed on the detection of detrusor instability are. Originally, it was 
suggested that clinical judgement should be exercised regarding the significance of 
phasic contractions of less than 15cmH2O in amplitude, but currently no lower limit is 
specified (Abrams et al 1990) as the relationship to the patient's symptoms is 
considered to be more important. If detrusor instability is present and there is objective 
evidence of a relevant neurological disorder, the instability may be termed detrusor 
hyperreflexia. A diagnosis of sensory urgency is made when initial catheterisation is 
painful, there is an early first sensation to void and a reduced bladder capacity. 
Although the patient usually complains of urgency during the test there is no rise in 
detrusor pressure. 
Genuine stress incontinence (GSI) is the involuntary loss of urine which occurs 
in the absence of a detrusor contraction. This is normally demonstrated during the 
provocative manoeuvres at the end of filling cystometry. Typically, such loss of urine 
occurs instantaneously and examination of the subtracted detrusor pressure should 
confirm that there is no associated cough induced detrusor instability before making the 
diagnosis of GSI. 
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Figure 4.2.: Cystometrogram patterns of filling detrusor pressure. 
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4.4.2.3. Voiding cystometry 
Having performed filling cystometry the CMG is completed with a voiding study. As 
previously indicated the filling catheter is removed prior to voiding to prevent any 
unnecessary urethral obstruction. The intravesical and rectal pressure recording lines 
are left in situ, allowing simultaneous measurement of detrusor pressure along with 
urine flow. As with uroflowmetry, the patient is asked to void while sitting on a 
flowmeter in private. 
During normal voiding there is a co-ordinated contraction of the bladder and at 
the same time relaxation of the urethra which is sustained until the bladder is empty. 
Women normally void with a detrusor pressure rise of less than 60cmH2O and a peak 
flow rate of > 15ml/s for a voided volume of at least 150ml (Benness 1997). Some 
women have an excellent flow of urine with little or no rise in detrusor pressure which 
is simply a reflection that the contraction has occurred in the presence of low outlet 
resistance. However, if the detrusor pressure during voiding is reduced with low flow 
rates and a significant post-micturition residual the patient is classified as having a 
voiding dijjlculty. In women, voiding problems are rarely due to bladder outflow 
obstruction and much more likely to be secondary to impaired detrusor contractility. 
Bladder outflow obstruction is characterised by a low flow rate and raised detrusor 
pressure during voiding. The patient may also be seen to use additional abdominal 
straining to try and improve the intravesical pressure. The situation is further 
complicated by the fact that in some women with outflow obstruction the detrusor 
decompensates with time, resulting in both a low detrusor pressure and low flow rate 
(Cutner 1997). Pressure flow measurements can be plotted graphically but the use of 
this technique in urogynaecological practice is not established and therefore not 
included in this review. 
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In some women, and particularly those with overt neurological disease, 
pathological contraction of the external sphincter occurs during a bladder contraction. 
This is termed detrusor sphincter dyssynergia (DSD). Characteristically there is a high 
detrusor pressure during voiding associated with a poor flow rate. In some women 
urinary retention may occur and catheterisation is therefore necessary. It must be 
remembered that both sphincteric relaxation and initiation of voiding are subject to 
powerful cortical influence, so the results of urodynamic investigation may be 
confounded by embarrassment or an unfamiliar testing environment. Most patients are 
able to pass urine at the end of the study, but their inability to do so does not necessarily 
indicate a functional abnormality. Some women will subsequently have free flow rates 
and residual urine assessments which indicate normality. 
At King's College Hospital almost all women presenting with lower urinary 
tract symptoms undergo videocystourethrography at their first clinic appointment. 
While this enables an early accurate diagnosis to be made, it is recognised that for many 
patients it is an embarrassing investigation with approximately 27% of women also 
fording the procedure painful (Gorton & Stanton 1999). In addition, there is a small 
(approximately 2%) risk of causing a urinary tract infection (Walter & Vejlsgaard 
1978). To try and reduce this risk women are advised to increase their fluid intake in 
the 48 hours after urodynamic investigation. Cystometry has been criticised as being 
unphysiological. For this latter reason ambulatory urodynamics have been introduced. 
However, this investigation was not used in this thesis and therefore it is not described 
further. 
86 
4.4.3. Urethral pressure profilometry 
The resting urethral pressure profile (UPP) is a graphical record of pressure within the 
urethra at successive points along its length. A number of measurements can be taken 
as shown in Figure 4.3., allowing an objective comparison of urethral function both 
between patients and also before and after different treatments. Although the concept of 
measuring the UPP appears physiological there is considerable uncertainty regarding its 
predictive value. Several authors have shown significant differences in urethral 
parameters between stress incontinent and continent women (Hilton & Stanton 1983a, 
Bump et al 1988). However, the standard deviation of values around the mean is so 
large that the degree of overlap between continent and incontinent women severely 
limits its clinical usefulness. 
The following technique was used to obtain a urethral pressure profile from the 
women in this thesis. After cystometry had been completed, the patient was asked to lie 
supine on the X-ray table. The bladder was again filled to 250m1 with normal saline 
using a urethral filling catheter, which was then removed. A catheter mounted solid 
state pressure transducer was then passed into the bladder with the two transducers 
(which are 6cm apart) directed to the 9 `o'clock position. Both intravesical pressure and 
urethral pressure were recorded simultaneously to ensure that any changes in urethral 
pressure were not caused by an abnormal detrusor contraction. The catheter was 
withdrawn at a set speed and the procedure repeated to ensure the reproducibility of the 
profile obtained. 
Finally, after the catheter had again been reinserted the patient was asked to give 
a series of coughs at one second intervals as the catheter was withdrawn to obtain a 
stress urethral profile. The principle of this test is to measure the pressure transmission 
ratio (PTR) from the abdominal cavity to the urethra. Pressure transmission ratios 
87 
provide a dynamic assessment of the response of the urethra to raised intra-abdominal 
pressure. In women with genuine stress incontinence the pressure transmitted to the 
urethra is often inadequate. However, as with the resting urethral pressure profile the 
specificity of the PTR is poor (Versi 1990, Rosenzweig et al 1991). The PTR is 
calculated using the formula: 
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OESTROGEN, THE MENSTRUAL CYCLE 
AND THE MENOPAUSE 
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5.1. OESTROGEN 
The three natural oestrogens in women are oestrone (E1), oestradiol (E2) and oestriol 
(E3), all derivatives of the basic cyclopentophenanthrene steroid nucleus (Figure 5.1. ). 
Oestrogens may circulate in three forms: 
1. Free 
2. Protein bound 
3. Conjugated 
Free oestrogens are lipophilic, freely traverse cell membranes and are therefore 
biologically active. Over 95% of circulating oestrogens are protein bound, primarily in 
a complex with albumin or sex hormone binding globulin (SHBG), and presumed to be 
biologically inactive. Oestrogens are conjugated in the liver as sulphates or 
glucoronates, which are water soluble and excreted in the urine or bile. 
Free oestrogens exert their metabolic effect by binding to high affinity oestrogen 
receptors in the nucleus of the target cell (King & Greene 1984, Welshons et al 1984). 
The hormone receptor complex initiates the production of messenger RNA (mRNA) 
and protein synthesis is observed several hours following oestrogen administration. The 
potency of a specific oestrogen depends primarily on the length of time the steroid 
receptor complex occupies the nucleus of the target cell. Of the natural oestrogens, 
oestriol exhibits the shortest occupancy of the nucleus (1-4 hours) and is therefore 
considered to be a "weak oestrogen" if given in a single dose. The other natural 
oestrogens exhibit an intermediate nuclear retention of 6-24 hours (Clark et al 1978). 
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ovarian follicular development ceases. Oestrone is the main oestrogen found after the 
menopause and is produced by conversion of adrenal androgens in peripheral fat. 
The relative potency of the various oestrogenic preparations clinically available 
is determined by multiple factors including the dose and route of administration, the 
efficiency of absorption and metabolic clearance, and the particular system or effect 
under evaluation. This is considered in more detail later in this chapter. As well as an 
action mediated through oestrogen receptors, recent work has also suggested that 
oestrogens may have a direct (non-genomic) mechanism which is outlined in Chapter 
six. 
5.1.1. Measurement of serum oestradiol 
In this thesis serum oestradiol was measured using a Heterogeneous Competitive 
Magnetic Separation Assay (MSA). Blood samples were taken by myself with the 
analysis being performed by laboratory technicians, as the instrumentation required 
could only be operated by trained staff in the Department of Biochemistry at Kings 
College Hospital (Personal Communication, Dr R Sherwood, Principal Biochemist, 
Kings College Hospital). The assay has a range of 30 - 13 212 pm/L. To ensure 
accuracy internal controls are analysed at regular intervals throughout the day. In 
addition, every month five control samples are received from an external laboratory. A 
satisfactory level of performance is achieved when the analyte values obtained for each 
control are within acceptable control ranges (normally +/- 2 standard deviations of the 
assigned value). 
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5.2. THE MENSTRUAL CYCLE 
The human menstrual cycle is under the control of follicle stimulating hormone (FSH) 
and luteinizing hormone (LH) secreted from the anterior pituitary gland. FSH, as its 
name suggests, is responsible for the early stimulation and growth of ovarian follicles. 
LH may contribute to follicular growth and oestrogen production but its principle 
actions are to cause ovulation and convert the ruptured Graafian follicle to a corpus 
luteum. FSH and LH are glycoproteins with a molecular weight of about 30 000. Each 
consists of two non-identical subunits - alpha and beta. The alpha unit is similar in all 
pituitary glycoproteins and human chorionic gonadotrophin (HCG). The beta units 
differ and give individual hormones their specificity. 
FSH and LH are produced during reproductive life in a rhythmic fashion (known 
as the menstrual cycle) and interact with ovarian hormones to produce regular ovulation 
(Figure 5.2. ). The level of each of these hormones is dependant upon several 
mechanisms of feedback control. At the beginning of the menstrual cycle, FSH 
production is allowed to rise by the fall in oestrogen production from the previous 
waning corpus luteum (Johnson & Everitt 1984). As the FSH level rises many ovarian 
follicles respond (perhaps as many as 1000 per cycle) but only one, or rarely two, fully 
develop and go on to ovulate. The rest undergo atresia at an early stage. During the 
early follicular phase, secretion of ovarian steroids is at a relatively constant and low 
level. Then as the follicle develops, ovarian secretion of oestradiol increases slowly at 
first then more rapidly to reach a peak on the day before the LH peak. There is a rapid 
rise in the level of LH which leads to final maturation of the follicle and ovulation some 
24-36 hours later. 
At the time of the LH surge there is a sharp fall in plasma oestradiol level and 
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Figure 5.2.: Diagrammatic representation of changes in hormone levels, 
the ovary and the endometrium during the normal menstrual cycle. 
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of the luteal phase of the menstrual cycle is the secretion of progesterone, which reaches 
a maximum about 8 days after the LH peak. There is also a parallel but smaller increase 
in oestradiol levels. As the steroids increase, LH and FSH gradually decline, the FSH 
rising again at the end of the luteal phase to initiate the growth of the next follicle if 
fertilisation of the ovum and a pregnancy do not occur. 
Women having regular menstrual cycles (frequency of 23-35 days, with no more 
than 2-3 days variation each month) have a greater than 95% chance that they are 
ovulating (Baien & Jacobs 1997). They will therefore experience the characteristic 
hormonal changes outlined above with a pre-ovulatory follicular phase of oestrogen 
dominance and a post-ovulatory luteal phase of progesterone dominance. 
5.3. THE MENOPAUSE 
Ovarian function starts to decline from as early as the 20th week of embryological life 
with oestrogen production falling to a critical level at the menopause. The problems of 
the "climacteric" have existed for centuries but according to a historical review it was 
not until 1816 that De Gardanne coined the term "La Menespausie" from the Greek men 
(month) and pausis (cessation) (Wilbush 1979). Aristotle (384-322BC) recognised that 
menstruation normally stopped around the age of 40 years but some women could 
continue with their periods until their 50th year. In the 17th century less than a third of 
women lived to experience the menopause. However, an increase in life expectancy in 
the twentieth century means that most women will spend a third of their adult life in the 
postmenopausal years. 
The average age of the menopause is now generally accepted to be 
approximately 51 years, but some variation exists between different countries and 
geographical regions (Report of a WHO Scientific Group 1994). Population predictions 
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indicate that the 467 million postmenopausal women in the world in 1990 will have 
increased to 1200 million by 2030 (Hill 1996) (Figure 5.3. ). Postmenopausal women 
make up over 15% of the population in industrialised countries with a growth rate of 
1.5% predicted until the 2020's. 
Serum FSH levels rise throughout the fifth decade of life and LH levels have 
been reported to increase as women approach the age of 50 (Lenton 1988). By 2-3 
years after the last menstrual period, serum FSH levels have increased in value to 10-15 
times higher than follicular phase levels in young women, and LH levels are about 3 
times higher (Chakravarti 1976). A major change in the source and nature of circulating 
oestrogens occurs after the menopause. Quantitatively, the most important circulating 
oestrogen is oestrone (rather than oestradiol which is predominant premenopausally), 
with serum levels averaging about 100 pmol/L. Most of the oestrone is derived from 
the extraglandular conversion of adrenal androgen precursors, particularly 
androstenedione. Serum oestradiol levels after the menopause are generally less than 
150pmoVL compared with a late premenopausal mean of 550 pmol/L. 
The menopause is associated not only with a cessation of menstrual periods but 
also a wide range of symptomatic and pathophysiological changes. These include hot 
flushes, night sweats, loss of energy, ischaemic heart disease, osteoporosis and 
urogenital atrophy. The role of oestrogen deficiency in the pathogenesis urogenital 
complaints and the use of oestrogen replacement therapy for the treatment of these 
conditions is considered in detail in Chapter six. 
A number of non-hormonal treatments have been used to treat menopausal 
problems with varying degrees of success. Galen (AD131-201) advised phlebotomy so 
that any "retained poisons" may be released and the use of purgatives and the 
application of leaches were popular in the sixteenth century. In 1777 John Leake 
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recommended "where the patient is delicate and subject to female weakness, night 
sweats or an habitual purging, with flushing in the face and a hectic fever: for such; ass's 
milk, jellies and raw eggs, with cooling fruits. At meals she may be indulged with half 
a pint of old, clear London porter, or a glass of Rhenish wine". In modern times 
treatments other than Hormone Replacement Therapy (HIRT) often only serve to 
manage a particular symptom. Sedatives and tranquillisers have been prescribed for 
many women but unfortunately they only add to the lethargy and general loss of interest 
in life which may accompany the menopause. Clonidine (Clayden et al 1974, Lindsay 
& Hart 1999), propanolol (Alcoff et al 1981), methyldopa (Tulandi et al 1984) and 
naproxen (Haataja et al 1984) have all been used, mainly for the treatment of vasomotor 
symptoms, with conflicting results. Unfortunately, all are associated with side effects. 
It has been recognised for some time that many hundreds of plants contain 
phytoestrogens, naturally occurring substances with some degree of oestrogenic activity 
(Bradbury & White 1954, Price & Fenwick 1985). Legumes are particularly rich in 
oestrogenic isoflavones while cereals contain oestrogenic lignans. Women living in 
Pacific rim nations eating a diet rich in soy experience less severe menopausal 
symptoms, whilst several chronic illnesses of menopausal women including breast 
cancer, colon cancer and cardiovascular disease have a much lower incidence than in 
Western countries (Morton & Griffiths 1998). Further work is required to establish the 
true benefit of phytoestrogens for women with established oestrogen deficiency. 
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5.4. HORMONE REPLACEMENT THERAPY 
Brown-Sequard (1889) is credited with pioneering the concept of HRT (O'Dowd & 
Philipp 1994). He reported the rejuvenating effects of injections of testicular extracts 
and postulated that ovarian extract would have the same effect. Two years later Murray 
developed the first effective form of HRT when he administered oral thyroid gland to 
treat myxoedema. The first three clinical trials of dried or fresh ovarian tissue to treat 
climacteric symptoms were published in 1896 and in 1912 Adler produced the changes 
of oestrus by injecting watery extracts of ovary into virgin animals. However, it was 
not until 1923 that Allen and Doisy isolated the ovarian hormone oestrogen. The first 
commercial preparations of HRT were based on the work of Zondek and Laquer and 
became available in 1926. Premarin, derived from pregnant mare's urine, was 
introduced in 1943 and is probably the most widely used preparation. The publication 
of Feminine Forever in 1966 brought HRT to the attention of the public with many 
demanding that it should be a NHS benefit. General Practitioners however were 
initially divided with some prescribing it enthusiastically and others being completely 
dismissive. 
Oestrogen replacement therapy can be administered orally, transvaginally, as a 
subcutaneous implant or through the skin as a percutaneous patch, cream or gel. There 
are a large and increasing number of preparations available. The classes most 
commonly prescribed are natural, synthetic and conjugated equine. Of these, synthetic 
oestrogens are primarily used for contraceptive purposes and include ethinyl oestradiol. 
Natural and conjugated equine oestrogens are primarily prescribed for hormone 
supplementation. The primary equine oestrogen is equilin sulfate, this consisting of 
33% of conjugated oestrogen. 
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The role of HRT and the advantagestdisadvantages of different preparations for 
the treatment of osteoporosis, ischaemic heart disease and other conditions related to the 
menopause is beyond the scope of this review. However, the use of oestrogen and 
progesterone to treat urinary symptoms is outlined in Chapter six. 
When serum concentrations of sex steroids are measured at short time intervals 
after administration or repeatedly during long term treatment it is clear that there are 
significant intra-individual and inter-individual variations (Kuhl 1990). Large 
fluctuations in oestradiol and oestrone level can be observed in an individual women 
from day to day or even from hour to hour. However, even with this in mind each type 
of oestrogen preparation has a characteristic pharmacokinetic profile (Figure 5.4. ). 
5.4.1. Oral oestrogen 
The most commonly prescribed method of oestrogen administration is the oral route. 
Oestradiol is preferentially converted to oestrone in the gastrointestinal tract (Ryan & 
Engel 1953), and then the portal system transfers the absorbed steroid to the hepatic 
system. Typically, an oestrone : oestradiol ratio of 4: 1 is achieved with oral therapy 
instead of the physiological ratio of 1: 2 which occurs in premenopausal woman (Kuhl 
1990). In the liver glucoronidation occurs so much of the oestrogen is metabolised and 
inactivated before the systemic circulation is reached - this is known as the "first pass" 
effect. As a consequence of these effects oral oestrogens need to be given at higher 
doses than parenteral oestrogens in order to achieve the same symptomatic relief (Studd 
& Barber 1992). Oral oestrogens are more potent than those given peripherally in 
elevating HDL cholesterol, thereby increasing the HDL/LDL ratio with the consequent 
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Figure 5.4.: Serum concentrations of oestradiol and oestrone after oral, 
percutaneous and subcutaneous administration of oestradiol, according 
to Kuhl (1990). 
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5.4.2. Transdermal and Percutaneous oestrogen 
Skin patch delivery systems are usually called transdermal as the drug reservoir 
remains outside of the skin. A number of differently constructed skin patches have been 
studied but only two are widely used in clinical practice: reservoir and matrix patches. 
Reservoir patches contain oestradiol in a gel with a small amount of alcohol as a flux 
enhancer, enabling penetration through the skin barrier. Oestradiol is released 
continuously through a rate limiting membrane, when the system is applied directly to 
the skin, for approximately 3.5 days after which a new patch is applied (Kuhl 1990). 
Several combination oestrogen-progestogen patches are now available and are preferred 
by many women to the standard oestrogen patch-oral progestogen regime. Side effects 
are relatively minor, the most common adverse effect being skin irritation occurring in 
approximately 15-40% of women (Fraser & Wang 1998). 
In the matrix patches, the oestrogen is evenly dispersed as a micronised 
suspension in a very thin adhesive matrix which is protected by a backing membrane of 
flexible translucent polyurethane film. The rate of drug delivery is controlled by 
diffusion through the skin, rather than by use of a rate limiting membrane as in the 
reservoir patches, and the absence of alcohol results in a very different pharmacokinetic 
behaviour. The rate of drug delivery from the system is relatively constant over the 
entire application period, resulting in less fluctuation of the plasma oestradiol level. 
New 7-day matrix patches are now available which tend to maintain a more constant 
blood hormone level than the traditional twice weekly patches. 
In the past few years a number of percutaneous oestrogen gels have been 
developed which are now available in clinical practice. The gel is generally applied to 
the lower abdomen, arms or shoulder once daily. Unfortunately, absorption is 
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dependant upon the surface area of application and the intensity that it is rubbed in, 
leading to considerable inter-individual variation in the systemic levels achieved. 
Oestrogen can also be given vaginally by tablet, cream or intravaginal ring but 
this method of delivery is often reserved for women with atrophic vaginitis. It may also 
have a role for prophylaxis against recurrent urinary tract infection in postmenopausal 
women and this is discussed further in Chapter eight. 
5.4.3. Oestradiol implants 
The use of subdermal implants has been advocated as a simple method of giving 
oestradiol for over 40 years. This form of HRT has the advantage that it is safe and 
simple to administer (usually every 6 months), has a long duration of action 
(approximately 5-12 months) and relatively stable absorption. In addition, first pass 
metabolism is avoided. From a research point of view, giving a woman an oestradiol 
implant rather than another form of HRT ensures compliance with treatment. 
After insertion of an implant into the subcutaneous fat, oestradiol is released 
from this depot in small daily amounts. The release rate and resulting serum oestradiol 
levels depend primarily on the surface area of the implants (Studd & Magos 1987). The 
dimensions of the oestradiol implants commonly used in clinical practice are shown in 
Table 5.1.. The mean oestradiol levels generally reach their maximum within the first 
month and thereafter show a gradual decline. This trend was observed in the study 
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5.5. SAFETY OF UNOPPOSED OESTROGEN THERAPY 
Many women feel that the main advantage of reaching the menopause is the cessation of 
menstruation. It is therefore not surprising that the resumption of vaginal bleeding 
associated with HRT is a major cause of dissatisfaction with this type of treatment. For 
postmenopausal women staring a 28 day sequential oestrogen and progestogen regimen 
the bleed is usually similar to or slightly less than previous menstruation, although 5% 
may not bleed at all (Sturdee 1998). 
When HRT was introduced, unopposed oestrogen was commonly given to 
women with a uterus. In 1979 only 6% of HRT preparations prescribed in the UK 
contained a progestogen (Thom et al 1979). This in part was because of the favourable 
bleeding pattern associated with unopposed oestrogen therapy compared to HRT which 
also contains a progestogen; with oestrogen only HRT approximately 23% of women 
will not have any vaginal bleeding, 48% will have regular bleeds and only 29% will 
have an irregular cycle (Sturdee et al 1978). 
The main problem with long term unopposed oestrogen is the significant risk 
that the patient will develop endometrial hyperplasia, a known precursor of endometrial 
carcinoma. Relatively little information is available on the background prevalence of 
endometrial hyperplasia, but some reports suggest it may be present in up to 5% of 
postmenopausal women who do not use HRT (Archer et al 1991). Unopposed 
oestrogen therapy is associated with an incidence of hyperplasia of 15-50%, depending 
upon the dose and duration of therapy used, and an increased risk of endometrial cancer 
up to 6 fold (Paterson et al 1980, Schiff et al 1982, Whitehead 1987). A recent review 
(Herrington & Weiss 1993) and meta-analysis (Grady et al 1995) have been undertaken 
to evaluate the risk of endometrial carcinoma with HRT. Herrington assessed 18 studies 
and found that unopposed oestrogen therapy for greater than 5 years increased the risk 
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of endometrial cancer by a factor ranging between 1.8-36. Grady identified 30 
controlled studies and found that unopposed oestrogen elevated the relative risk 2.3 
fold, with prolonged therapy of greater than 10 years increasing the relative risk to 9.5. 
Six studies reported that the relative risk of developing endometrial carcinoma when 
oestrogen alone was used for six months or less was negligible (range 0.6-1.4). 
When deciding upon a suitable treatment interval for the placebo controlled trial 
reported in Chapter 12 a balance needed to be achieved between giving oestrogen for 
an adequate period of time without jeopardising patient safety. In view of the reported 
data a treatment period of six months was felt to be ethically acceptable, providing the 
endometrium was assessed at the start of the trial. It is unknown whether six months is 
an adequate period of time to observe maximal therapeutic benefit of oestrogen therapy 
for urinary symptoms, but if no benefit had been achieved after this period then few 
women would find HRT an acceptable way of managing their urinary complaint. The 
action of progestogens counteracts the proliferative effect of oestrogens on the 
endometrium and the concurrent use of a progestogen has been shown to significantly 
reduce the risk of endometrial hyperplasia. When added for seven days the risk of 
endometrial hyperplasia is reduced to 4%, with 10 days of progestogen 2% and with 12 
days 0% if given at an adequate daily dosage (Sturdee et al 1978). It was therefore 
decided to treat women developing vaginal bleeding during the study with an oral 
progestogen. 
During the study reported in Chapter 12 those women randomised to oestrogen 
received unopposed therapy, regardless of whether they had a uterus or not. This was 
done for the following reasons: 
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1) Progestogens may adversely effect lower urinary tract function, as outlined in 
Chapter six and investigated further in Chapter nine. Progestogens are associated 
with irritative bladder symptoms (Cutner et al 1993) and incontinent women taking 
HRT have been shown to loose more urine during the progestogenic phase of their 
treatment (Benness et al 1991). Therefore, the concurrent use of a progestogen 
introduces a confounding variable into the analysis which would make interpretation 
of the efficacy of oestrogen problematic, particularly in view of the unknown 
magnitude of the progestogenic effect. 
2) If a progestogen had been administered on a monthly basis those women being 
treated with oestrogen would have had a withdrawal bleed, rapidly unblinding the 
trial. An alternative to this would have been only to include hysterectomised 
women, but it was felt that sufficient numbers would not be recruited from a single 
centre over the time span of this thesis to produce a study with sufficient statistical 
power. Therefore, it was decided to treat the women with unopposed 25mg 
oestradiol implants. This relatively low dose implant was chosen to try and 
minimise the effects of on the endometrium while providing an adequate therapeutic 
dose of oestradiol. 
5.5.1. Endometrial assessment 
Transvaginal ultrasonography is now a widely used technique for the evaluation of the 
endometrium as it is less invasive than performing a Dilatation and Curettage (D & C) 
or taking an endometrial pipelle (Lindgren et al 1999). In untreated postmenopausal 
women an endometrial thickness <4mm has rarely been found to be associated with 
significant pathology. Using this cut off level an endometrial abnormality is found in 
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less than 1% of asymptomatic postmenopausal women. This technique was therefore 
used for the baseline assessment of the endometrium in the study presented in Chapter 
12. When HRT is given the endometrial thickness frequently increases and a cut off 
level of 4mm is therefore no longer appropriate as it may lead to unnecessary biopsies 
being performed. In a study of 564 climacteric women taking HRT Lindgren and 
colleagues (1999) found that 53% of the women had an endometrial thickness of >4mm 
on ultrasound. 
In those patients with a thickened endometrium or unexplained vaginal bleeding 
endometrial sampling is necessary so that histological evaluation can take place. An 
accepted alternative to the traditional D&C is the use of a Pipelle sampler (Cornier 
1984). This device has a flexible polypropylene outer sheath with an external diameter 
of 3.1mm which is gently pushed through the cervix to the uterine fundus. An inner 
piston is withdrawn to the end of the sheath, so applying negative pressure, and the 
Pipelle rotated with a gentle "to and fro" movement. The device has been found to 
produce an adequate sample in both premenopausal and postmenopausal women with 
95-100% of carcinomas being detected (Fothergill & Brown 1992, Batool et al 1994). 
As with all blind sampling techniques it is important not to be reassured by non-specific 
reports arising from an inadequate specimen. In this situation the options are to either 
repeat the Pipelle sampling or perform a formal D&C. If scanning is employed, one 
reduces the likelihood of missing endometrial pathology such as polyps. Furthermore 
by having a cut off of an endometrial thickness of 4mm in untreated women, many 
potentially inadequate samples are avoided and the sensitivity of the biopsy technique 
increases (Goldchmit et al 1993). In summary, transvaginal ultrasound was performed 
to assess the endometrium in this thesis, with an endometrial biopsy being taken using a 
Pipelle sampler or D&C when necessary. 
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CHAPTER 6 
OESTROGEN AND THE FEMALE 
LOWER URINARY TRACT 
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6.1. INTRODUCTION 
Oestrogen has an important role in the function of the female lower urinary tract 
throughout adult life. Sex steroid receptors have been located in areas of the brain 
involved in the initiation and control of micturition as well as tissues of the bladder, 
urethra and pelvic floor. Fluctuations in the circulating level of oestrogen and 
progesterone are thought to be responsible for changes in the prevalence of urinary 
symptoms and the results of urodynamic investigations which occur during the 
menstrual cycle and in pregnancy. In addition, there is epidemiological evidence from 
several studies implicating the menopause and subsequent oestrogen deficiency in the 
pathogenesis of a number of urinary complaints including incontinence, the "arge 
syndrome" and recurrent urinary tract infections. Oestrogen has been used widely to 
treat urinary symptoms in postmenopausal women but there are relatively few 
randomised studies which makes it difficult to draw accurate conclusions about its true 
efficacy. The aim of this chapter is therefore to critically review the role of oestrogen in 
the pathogenesis and treatment of lower urinary tract dysfunction. 
6.2. THE EFFECT OF OESTROGEN ON THE FEMALE LOWER URINARY 
TRACT 
For a woman to remain continent urethral pressure must exceed the intravesical pressure 
at all times except during micturition (Abrams et al 1990). As described in Chapter 
two, this effect is maintained by the complex interaction of neurological and muscular 
factors in conjunction with a variety of different pelvic fascial supports, particularly of 
the urethra. Oestrogen influences the female lower urinary tract and continence 
mechanism in a number of important ways. Sex steroids appear to be involved in the 
neuronal control of the continence mechanism and evidence is emerging that hormones 
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may have a direct (non-genomic) effect on detrusor smooth muscle function. In 
addition, the functional layers of the urethra which help to maintain a positive urethral 
closure pressure (epithelium, vasculature, muscle and connective tissue) all appear to be 
target sites for oestrogens. 
6.2.1. Neuronal control 
During a woman's reproductive life gonadal steroids interact with neurotransmitters and 
neuropeptides at the hypothalamic level modifying the synthesis and release of 
gonadotrophin-releasing hormone (GnRH). It is now clear that oestrogens are also of 
critical importance in a number of other cerebral functions including pain control, 
thermoregulation, mechanisms such as hunger and thirst, and psychological well being. 
Oestrogen receptors are found throughout the brain cortex, limbic system, hippocampus 
and cerebellum (Maggi & Perez 1985, Smith 1993). In these regions oestrogens are 
able to alter the synthesis, release and metabolism of neurotransmitters such as 
dopamine, acetylcholine, serotonin and melatonin. This may explain why oestrogens 
can improve cognitive function and enhance mood in the perimenopausal and 
postmenopausal period (Schneider et al 1977, Sherwin 1988, Ditkoff et al 1991, Best et 
al 1992). 
Recent animal studies have shown that androgen receptors are present in the 
pontine micturition centre (Blok & Hofstege 1998). They are also found in the preoptic 
area of the hypothalamus, an area of the forebrain which may play an important role in 
the initiation of micturition. Further work is required to establishhe exact type and 
distribution of sex steroid receptors in the human micturition pathways and their 
importance in the control of the continence mechanism. 
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6.2.2. Bladder 
Oestrogen receptors are not found in the transitional epithelium of the bladder apart 
from in areas of the trigone which have undergone squamous metaplasia (Wilson et al 
1984, Wolf et al 1991, Blakeman et al 1996a). However, oestrogen has a direct (non- 
genomic) effect on detrusor function which is thought to be secondary to modifications 
in muscarinic receptors (Shapiro 1986, Batra & Anderson 1989, Elliott & Castleden 
1994) and inhibition of movement of extracellular calcium ions into muscle cells 
(Elliott et al 1992a). Animal studies have shown that oophorectomy alters the pressure 
flow characteristics of micturition in the female rat (Diep & Constantinou 1999). This 
effect may only be partly reversed by oestrogen supplementation and is possibly age 
dependent. It is at present unknown if similar effects occur in humans. Oestradiol 
reduces the amplitude and frequency of spontaneous rhythmic contractions, which have 
been associated with detrusor instability (Shenfield et al 1998), and in vivo oestrogen 
pre-treatment reduces the contractile response of isolated rat detrusor muscle (Elliott et 
al 1992b). There is also some evidence to suggest that in women the sensory threshold 
of the bladder may be raised by oestrogen supplementation, allowing patients to hold 
more urine before they need to void (Fantl et al 1988). 
6.2.3. Urethra and pelvic floor 
The female lower urinary and genital tracts have a common embryological origin, both 
arising from the primitive urogenital sinus (Chapter two). It is therefore not surprising 
that oestrogen receptors are consistently expressed in the squamous epithelium of the 
bladder trigone, urethra and pubococcygeus muscle of the pelvic floor as well as the 
vagina (Iosif et al 1981, Ingelman-Sundberg et al 1981, Smith 1993, Blakeman et al 
1996a). The "classical" oestrogen receptor (ERa) was discovered in 1958 (Enmark & 
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Gustafsson 1999). For many years it was considered that only one type of oestrogen 
receptor existed. However, in 1996 a second oestrogen receptor was isolated, now 
recognised as oestrogen receptor ß (ER ß)(Kuiper et al 1996). This fording suggests 
that the mechanisms behind the effects of oestrogen are far more complicated than 
previously assumed, with possible different physiological roles for each oestrogen 
receptor subtype. At present there are only very limited published data on the different 
types of oestrogen receptor in the urogenital tract (Chen et al 1999). Preliminary work 
suggests that while ERa is consistently found in both the vaginal wall and uterosacral 
ligaments, ERP expression is more variable and may be dependant upon menopausal 
status. Further work is awaited with interest. 
A number of authors have shown that oestrogen increases urethral closure 
pressure and improves pressure transmission to the proximal urethra, effects which 
probably occur by a combination of different mechanisms (Rud 1980, Hilton & Stanton 
1983b, Bhatia et al 1989, Karram et al 1989). In response to oestrogen there is an 
increase in cell cycle activity and an improved "maturation index" of the urethral 
epithelium (Samsioe et al 1985a, Bergman et al 1990, Blakeman et al 1996b) with 
similar changes also occurring in the in the vagina of postmenopausal women (Smith 
1976, Semmens et al 1985). Alterations in urinary cytology during the menstrual cycle 
are comparable with those seen in vaginal cytology (McCallin et al 1950), changes 
which can also be identified in the urinary sediment following treatment with 
oestrogens (Soloman et a! 1958). 
The vasodilatory effects of oestrogens which occur in the systemic and cerebral 
circulations also take place in the female urethra (Ganger et al 1991, Penotti et al 1997, 
Jackson & Vyas 1998). Versi and Cardozo (1986) have shown that vascular pulsations 
seen on urethral pressure profilometry (UPP), secondary to blood flow in the urethral 
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submucosa and urethral sphincter, increase in size in response to oestrogen. Attempts 
have been made to quantify changes in urethral blood flow in response to oestrogen 
therapy using Doppler ultrasound (Jackson et al 1997). Unfortunately, difficulties in 
imaging the same vessel repeatedly and natural variation in blood flow through pelvic 
vessels limit the reproducibility of the technique. 
Oestrogen sensitises the alpha-adrenergic receptors in the urethral sphincter and 
therefore may contribute to its muscular tone (Screiter et al 1976). 
Connective tissue metabolism and production of collagen is stimulated by 
oestrogens, therefore possibly reversing the reduction in total vaginal and periurethral 
collagen which is associated with genuine stress incontinence and genitourinary 
prolapse (Jackson et al 1996, James et al 1999a, James et al 1999b). Evidence is 
emerging that these conditions are both associated with a systemic change in 
collagenase activity (Kushner et al 1999). However, studies are still required to 
determine if prophylactic treatment with hormone replacement therapy or other 
medications will be sufficient to prevent their development, particularly in view of the 
fact that both have a multifactorial aetiology. 
The oestrogen status of the patient can therefore have a significant effect on 
urethral pressure (Rud 1980), and this may be particularly important when there is 
already a degree of weakness. 
6.3. THE EFFECT OF PROGESTOGENS ON THE FEMALE LOWER 
URINARY TRACT 
Progesterone receptors are expressed inconsistently in the lower urinary tract and may 
be dependent on the oestrogen status of the woman (Batra & losif 1987, Blakeman et al 
1996a). Unfortunately, there is very little data on the physiological effects of 
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progesterone on the lower urinary tract outside pregnancy but in general progestogens 
have an adverse effect on the bladder and urethra. The physiological hydroureter of 
pregnancy is thought to arise from a combination of both mechanical and hormonal 
factors. The relative contribution of each is uncertain but progesterone does cause some 
degree of relaxation of ureteric smooth muscle both in-vitro and in-vivo (Swift & 
Ostergard 1993). Urodynamic studies performed in pregnancy have shown a higher 
prevalence of detrusor instability antenatally than that found postpartum (Cutner 1993). 
The exact mechanism for this is unclear, but the high physiological levels of 
progesterone found in pregnancy are thought to be an important aetiological factor. 
Animal studies have suggested that progesterone may cause smooth muscle relaxation, 
induce Beta-adrenergic receptor formation, antagonise the inhibitory effect of oestradiol 
on rat detrusor muscle contraction and increase bladder sensitivity to contraction 
evoking bethanacol (Ekstrom et al 1993, Elliott & Castleden 1994). 
Clinically progestogens are associated with an increase in irritative bladder 
symptoms. Cutner and colleagues (1993) studied nine women with premature ovarian 
failure who were undergoing in-vitro fertilisation (IVF) and having their artificial 
menstrual cycles manipulated with physiological levels of oestrogen and high does of 
progesterone. Urinary symptom questionnaires and urodynamic investigations were 
completed during the two phases of treatment (oestrogen alone and oestrogen with 
progesterone). The authors found that the number of voids per 24 hours was 
significantly greater in the progesterone phase as was the pressure at the end of filling 
cystometry. Burton (1992) questioned 217 women with premature ovarian failure on 
continuous oestrogen and cyclical progesterone therapy. They found an increase in the 
symptoms of urgency during the progesterone phase of the cycle but no change in the 
incidence of stress incontinence or urge incontinence. However, using pad testing 
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Benness (1991) did find an increase in urinary loss during the progesterone phase of 
treatment in 14 postmenopausal women with urinary incontinence who were taking 
HRT. Despite these findings, progestogens do not appear to alter the urethral pressure 
profile significantly (Raz et al 1973, Rud 1980). 
6.4. THE EFFECT OF ANDROGENS ON THE FEMALE LOWER URINARY 
TRACT 
Androgen receptors are found both in the female bladder and urethra, but their role is at 
present unclear (Blakeman et al 1997). The use of androgens to treat urinary symptoms 
in women is limited by their masculinising side effects and is therefore not considered 
further. 
6.5. EVIDENCE OF AN ASSOCIATION BETWEEN SEX STEROID LEVELS 
AND URINARY SYMPTOMS 
6.5.1. Menstrual cycle 
The characteristic hormonal changes occurring during the normal menstrual cycle are 
outlined in Chapter five. It has long been recognised that women may notice a change 
in their urinary symptoms during the menstrual cycle which seem to coincide with the 
cyclical variations in the level of sex steroids. In particular some women report an 
increase in irritative bladder symptoms and a deterioration in their ability to maintain 
continence just prior to menstruation. It is thought that this may be secondary to an 
increase in circulating progesterone levels which occurs in the luteal phase of the 
normal menstrual cycle. However, the proportion of women affected by such 
fluctuations in hormone levels has not been prospectively evaluated. This area is 
therefore investigated further in the study in Chapter nine. 
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There are a limited number of reports relating to urodynamic changes during the 
menstrual cycle. Van Geelen (1981) serially measured the urethral pressure profile 
(UPP) of 27 nulliparous women with normal ovulatory cycles. No significant changes 
were found in the pressure measurements but there was an increase in the functional 
urethral length midcycle and early in the luteal phase. The data suggested a causal 
relationship between changes in serum oestradiol and alterations in urethral length. As 
with other studies (Raz et al 1973, Rud 1980) the authors could find no relationship 
between progesterone levels and the UPP parameters. 
Information regarding the effect of the menstrual cycle on cystometry is very 
limited. In a case report Lewis and Warrell (1989) described an 18 year old women 
who noticed deterioration in her urinary symptoms during menstruation. Cystometry 
performed mid-cycle failed to show any significant abnormality. However, when this 
was repeated during menstruation the patient was found to have detrusor instability. 
The authors suggested that the cause for this was cyclical prostaglandin synthesis and 
this is supported by the fact that the patient's symptoms completely resolved when she 
was given the prostaglandin synthesis inhibitor mefenamic acid. Sorenson and 
colleagues (Sorensen et al 1988) performed urodynamic investigations on 10 healthy 
women three times during the menstrual cycle. No significant changes attributable to 
the menstrual hormonal changes were observed in the profilometry data, cystometric 
parameters or in the pressure-flow studies. There were no cases of detrusor instability 
but this is perhaps not surprising as all the women were well and asymptomatic. In 
contrast Shimonovitz (1997) performed a retrospective analysis of cystometry results 
from a urodynamic database. The study group comprised 57 women with regular 
menstrual cycles who had their investigations performed on a single occasion. 
Abnormal urodynamic diagnoses including detrusor instability were made more 
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frequently in the follicular phase and significantly more normal results were found in 
the women who felt that their symptoms were influenced by the menstrual cycle 
compared to those who felt there was no association. However, the retrospective nature 
of this study and small number of patients investigated in each phase of the menstrual 
cycle make it difficult to make any definite conclusions. In view of the limitations of 
these studies the impact of the menstrual cycle on the results of urodynamic 
investigation in symptomatic women is investigated further in Chapter nine. 
6.5.2. Pregnancy 
Many women complain of urinary symptoms during pregnancy which are only in part 
due to an increase in urine output and pressure effects from the gravid uterus (Stanton et 
al 1980, Cutner 1993, Chaliha et al 1998). As described earlier, progesterone levels are 
increased in pregnancy and this may account for the physiological hydroureter and 
increased prevalence of detrusor instability (Cutner et al 1992). 
6.5.3. Menopause and oestrogen deficiency 
Hormonal changes occurring at the time of the menopause have an impact on all 
oestrogen sensitive tissues and the female urogenital tract is no exception. Oestrogen 
deficiency, particularly when prolonged, is associated with a wide range of urinary 
symptoms including frequency, nocturia, incontinence, urinary tract infections and the 
"urge syndrome. " These may co-exist with vaginal atrophy and symptoms of dryness, 
itching, burning and dyspareunia. Urinary symptoms secondary to oestrogen deficiency 
may only develop many years after the menopause and, therefore, may be under- 
reported in epidemiological studies by both patient and doctor. losif and Bekassy 
(1984) studied 902 Swedish women aged 61 years and found the prevalence of lower 
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urinary tract disorders was high with 49% of women having some symptoms. Of the 
29% of women with incontinence, 70% related the onset of their urinary leakage to the 
time of their final menstrual period. In a survey of 2045 British women aged between 
55 and 85 years, Barlow and colleagues (1997) showed that urogenital symptoms had 
affected 49% of postmenopausal women at some time and 11% were currently troubled 
by individual symptoms. At least two thirds of women did not relate their vaginal or 
urinary complaint to the menopause which may have occurred many years previously. 
Urinary tract symptoms are certainly common following the menopause with one in five 
women attending a menopause clinic complaining of severe urgency, and nearly 50% 
stress incontinence (Cardozo et al 1987). 
The prevalence of postmenopausal incontinence in the community is thought to 
be between 16 and 29% (Vetter et al 1981, Jolleys 1988, Rekers 1992). While there are 
clearly a number of important factors in the pathogenesis of urinary incontinence there 
is conflicting evidence regarding the role of the menopause. Thomas (1980) (Figure 
6.1. ) and Jolleys (1988) (Figure 6.2) found the peak prevalence of urinary incontinence 
in community dwelling women to occur in the perimenopausal age group. Urge 
incontinence in particular is found more commonly after the menopause (Kondo et al 
1990) with the prevalence appearing to rise in line with increasing years of oestrogen 
deficiency (Figure 6.3. ). However, most studies show that many women develop 
incontinence at least 10 years before their last period, with Jolleys (1988) and Burgio 
(1991) finding that significantly more premenopausal women than postmenopausal 
women were affected. The prevalence of stress incontinence in the community also 
starts to fall following the menopause, particularly in age groups which are most likely 
to be affected by relative oestrogen deficiency, and the increase in urge incontinence 
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Figure 6.1.: Changing prevalence of occasional or regular incontinence with age 
among 9323 women responding to a postal questionnaire. Adapted from Thomas 
(1980). 
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Figure 6.2.: Changing prevalence of incontinence with age among 937 women 
registered with a rural general practice. Adapted from Jolleys (1988). 
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Figure 6.3.: Changes in the prevalence of stress and urge incontinence with age 
among 1100 Japanese women. Adapted from Kondo (1990). 
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6.6. THE EFFECT OF AGEING 
Many women consider the development of urinary symptoms as they get older to be a 
normal phenomenon rather than the manifestation of a disease (Svanberg 1977). In a 
study of Gjorup and colleagues (1987), over 50% of women aged more than 75 years 
thought their symptoms were normal for elderly people. The ageing population are at 
risk of a number of systemic illnesses and transient problems which may present with 
lower urinary tract symptoms, including diabetes mellitus, congestive cardiac failure 
and renal disease. A patient with impaired mobility may develop incontinence of urine 
if suitable access to a toilet is not available, a situation which may be exacerbated if 
medications such as diuretics or hypnotics are being taken. However, symptomatic and 
functional changes certainly do occur in the lower urinary tract as a result of the ageing 
process itself, which are difficult to differentiate from those due to oestrogen deficiency. 
The prevalence of nocturia increases with age from 10.5% (50-59 years) to 50% 
(z 80 years) (Swithinbank et al 1998). In addition, the proportion of women with 
nocturia secondary to nocturnal polyuria also rises following the menopause. Younger 
women tend to excrete the bulk of their fluid intake during the day, whereas in the 
elderly this pattern may be reversed. Postural effects may lead to daytime pooling of 
extracellular fluid, particularly in the ankles. When this fluid returns to the systemic 
circulation during the night there is a consequential increase in urine output. This 
combined with abnormal sleep patterns may lead to nocturia. Impaired secretion of 
ADH may also be a factor in some subjects. 
Urodynamic studies have shown that the bladder becomes less efficient with age 
(Rud et al 1980, Malone-Lee & Waheda 1993, Collas & Malone-Lee 1996). Elderly 
women have a reduced urine flow rate, increased urinary residual, higher first sensation 
to void and increased bladder capacity, although the later may fall in the eight and ninth 
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decades. Detrusor pressures at urethral opening and closure during voiding fall in 
absolute terms as women become older (Wagg et al 1996). Histologically there is an 
age-related increase in fibrosis in the bladder neck (Brocklehurst 1972) and collagen 
content of the female bladder (Susset et al 1978). In a post-mortem study of the female 
urethral sphincter, Perucchini and colleagues (Perucchini et al 1997) demonstrated a 
reduction in the number of striated muscle fibres and their density with increasing age, 
but the size of individual fibres remained unchanged. However, the number and 
diameter of the fibres in the muscles of the pelvic floor does appear to decrease with age 
(Kolbl et al 1989) although neuronal damage secondary to childbirth may be a 
confounding factor (Smith et al 1989, Allen & Warrell 1992). 
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6.7. OESTROGEN FOR THE TREATMENT OF URINARY SYMPTOMS 
If oestrogen does significantly affect the genitourinary tract then it is a reasonable 
assumption that it will be of some therapeutic benefit in postmenopausal women with 
urinary complaints. Salmon (1941) was the first to report the successful use of 
oestrogens to treat urinary incontinence over 50 years ago. Indeed, there are a number 
of reasons why oestrogens may be useful for the treatment of lower urinary tract 
dysfunction (Table 6.1. ). It is now well recognised that there is a poor correlation 
between a woman's symptoms and the subsequent diagnosis following appropriate 
investigation (Jarvis et al 1980). Unfortunately, initial trials took place before the 
widespread introduction of urodynamic studies and therefore almost certainly included 
women with a number of different pathologies. Lack of objective outcome measures 
also limit their interpretation. 
Increased urethral closure pressure 
" Increased urethral cell maturation 
" Increased urethral blood flow 
" Increased alpha-adrenergic receptor sensitivity in urethral smooth muscle 
Improved abdominal pressure transmission to proximal urethra 
Stimulation of periurethral collagen production 
Improved neuronal control of micturition 
Increased sensory threshold of the bladder 
Improved mood and quality of life 
Reduced incidence of urinary tract infection 
Table 6.1.: Mechanisms by which oestrogen may improve urinary incontinence. 
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6.7.1. Oestrogens for stress incontinence 
There are a large number of reported studies of oestrogen for the treatment of urinary 
stress incontinence but most have to be interpreted with caution because they are 
observational and not-randomised, blinded or controlled. Comparison of the different 
reports is also difficult because a number of different types of oestrogen have been used 
with varying doses, routes of administration and durations of treatment. The concurrent 
use of progestogens, to prevent endometrial hyperplasia in those women with a uterus, 
probably also influences success rates. A summary of the controlled trials comparing 
oestrogen with a placebo is shown in Table 6.2.. 
A meta-analysis from the Hormones and Urogenital Therapy (HUT) committee 
has helped to clarify the situation (Fantl et al 1994). Of 166 articles identified which 
were published in English between 1969-1992, only 6 were categorised as randomised 
trials and 17 uncontrolled series. Subjectively, oestrogen was found to produce a 
significant improvement for all patients and those with genuine stress incontinence, but 
this may have been because oestrogens improve feelings of wellbeing and quality of 
life. Consistent with other therapies for incontinence there was also a marked 
improvement in the placebo arm ranging from 10-56%. Analysis of objective 
parameters failed to show any reduction in the volume of urine lost compared to pre- 
treatment levels. Maximum urethral closure pressure did increase significantly, but this 
result was influenced by only one study showing a large effect. However, even this 
meta-analysis may have some serious methodological flaws. For example, a study by 
Judge (1969) was included and described as a randomised trial. Allocation to treatment 
in this report was based upon place of residence (in one of two different nursing homes) 
and may therefore be open to significant bias. In addition, the study population was not 
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to oestrogen deficiency. All the women included had neurological disease and 12 
patients were described as being confused. The other problem with meta-analysis is 
that only studies with a positive outcome are likely to be reviewed, as research which 
does not show a treatment to be of benefit is less likely to be published. 
In a further review of the literature, Sultana and Walters (1995) examined 8 
controlled and 14 uncontrolled prospective trials and included all types of oestrogen 
treatment. They also found that oestrogen was of no benefit for stress incontinence but 
may be useful for the often associated symptoms of urgency and frequency. 
Two further studies using oral oestrogen, which were not included in the HUT 
meta-analysis, have subsequently been reported. Fantl (1996) performed a randomised 
trial of 83 hypo-oestrogenic patients with urodynamically proven genuine stress 
incontinence and/or detrusor instability. Women were treated for three months with 
cyclical conjugated equine oestrogens 0.625mg and medroxyprogesterone 10mg or a 
placebo. At the end of the study period the clinical and quality of life variables had not 
changed significantly in either group. While this may have been due to the lack of 
efficacy of the oestrogen prescribed, the mixed pathology of some of the women and the 
concurrent use of progestogens makes it difficult to draw any firm conclusions. 
Jackson and co-workers (1999) treated 67 postmenopausal women with genuine 
stress incontinence or mixed incontinence with oestradiol valerate 2mg or placebo daily 
for 6 months in a double blind, placebo controlled study. Six of the 33 women 
randomised to receive oestradiol experienced breakthrough bleeding during the trial and 
were subsequently treated with an additional monthly progestogen. Although this is one 
of the largest studies yet reported with the longest duration of treatment, there were 
again no significant changes in the subjective or objective outcome measures. It should 
be noted that similar to other reports the mean age of the women treated was 63 years. 
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It is possible that irreversible changes in the lower urinary tract may already have taken 
place in this age group, with only those women in the perimenopausal years likely to 
benefit from this form of treatment. At present it is unclear if oestrogen 
supplementation can be used as prophylaxis against the development of urinary 
incontinence. 
6.7.2. Oestrogen in combination with other therapies for stress incontinence 
Alpha-adrenergic receptors in the urethral sphincter are sensitised by oestrogens helping 
to maintain muscular tone (Screiter et al 1976). Several studies have utilised this effect 
and shown that oestrogen may be a useful treatment for stress incontinence if given in 
combination with an alpha-adrenergic agent such as phenylpropanolamine (Table 6.3. ). 
This type of therapy may be particularly useful for women with mild stress incontinence 
or for those not suitable for surgery. 
6.7.3 Oestrogens for urge incontinence 
There are a number of causes of urinary frequency and urgency in postmenopausal 
women (Table 3.5. ) and investigation is often required to make an accurate diagnosis. 
Oestrogen has been used to treat urgency and urge incontinence for many years 
regardless of the underlying pathology and even in women who initially developed their 
symptoms many years before the menopause. Perhaps for these reasons very few trials 
have shown oestrogen to be of benefit for this condition, although again there is a lack 
of large, randomised controlled studies with a long duration of treatment from which to 
make conclusions (Table 6.4. ). Walter (1978) found that a combination of oestradiol 
2mg and oestriol 1mg daily cured the symptoms of frequency, urgency and urge 
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Samsioe (1985b) used oral oestriol 3mg daily to treat 34 women aged 75 years in a 
double blind placebo controlled crossover study (Table 6.2. ). Although oestriol was 
found to have no effect on stress incontinence a significant subjective improvement was 
found in the 12 women with urge incontinence and 8 women with mixed incontinence. 
Enzelsberger (1991) treated 30 women with urge incontinence using vaginal oestriol 
(lmg or 3mg) or a placebo. At the end of the three week study period there was a 
significant improvement in urinary symptoms but only in the women receiving the 
higher dose of oestrogen. Patients diagnosed as having detrusor instability failed to 
respond and there were no objective changes. A large placebo effect is known to occur 
in the treatment of this condition and these reports therefore need to be interpreted with 
caution, particularly in view of the small number of women treated. 
In a double blind multicentre study 64 postmenopausal women with the "urge 
syndrome" were randomised to treatment with oral oestriol 3mg daily or placebo for 3 
months (Cardozo et al 1993b). Urodynamic studies were performed at baseline and 
compliance was confirmed by a significant improvement in the maturation index of 
vaginal epithelial cells in the active but not the placebo group. Oestriol produced 
subjective and objective improvements in urinary symptoms but it was not significantly 
better than placebo. The authors had hoped to recruit 100 women into the study from 
10 centres over an 18 month period. However, four centres did not enrol any patients at 
all and in another four only a very small number of women agreed to participate. The 
requirements set out by the power calculation were therefore not met. 
Sustained release oestradiol vaginal tablets (Vagifem, Novo Nordsk) or placebo 
were used by Benness and colleagues (1992) to treat 110 postmenopausal women with 
lower urinary tract symptoms. At the end of the 3 month treatment period the only 
significant differences between the active and placebo groups was an improvement in 
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the symptom of urgency in the women who had a urodynamic diagnosis of sensory 
urgency. In these women it was possible that the oestrogen was reversing atrophic 
changes in the lower urinary/genital tract rather than treating any underlying bladder 
pathology. 
These studies may not have shown any benefit possibly because the wrong type 
of oestrogen was used for too short a time period or it may have been given by the 
wrong route. Oestriol, although a naturally occurring oestrogen, has little effect on the 
endometrium and does not prevent osteoporosis. It is therefore also questionable 
whether the low dose used in these studies is sufficient to treat urinary symptoms. 
Sustained release oestradiol vaginal tablets are well absorbed and have been shown to 
induce maturation of the vaginal epithelium within 14 days (Nilsson & Heimer 1992) 
but higher systemic levels may be needed for therapy to be effective. The other concern 
regards compliance with treatment, particularly when oestrogen is given vaginally to 
elderly patients. To try and overcome this and other problems associated with the 
previous studies 25mg oestradiol implants were administered to women with the "urge 
syndrome" who were then assessed over a six month period. This study is reported in 
detail in Chapter 12. The safety and rationale for using unopposed oestrogen in this 
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7.1 EATING DISORDERS 
Studies assessing the impact of oestrogen deficiency on the bladder are usually 
hampered by the fact that postmenopausal women are almost always older than 
premenopausal women, and are therefore more likely to have been subjected to the 
effects of the ageing process. To try and overcome this problem the prevalence of 
urinary symptoms in young women with severe eating disorders was investigated and 
the results reported in Chapter 10. 
7.2. DEFINITION 
The two most well established eating disorders, anorexia nervosa (AN) and bulimia 
nervosa (BN), occur primarily in females during adolescence and young adulthood. The 
psychopathology of both are complex and varied in form with frequently some overlap 
between the two groups. The former is characterised by failure to maintain a normal 
body weight, while the latter is characterised by recurrent episodes of binge eating and 
extreme weight control measures such as laxative misuse and self-induced vomiting. 
Disturbances regarding self-perception of body weight and shape are core features of 
both disorders. 
Current diagnostic criteria subdivides AN into a restricting type and a binge 
eating/purging type, with each group having a different psychological and medical 
profile. Restricting anorexics tend to be highly controlled, rigid and often obsessive 
(Wilson et al 1996), whereas those who binge have higher rates of impulsivity and 
stronger personal and family histories of obesity (Strober 1980). A woman cannot be 
diagnosed with both AN and BN, so that an emaciated individual who is bingeing and 
purging will be diagnosed with AN, bulimia subtype. The prognosis may be very 
different for the two groups. Often BN can be treated successfully with good 
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probability for complete recovery (Fairburn et al 1995). However, AN remains resistant 
to successful long-term treatment (Hsu 1991). 
7.2.1. Body mass index 
The most commonly used method of assessing body composition is the body mass 
index (BMI). The Belgian astronomer, statistician and epidemiologist Quetelet 
observed that among adults the average weight appeared to be proportional to the square 
of the height. He therefore used the formula Kg/m2 as an index of relative body weight, 
which is now referred to as the BMI. BMIs between 20 and 25 are very common and 
generally believed to be healthy, whereas a BMI of approximately 28 or greater is 
generally taken to indicate obesity (Sichieri et al 1991). BMIs between 10 and 12 
appear to represent the lower limit of human survival (Henry 1994). It is not 
uncommon for hospitalised anorexic patients to achieve BMIs of 15 and lower. In a 
gynaecological setting, women with a BMI of less than 20 frequently present with 
amenorrhoea. The hormonal reasons for this are discussed later. 
7.2.2. Psychopathology 
Women with eating disorders present with a diversity of pathological thoughts and 
behaviours. A number of self-report measures have been developed to provide a 
measure of symptom severity and a means of evaluating treatment outcome. These 
assessments have the advantage over personalised interviews in that they are relatively 
inexpensive, brief, easily administered as part of epidemiological investigations and are 
objectively scored. 
The Eating Attitudes Test (EAT) is probably the most widely used rating scale 
in the study of AN. Originally produced with 40 items designed to evaluate a range of 
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attitudes and behaviours (Garner & Garfinkel 1979), factor analysis yielded a 26 item 
version (EAT 26) (Appendix), which was highly correlated with total scores on the 
original EAT (r =0.98) (Garner et al 1982). The EAT 26 is a valid and reliable tool with 
a high level of internal consistency. It takes less than 10 minutes to complete and each 
question is scored on a6 point Likert scale (1 = never, 6= always). The items are 
awarded 3 points for extreme "anorexic" responses, 2 points for the adjacent alternative, 
1 point for the next alternative and no points for the remaining three alternatives. Using 
a "cut off score" of 20 to discriminate between AN and control groups, the EAT 26 
questionnaire correctly diagnoses 83.6% of cases. While high EAT scores may indicate 
the presence of symptoms common to AN, it is inappropriate to assume that a score 
over 20 in a non-clinical setting is diagnostic for this eating disorder. Although the 
questionnaire may indicate the presence of disturbed eating patterns, it does not identify 
the psychopathology behind this behaviour. For example, the EAT 26 has not been 
found to discriminate between AN and BN (Gross et at 1986, Williamson et at 1993). 
The EAT 26 questionnaire is therefore suitable either as an outcome measure in 
clinical groups or a screening instrument in non-clinical settings. 
7.3. EPIDEMIOLOGY 
Epidemiological studies of AN are hampered by the fact that eating disorders have a 
relatively low prevalence in the community and sufferers tend to conceal their illness 
and avoid professional help (Hsu 1996)(Table 7.1. ). This makes it necessary to study a 
very large number of subjects from the general population to reach enough differential 
power for the cases. Several strategies have been used to circumvent this problem, in 
particular case register and other record based studies, and assessment of special 
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other mainly hospital-based studies include only patients who have come into the 
mental health care system. Their validity therefore depends upon their diagnostic 
accuracy and the coverage of cases. Women who have never entered the health care 
system or have not been diagnosed as having an eating disorder will not be included in 
the results. Studies of special populations, selected because they are thought to contain 
an at risk group such as female students, ballet dancers or athletes, may not be 
applicable to the general population. The current incidence of AN is thought to be at 
least 8 per 100 000 population per year and the incidence of BN is at least 13 per 
100 000 population per year (Hoek et a! 1995). An average 1-year prevalence of AN in 
young females is 0.28% although the studies may have the limitations described above. 
7.4. PATHOPHYSIOLOGY 
Eating disorders, particularly anorexia nervosa, have been well known since the latter 
half of the 19th century, when anorexia was first described by Gull (1873) in London 
and Lasegue (1873) in Paris. It seems likely that patterns of behaviour resembling 
eating disorders were in existence for centuries prior to their "discovery" but in forms 
not thought of as illnesses. Many hypotheses about the aetiology of eating disorders 
have been proposed but it is generally accepted that a precise understanding of their 
cause remains elusive. However, it is clear that many factors contribute to their 
development including individual personality, family dynamics, genetic and biological 
predispositions, and sociocultural factors. The latter are of particular importance in 
understanding why eating disorders have become more prevalent in the most vulnerable 
group of young women aged 15-24 years over the last 50 years. 
Anorexia nervosa is found in many different countries and is certainly not 
confined to industrialised parts of the world (Hoek et al 1995). However, it does appear 
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that anorexia nervosa is more common in countries where food and material prosperity 
abound. Recent media promotion of tall, thin women and in particular supermodels has 
been thought to provide a psychological environment in which anorexia nervosa is more 
likely to develop if there are susceptible underlying personality characteristics. 
However, there is no consensus that the prevalence of anorexia nervosa has increased as 
a result of this factor alone (Fombonne 1995). Family relationships may be strained or 
disordered in anorexia nervosa but it is unclear if this is a cause or effect of the eating 
disorder (Thienemann & Steiner 1993). Siblings of individuals with anorexia nervosa 
are much more likely to be affected by an eating disorder than the general population 
(Strober et al 1985) and this has been taken as evidence of a genetic liability to anorexia 
nervosa. However, chromosomal analysis using routine karyotyping tends to be normal 
and it is likely that the increased prevalence in this setting is due to the fact that siblings 
are usually exposed to a similar psychosocial environment. 
In early childhood the ovaries are amorphous with very small follicles. As 
weight increases at an age dependent rate the ovaries enlarge and demonstrate multiple 
small follicles. At puberty the ovaries develop a dominant or ovulatory follicle. These 
changes are accompanied by a rise in follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) levels. There is controversy as to whether there is a 
minimum weight upon which the onset of puberty is dependent. Frisch and Revelle 
(1971) suggested that there must be at least a critical body composition (17% as stored 
fat) but others have disputed this view (Billewicz et al 1981). However, it does appear 
certain that pre-pubertal malnutrition may lead to delay or arrest of pubertal 
development. As a consequence women suffer hypogonadotrophic hypogonadism with 
a resulting hypo-oestrogenic state which may be of long duration and continue even 
after some weight has been gained. Depending upon the timing of onset of AN women 
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may have either primary or secondary amenorrhoea. Starvation associated with 
anorexia nervosa leads to changes in the production and functioning of several 
hormones, particularly along the hypothalamic-pituitary-gonadal axis. In post-pubertal 
girls there is suppression of the pulsatile secretion of gonadotrophic hormones from the 
anterior pituitary with levels falling to those of a pre-pubertal, infantile state. As 
women with anorexia nervosa begin to lose weight even adrenarche, the secretion of 
androgen hormones such as dehydroepiandrosterone by the adrenal gland about two 
years prior to puberty, is reversed (Pirke & Platte 1995). Growth hormone levels may 
also be suppressed and this is particularly important if the speed and timing of the 
normal growth spurt are affected (Christie et al 1998). Alterations in the level of several 
other hormones, including corticotrophin releasing hormone (CRH), 
adrenocorticotrophin hormone (ACTH) and cholecystokinin (CCK) have been reported 
but are unlikely to have an effect on the female lower urinary tract and are therefore not 
considered further. 
7.5. MEDICAL COMPLICATIONS 
Long term follow-up studies of women with AN have shown that even after treatment in 
a specialised centre only 40% of patients can be regarded as cured (Herzog et al 1992). 
The remaining patients remain susceptible to the somatic complications of acute and 
chronic malnutrition. Because patients with AN and BN tend to deny their disease and 
the resulting physical damage, medical complications of starvation are often the reason 
they receive treatment for the first time. 
The most common physical problems associated with eating disorders are shown 
in Table 7.2.. 
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ACUTE PHASE CHRONIC PHASE 
Disturbances of electrolyte and acid-base balance Chronic renal failure 
Acute renal failure Cardiac arrhythmia 
Cardiac arrhythmia Constipation 
Impaired gastric emptying Anaemia 
Gastroduodenal ulcers Amenorrhoea 
Opportunistic infection Infertility 
General weakness Osteoporosis 
Hypothermia Dental defects 
Table 7.2.: Common medical complications in eating disorders. 
7.5.1. Acute changes 
Patients with AN and BN may develop a number of potentially fatal somatic 
complications which require immediate hospitalisation. Hypokalemia is found in about 
a third of women with severe eating disorders (Bonne et al 1993), particularly in 
association with purging behaviour, and at its extreme may result in tachyarrythmias 
and nephropathy. Deficiencies of sodium, magnesium, phosphate and calcium also 
occur commonly. Serum glucose levels are low in most cases of AN. Self induced 
vomiting may give rise to metabolic alkalosis (McClain et al 1993) and laxative abuse 
metabolic acidosis (Mitchell et al 1987). Disturbances of the immune, haematological, 
cardiovascular and gastrointestinal systems also occur but are beyond the scope of this 
review. 
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7.5.2. Chronic changes 
7.5.2.1 Reproductive function 
As described earlier, disturbance of the hyothalamo-pituitary-gonadal axis occurs 
almost universally in women with AN and may result in either primary or secondary 
amenorrhea, depending on the age of the patient at first manifestation. Failure of 
follicular maturation and anovulation are associated with infertility (Bates et a! 1982). 
7.5.2.2. Osteoporosis 
Chronic oestrogen deficiency may result in osteoporosis in approximately 17% of 
women 12 years after first treatment (Herzog et al 1993). Apart from a typical reduced 
bone density (Treasure et al 1986) pathological fractures have been reported in 44% of 
cases (Herzog et al 1993). The development of osteopenia can be characterised by two 
mechanisms which supplement and reinforce each other. Firstly, because of the early 
onset of the disease there is a reduced peak bone mass (Biller 1989). Secondly, 
premature and increased bone destruction occurs (Matthews et al 1985). Almost all 
authors agree that the duration of amenorrhea and oestrogen deficiency are the most 
important aetiological factors in the development of bone disease in women with eating 
disorders, and are strongly correlated with the degree of osteopenia. 
There is evidence that weight gain can prevent further loss of bone mass and 
may even lead to an increase in bone density (Bachrach et al 1991). At present there 
has been only one controlled, prospective study of hormone replacement therapy in a 
group of 48 women with AN (Klibansky et al 1995). While there does appear to be 
some therapeutic effect, particularly for women with a body weight of less than 70% of 
the ideal, the optimal dose of oestrogen and duration of replacement therapy remain 
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unknown. Furthermore, it is clear that sufficient intake of vitamin D and calcium is 
essential for therapy to be effective. 
7.5.2.3. Urinary symptoms 
In the first report of the prevalence of urinary symptoms in women with eating 
disorders, my colleague Kelvin Boos and myself performed a pilot for the study 
reported in Chapter 10 (Boos et al 1999). The urinary symptoms of twenty nine 
women with severe AN were prospectively evaluated using a structured questionnaire. 
The median age of the women was 23.8 years (range 17-40 years) and mean BMI 14 
(range 13-16). The median age of onset of AN was 17 years (range 13-36 years) with a 
median duration of 6 years (range 3-19 years). Three women suffered primary and 
twenty six women secondary amenorrhoea with a median duration of absent menses of 
4.4 years (range 1-6 years). The type and frequency of the urinary symptoms described 
by the subjects is shown in Table 7.3.. 
URINARY SYMPTOM NUMBER OF WOMEN (%) 
(n=29) 
Frequency 17 (59) 
Nocturia 15 (52) 
Urgency 18(62) 
Urge Incontinence 7 (24) 
Stress incontinence 2 (7) 
Recurrent urinary tract infection 9 (31) 
Table 7.3.: Prevalence of urinary symptoms in women with severe anorexia 
nervosa. Adapted from Boos et al (1999). 
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Our study therefore found that the prevalence of urinary symptoms in women 
with severe AN was much higher than that expected in the general population. This 
finding was very important because it suggested that young women with severe 
oestrogen deficiency may also develop similar urinary symptoms to those found after 
the menopause. However, an age matched control group was not used for comparison 
and no estimation of the level of oestrogen deficiency was made. Therefore, to 
investigate the prevalence of urinary dysfunction in this group of oestrogen deficient 
women further, the study described in Chapter 10 was performed. 
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CHAPTER 8 
OESTROGEN AND URINARY TRACT 
INFECTION 
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8.1. URINARY TRACT INFECTION 
Urinary tract infections (UTI) may occur in women of all ages but they are particularly 
prevalent in the elderly. The menopause and subsequent oestrogen deficiency have 
been implicated as aetiological factors in this process. However, studies assessing the 
efficacy of oestrogen replacement therapy for prophylaxis against recurrent urinary tract 
infections in women have given conflicting and largely disappointing results. It is 
therefore possible that changes in the prevalence of UTI as women become older are a 
result of the ageing process, rather than as a consequence of pathophysiological changes 
occurring in the urogenital tract as a result of the menopause. 
8.2. DEFINITION 
Urinary tract infection describes a condition in which there are micro-organisms present 
and multiplying within the urinary tract either in the bladder, prostrate, collecting 
systems or kidney (Cattell 1996). It is usually caused by bacteria but may involve a 
fungal or more rarely a viral pathogen. A UTI is therefore almost always characterised 
by the presence of bacteria in the urine, with the exceptions of bacterial prostatitis, 
infected renal cysts or a perinephric abscess. Bacteriuria literally indicates the presence 
of bacteria in a voided sample of urine. 
Urine can be obtained from the bladder for microbiological examination using a 
number of different methods including suprapubic aspiration, insertion of a urethral 
catheter or sampling from a catheter bag. However, collection of a mid-stream urine 
(MSU) specimen is by far the most frequently used technique both in hospital and 
general practice. 
Clear instructions are required by most patients (preferably in a printed form) 
before they attempt to collect an MSU sample. It is recommended that the hands are 
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washed and in women that the periurethral area is cleaned in a front to back motion 
before collection. The distal urethra is colonised with organisms in almost all females 
and approximately a third of males and therefore the initial part of the urine stream is 
most likely to be contaminated (Henning & Tornvall 1975, Marrie et al 1978). Using 
the MSU technique the initial urine flow is discarded by the patient and the following 
middle part collected by inserting a sterile pot into the stream a moment or two after 
starting voiding. Unfortunately, there are a number of sources of contamination 
including the flora of the hands, labia, vagina and perineum. It is also recognised that 
many urine samples are collected without cleaning or using only a cursory attempt and 
therefore this technique, while widely practised, has some limitations. 
Urinary tract infection occurs when a single strain of bacteria gains entry to the 
bladder or kidney and begins rapid multiplication either on or in the urothelium or 
adjacent urine. Kass (1956) suggested that counts of 105 organisms/ml or above 
indicated infection. This threshold has been adopted by most laboratories, including the 
microbiology department at King's College Hospital, since it allows reports to be made 
on a clearly determined end point. Counts below 103 organisms/ml and sometimes 104 
organisms/ml are regarded as indicating contamination. Bacterial counts of 104-105 
organisms/ml in a pure growth may mean that the patient has a urinary tract infection 
but the result needs to be related to the patient's symptoms and circumstances for an 
accurate diagnosis to be made. In a laboratory context a robust definition is essential, as 
many samples will culture some organisms. The breakpoint counts of 103/ml and 
105/ml are therefore widely used to distinguish infection from contamination 
respectively. Changing these thresholds obviously alters the sensitivity and specificity 
of urine culture for diagnosing urinary tract infection. 
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The relevance of bacterial counts below 105/ml in patients with symptoms 
remains contentious. Low counts of organisms may be obtained if the patient is already 
on antibiotics, there is a high fluid intake (perhaps on the advice of a doctor) or when 
the urinary pH is low. It is good practice to be aware that infection may be present 
when there are low counts of pathogens but further research on the pathogenic role of 
low numbers of organisms is necessary. There are a number of other reasons why a 
patient may have urinary symptoms in this situation and the results of cultures less than 
105 organisms/ml need to be interpreted with caution. Mixed cultures of organisms 
should be repeated even in the presence of pyuria and relevant urinary symptoms, with 
particular care made to avoid contamination (Sanderson 1998). 
8.3. EPIDEMIOLOGY 
Urinary tract infection is a common condition occurring in the general population with a 
prevalence strongly related to age and gender. The number of population based reports 
are very limited mainly because studies of the necessary size and duration are expensive 
and difficult to conduct. Varying definitions of UTI and bacteriuria, intervals between 
sampling and the spontaneous resolution of infections also make interpretation of the 
available results difficult (Monane et al 1995). Many women with symptoms of a 
urinary tract infection may not present to their doctor, and even in those that do 
antibiotics may be given without confirmation of an infection on urine culture. The 
setting for a study may also influence the prevalence of bacteriuria. For example, the 
prevalence of UTI in ambulatory elderly people living in the community is lower than 
of people living in old people's homes, which in turn is lower than the prevalence of 
UTI in patients living in long term residential or hospital based care (Brocklehurst et al 
1968, Lye 1978, Boscia et al 1986). 
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Epidemiological studies documenting the prevalence of bacteriuria in the 
community were initially performed 20-30 years ago (Table 8.1. ). Unfortunately, less 
attention has been focused on urinary tract infection in the recent past (Ronald 1996). 
The observed levels of infection from the different study populations are remarkably 
consistent and all show the same trend of increasing prevalence with age. Nuns have a 
lower prevalence of bacteriuria than the other study populations and this suggests that 
sexually active women have a higher prevalence of bacteriuria than those who are not. 
None of the studies in Table 8.1. specifically examined the effect of the menopause and 
oestrogen deficiency on the prevalence of UTI. However, there does not appear to be a 
dramatic change in the rate of increase of bacteriuria in the age groups above the 
expected mean age of the menopause in any of the reports. This is considered further 
below. 
In Table 8.2. the differences in the prevalence of bacteriuria between men and 
women, and those living in different environments, are demonstrated. Although the 
prevalence of infection is much higher than in the studies listed in Table 8.1., this is a 












Miall et al 1962 Jamaican 2365 15-24 1.4 




Freedman et al Hiroshima 3191 <20 0.8 





Kunin & US working 2698 15-34 4.8 
McCormack women 35-54 4.5 
1968 z 55 6.4 
US nuns 3304 15-34 0.3 
35-54 1.5 
Z55 4.7 
Takala 1977 Middle aged 1223 40-49 2.5 
Finnish women 50-59 5.1 
60-64 8.5 
Evans et al 1978 Working class 7834 16-19 1.1 
community 20-29 1.7 
population, 30-39 3.7 
Boston, US 40-49 2.5 
50-59 4.3 
60-69 5.8 
Table 8.1.: Prevalence of bacteriuria with age in women. 
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TYPE OF PATIENT % WITH BACTERIURIA 
Males Females 
Living at home 
Brocklehurst et al 1968 13 20 
Akhtar et al 1972 5.9 17 
Living in elderly people's home 
Dontas et a11981 14 28.6 
Kasviki-Charvati et al 1982 19 27.2 
In hospital or nursing home 
Walkey et al 1967 31 34 
Baldassarre & Kaye 1991 20 25 




8.4.1. Host factors 
In women, there are a number of important barriers to the entry and proliferation of 
bacteria in the bladder. In addition to the anatomical integrity of the lower urinary tract, 
almost continuous flow of urine in to the bladder has a diluting effect with regular and 
complete voiding providing a very effective hydrokinetic defence mechanism. The low 
pH of urine, relatively high urea concentration and local secretion of IgA, which 
interferes with bacterial attachment, also help to prevent colonisation (Choudhury & 
Brocklehurst 1998). Normal perineal and periurethral flora, including lactobacilli, 
anaerobic organisms, streptococci and coagulase-negative staphylococci, are thought to 
prevent other micro-organisms from becoming established in these areas and so prevent 
colonisation with uropathogens. 
There are many different reasons why women may develop a urinary tract 
infection and frequently patients may have a combination of risk factors. The most 
common are detailed in Table 8.3.. Urinary tract infection almost always follows 
invasion of the pathogens through the ascending route via the urethra, with the 
exception of UTI caused by Salmonella or Mycobacterium tuberculosis. The female 
urethra is shorter than the male and is therefore closer to the perineum and vagina, 
which may become colonised with urinary pathogens particularly if the patient has poor 
perineal hygiene or soiling secondary to urinary or faecal incontinence. Poor fluid 
intake, infrequent toileting and incomplete bladder emptying all predispose to urinary 
tract infection as they result in urinary stasis (Eykyn 1998). This may also be caused by 
anatomical problems such as ureteric reflux, urethral strictures and urogenital prolapse. 
Impairment of mobility may reduce the patient's access to fluid and difficulty getting to 
the toilet can result in urinary retention (Brocklehurst et al 1977). The urine itself may 
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AETIOLOGICAL FACTOR CAUSE 
Periurethral contamination Faecal and urinary incontinence 
Increased dependency 
Hospital environment 
Increased urinary stasis Poor fluid intake 
Impaired mobility 
Infrequent toileting 




Intravesical foreign body Tumour 
Calculi 
Indwelling catheter / other instrumentation 
Miscellaneous Diabetes mellitus 
Immunosuppressive therapy 
Sexual intercourse 
Diaphragm for contraception 
Frequent intercourse / multiple sexual partners 
Reflux nephropathy 
Debilitating illness 
Menopause and oestrogen deficiency? 
Table 8.3: Common predisposing host factors for female urinary tract infection. 
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also become an attractive culture medium to bacteria if the patient has diabetes mellitus 
and consequent glycosuria. Foreign bodies such as bladder calculi, tumours and 
indwelling catheters also provide a site where bacteria multiply and persist despite 
treatment to provide a chronic source of infection and predispose to recurrent 
symptoms. 
Generations of women have recognised the association between sexual 
intercourse and the development of urinary symptoms. Nulliparity and a rigid perineum 
contribute to the development of postcoital dysuria, also known as "Honeymoon 
cystitis. " Organisms are massaged into the urethra and bladder during intercourse and if 
they are not voided out soon after, they multiply and cause infection. Buckley and co- 
workers (1978) found an increase in the urinary bacterial count in 30% of women after 
coitus, and Nicolle and associates (1982) reported that both symptomatic and 
asymptomatic bacteriuria was more common the day after intercourse. Several 
behavioural factors have been shown to enhance the risk of urinary tract infection 
following sex. These include deferred voiding after sexual intercourse (Strom et al 
1987), frequency of sexual intercourse (Foxman & Frerichs 1985), low fluid intake 
(Ervine et al 1980) and deferred voiding after the initial urge to micturate (Adatto 
1979). 
A recent large study has examined the risk factors for urinary tract infection in 
young women. Hooton and colleagues (1996) prospectively recruited 796 healthy, 
sexually active women who were included on the basis that they were starting a new 
contraceptive method and were willing to participate in the study. Two cohorts of 
women were investigated for a total of 323 person-years of follow-up. The annual 
incidence of acute cystitis was 0.7 episodes per person-year among university women 
(90% were confirmed infections on culture) and 0.5 per person-year among women 
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enrolled in a health maintenance programme. Using multivariate analysis the authors 
were able to identify contraceptive diaphragm and spermicide use, recent sexual 
intercourse and a history of recurrent urinary tract infection as independent risk factors 
for urinary tract infection among women at each study site. The relative risk of urinary 
tract infection increased from 1.0 for unmarried women who had not been sexually 
active in the previous week to 9.0 for women who had had intercourse seven times 
during that period. 
As women become older they are more likely to develop one of the risk factors 
listed in Table 8.3. and this may in part explain the changes in prevalence of UTI with 
ageing. The effect of changes in immune response in the elderly is controversial. At 
present, there is no conclusive evidence that impairment of immune function as a result 
of ageing per se is an independent risk factor for the development of urinary tract 
infection (Horan & Parker 1998). However, once an infection is acquired the old are 
usually sicker and at considerably greater risk of dying than the young. 
The role of the menopause and oestrogen deficiency is considered below. 
8.4.2. Microbiology 
Escherichia coli is the most frequent urinary'pathogen isolated from between 50-90% of 
all uncomplicated urinary tract infections arising in the community (Gruneberg 
1994)(Table 8.4. ). Colonisation of the gastrointestinal tract by the organism occurs 
soon after birth when the source of the organisms is usually maternal. Several virulence 
factors are known to be involved. Adherence of the bacteria to the vaginal interoitus 
and subsequently the urothelium is important in the initiation of infections in the lower 
urinary tract. Uropathogenic strains of Escherichia coli have several fimbrial types 
including both type 1 (mannose sensitive) and type 2 (mannose resistant) 
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Table 8.4.: Organisms causing urinary tract infection. Adapted from Gruneberg 
(1994). 
haemagglutinins which are important for cell adhesion (Steadman & Topley 1998). In 
addition, an extracellular coat of negatively charged polysaccharides limits phagocytosis 
by host cells. Possession of somatic (0) antigens, which are responsible for the 
initiation of inflammation, and therefore symptoms, and capsular (K) antigens also 
determine the pathogenicity of Escherichia coli in the urinary tract. 
Enterococci are found in relatively small numbers in the gut (about 104/g 
faeces). They are commonly associated with infections following instrumentation of the 
lower urinary tract and have been implicated in the development of recurrent urinary 
tract infections following the menopause. 
Klebsiella species are also part of the normal gut flora and may account for 
approximately 5% of urinary tract infections. They more commonly cause infection in 
in-patients than the community dwelling subjects and have been associated with 
diabetes mellitus (Ly et al 1992). 
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Proteus can cause urinary tract infection in healthy subjects with no 
predisposing factors and therefore be regarded as a true uropathogen. Although found 
in the human gastrointestinal tract, isolation rates from faeces are generally less than 
30% (MacLaren 1998). Proteus multiplies rapidly and has been found to possess 
multiple adhesins and fimbriae which aid its ability to cause ascending infection. 
However, probably its most important virulence factor is the production of urease, 
which splits urea into carbon dioxide and ammonia which is toxic to renal cells. 
8.5. OESTROGEN DEFICIENCY AND URINARY TRACT INFECTION 
Alterations in vaginal physiology and flora following the menopause are thought to 
place women at an increased risk of urinary tract infection, particularly if they are 
sexually active (Semmens & Wagner 1982, Semmens et al 1985). There is a rise in 
vaginal pH and fall in the number of lactobacilli, allowing colonisation with organisms 
from the gastrointestinal tract which act as uropathogens (Stamey & Kaufman 1975). 
Oestrogen reverses the changes which occur as a result of the menopause, probably by 
increasing glycogen production in the vagina leading to recolonisation by lactobacilli 
and a reduction in vaginal pH (Stamey & Timothy 1975). This effect enables oestrogen 
to be used for treatment or prophylaxis against recurrent urinary tract infection. 
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8.5.1. Uncontrolled trials of oestrogen for recurrent urinary tract infection 
Initial small uncontrolled studies of oestrogen therapy for prophylaxis against recurrent 
urinary tract infections produced encouraging results (Table 8.5. ). Parsons and Schmidt 
(1982) gave 5 women with severe recurrent cystitis intravaginal conjugated oestrogens 
until the vaginal flora reverted to that seen in premenopausal women. Of the 5 women, 
4 had no further urinary tract infections in up to 15 months of follow up. 
Brandberg and colleagues (1987) treated 41 female geriatric inpatients with 
recurrent urogenital infections using oral oestriol (3mg per day for one month and 1mg 
per day thereafter). The mean age of the women was "between 80 and 90 years" and no 
indication was given of the mean duration of symptoms. After one month of treatment 
the vaginal flora of all women showed a dominance of lactobacilli. The prescription of 
antibacterial agents for urogenital infections given before the trial started was analysed 
retrospectively and found to be 16 times greater than that during the study period. 
Privette and associates (1988) studied 12 postmenopausal women who 
experienced frequent urinary tract infections and were also found to have atrophic 
vaginitis. The mean age of the patients was 61 years (range 51-73 years) with a mean 
duration of time after the menopause of 12.2 years. Oral conjugated oestrogens were 
given to all women initially but 3 were changed to vaginal therapy because they 
developed side effects consistent with the systemic actions of oestrogen. Prior to 
oestrogen therapy, the frequency of infection was four episodes per patient per year. 
During a follow-up observation period ranging from 2-8 years there were only 4 
infections in the entire group. It is difficult to draw any reliable conclusions from this 
study as the women were also taking prophylactic antibiotics, forced fluids and 
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8.5.2. Case controlled trials of oestrogen for recurrent urinary tract infection 
Orlander and colleagues (1992) examined the automated database of 276 general 
practices in the United Kingdom. Women aged 50-69 years coded as presenting with 
their first UTE were selected, although no information was available about the results of 
urine culture. Each woman with a UTI was matched to five randomly selected female 
controls by age (within 3 years) and practice. Only 18% of the study subjects and 10% 
of the control cases were currently taking HRT, with less than 4% in each group on long 
term therapy (greater than 12 months). Long term oestrogen use was associated with a 
two fold increase in the risk of UTI, odds ratio (OR) 2.0 (95% CI 1.7 - 2.5). However, 
this effect was only seen in women with a uterus and not those who had previously 
undergone a hysterectomy. The data did not provide an obvious reason to account for 
these differences. 
More recently, Oliveria and co-workers (1997) performed a case controlled 
study of 254 women aged 45-89 who were identified from a database as having a 
culture proven UTI. For each case up to five control women were selected, matched by 
year of birth. The patients were all members of a community health plan, and pharmacy 
records were searched for evidence of HRT use. This was similar to that reported by 
Orlander above, with 20% of the women with a UTI taking HIRT and 17% of the 
controls. The authors could find no difference in the risk of developing a UTI between 
those women currently taking HRT and patients who apparently had never used 
oestrogen replacement. The results therefore did not suggest a protective effect of HRT 
on the risk of developing a UTI. 
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8.5.3. Randomised controlled trials of oestrogen for recurrent urinary tract 
infection 
Randomised trials of oestrogen for the prevention of recurrent urinary tract infection 
have produced rather mixed results (Table 8.8. ). Kjaergaard and colleagues (1990) 
randomised 21 postmenopausal women with recurrent cystitis to vaginal oestradiol 
tablets or a placebo. At the end of the five month study period the number of positive 
urine cultures was not statistically different between the two groups. 
Kirkengen and associates (1992) randomised 40 elderly women with recurrent 
urinary tract infections to receive either oral oestriol 3mg / day for 4 weeks followed by 
l mg: / day for 8 weeks or matched placebo. The study was double blind and all 
chemotherapeutic agents were stopped at least two weeks before inclusion. However, 
the study population was rather heterogeneous in that 19 women were hospital 
inpatients and 21 women were living in the community. After the first treatment period 
both therapies reduced the incidence of urinary tract infection but no difference was 
found between oestriol and placebo. However, following the second treatment period 
oestriol was significantly more effective than placebo in reducing the incidence of 
urinary tract infection. In the oestriol group vaginal pH decreased from 6.5 in week one 
to 5.5 in week 12 with no significant changes occurring in the group receiving placebo. 
In a large double blind, placebo controlled study Raz and Stamm (1993) 
recruited 93 postmenopausal women with recurrent urinary tract infection and 
randomised them to either treatment with intravaginal oestriol cream or a placebo. 
Midstream urine cultures were obtained at enrolment, monthly for eight months and 
whenever urinary symptoms occurred. Changes in the vaginal pH and colonisation with 
lactobacilli were present within in the oestriol group only within 1 month of the start of 
treatment. The incidence of urinary tract infection in the group given oestriol was 
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significantly reduced as compared with that in the group given placebo (0.5 versus 5.9 
episodes per patient per year). However, the incidence of urinary tract infection was 
extremely high in this study group and it is therefore unclear if the results are applicable 
to other populations of women with less frequent problems. 
Unfortunately a double blind placebo controlled study of oral oestriol 3mg daily 
for the prevention of recurrent urinary tract infections in 72 elderly women did not 
reproduce these results (Cardozo et al 1998). All women recruited were over the age of 
60 years and had had at least two documented urinary tract infections in the previous 18 
months. The study was apparently difficult to conduct because of its design and the age 
of the participants with a dropout rate of 31%. Although both oestriol and placebo 
improved urinary symptoms during the trial, the incidence of urinary tract infection did 
not differ significantly between the two groups. At the end of the treatment period the 
percentage of women remaining infection free was 43% for the oestriol group and 49% 
for the women receiving placebo. It is possible that the results of this study did not 
match those of Raz and Stamm (1993) because of the oestriol was given orally, rather 
than vaginally, and therefore may not have provided an identical therapeutic dose of 
oestrogen. 
In the largest study to date, Eriksen (1999) recruited a total of 108 women into a 
multicentre, randomised, open, parallel-group study with an untreated control group. 
Postmenopausal women with recurrent, symptomatic, bacteriologically confirmed U TI 
were randomly assigned to have either an Estring (2mg oestradiol) for 12 weeks or no 
oestrogen treatment. Follow up was continued for 36 weeks for the Estring group and 
either 36 weeks or until the first recurrence for the control group. The proportion of 
women remaining infection free was significantly higher in the Estring group than in the 
control group (P=0.008). In addition, after 36 weeks of study the cumulative likelihood 
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of remaining free of disease was 45% in the women with a vaginal ring compared with 
approximately 20% in the control group. However, it is difficult to be certain that the 
results were secondary to the effect of oestrogen rather than having a foreign body (the 
Estring) in the vagina. It would perhaps have been better if some of the women in the 
control group had been given a vaginal ring which did not release oestrogen. 
The HUT committee have recently reported a systematic review of estrogens for 
recurrent UTI's and concluded that vaginal oestrogen administration seemed to be 
effective for this condition (Cardozo et at 1999). However, it is important to note that 
although UTI is one of the most common reasons why a woman may present to her 
doctor, fewer than 400 women have taken part in randomised studies of oestrogen for 
this condition. 
The relatively few studies of oestrogen for prophylaxis against recurrent urinary 
tract infections have therefore produced rather variable results. It is clear that oestrogen 
induces changes in the vaginal epithelium and flora which appear to be favourable for 
the prevention of colonisation with urinary pathogens. However, as this effect does not 
consistently produce an improvement in infection rates above that of placebo, it is 
possible that the menopause and subsequent oestrogen deficiency are not the primary 
aetiological factors in the development of recurrent urinary tract infections in elderly 
women. It can be hypothesised that the effects of ageing on the urogenital tract are 
more important than those of oestrogen deficiency, which may have been overstated. If 
this was the case then the incidence of urinary tract infection should increase steadily 
with age (assuming ageing occurs at a constant rate), with no obvious changes occurring 
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HORMONAL INFLUENCES ON 
URINARY SYMPTOMS AND THE RESULTS 
OF URODYNAMIC INVESTIGATION 
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9.1. RATIONALE 
The background to this study has been discussed in Chapter six. There is anecdotal 
evidence to suggest that many women recognise a change in their urinary symptoms 
during the menstrual cycle. However, the extent of this problem has not been evaluated. 
In addition, data from retrospective reports suggests that the timing of cystometry with 
respect to the menstrual cycle may influence the results of urodynamic investigation. A 
cross sectional study was therefore performed to establish if the menstrual cycle had a 
clinically significant effect on female lower urinary tract symptoms and the results of 
urodynamic investigation. 
9.2. NULL HYPOTHESIS 
This study was designed to test the hypothesis that the menstrual cycle had no impact on 
the severity of urinary symptoms and the diagnosis of abnormal detrusor activity on 
videocystourethrography. 
9.3. OBJECTIVES 
9.3.1. Primary objective 
The primary objective of this study was to assess the menopausal status of women 
referred to the urodynamic clinic at King's College Hospital. I then wished to 
determine the proportion of premenopausal women who complained of a cyclical 
change in their urinary symptoms and establish if the most bothersome period coincided 
with the luteal (progestogenic) phase of the menstrual cycle. 
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9.3.2. Secondary objective 
The secondary objective was to determine if the timing of videocystourethrography with 
respect to the menstrual cycle had an impact on the diagnosis of abnormal detrusor 
activity in premenopausal women with a regular menstrual cycle. 
9.4. PATIENTS AND METHODS 
9.4.1. Study population 
Consecutive women referred with urinary symptoms to the urogynaecology department 
by general practitioners or consultants from other hospitals were prospectively recruited 
to the study over a six-month period. The following inclusion and exclusion criteria 
were met. 
9.4.2. Inclusion criteria 
All consenting English speaking women referred to the urogynaecology unit for 
videocystourethrography were eligible for inclusion in the study. 
9.4.3. Exclusion criteria 
Women were excluded from the study if they met one of the following exclusion 
criteria: 
1. Questionnaire not completed satisfactorily. 
2. Pregnant. 
3. Current urinary tract infection. 
4. Urogenital prolapse only with no urinary symptoms. 
5. Currently taking anticholinergic medication or hormonal therapy. 
6. Routine follow up urodynamics following continence surgery. 
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9.4.4. Methods 
All women recruited to the study completed a questionnaire about their menstrual status 
and urinary symptoms. Three pilot versions of the questionnaire were produced and 
tested on women referred for videocystourethrography. Redundant or confusing 
questions were either modified or excluded before the final version was used 
(Appendix). On registering their arrival at the reception desk in the urodynamic clinic 
women were given the questionnaire which they were asked to fill in while waiting for 
their investigation to be performed. The questionnaire took approximately five minutes 
to complete and was then handed back to the receptionist, so that it was not seen by the 
medical team before consultation. 
Women were categorised into the following menstrual groups on the basis of 
answers given in the questionnaire. It was decided not to perform serum analysis for 




3. Less than 12 months of amenorrhoea. Patients in this category were probably 
postmenopausal but could not be definitely classified as such because they had 
had at least one period in the last year. 
4. Perimenopausal (age 45-55 years) and taking hormone replacement therapy. 
5. Previous hysterectomy so menopausal status uncertain. 
Women over the age of 55 who were taking hormone replacement therapy or who had 
previously undergone a hysterectomy were coded as being postmenopausal. 
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Videocystourethrography was then performed on the same day by myself or one 
of my urogyanecological registrar colleagues using the protocol described in Chapter 
four. Abnormal detrusor activity was diagnosed when there was low compliance on 
filling, systolic or provoked detrusor instability. Cystometry was deferred for women 
complaining of symptoms of urinary tract infection with either leukocytes, protein or 
haematuria on urinalysis until they had been treated with the appropriate antibiotics. 
They were therefore excluded from the study. 
9.4.5. Statistical analysis 
The number of days from the start of the last menstrual period to the date of 
investigation was categorised as 1-7,8-14,15-21,21-28 days. The data were entered 
onto a Microsoft Excel spreadsheet, checked for accuracy and then analysed using the 
statistical package SPSS (version 8.0 for windows). All data entry, processing and 
analysis was performed by myself. Data relating to diagnosis of abnormal detrusor 
activity were analysed using the Chi-squared test. This statistical test tabulates a 
variable into categories and computes an observed and expected frequency for each 
group. The difference between the observed and expected proportion of values in each 
category was considered significant when P was less than 0.05. 
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9.5. RESULTS 
548 consecutive women referred for videocystourethrography were asked to complete 
the questionnaire on arrival in the department. 65 patients were excluded for the 
reasons outlined in Table 9.1.. 
REASON NUMBER OF WOMEN (%) 
Follow-up after continence surgery 21(32%) 
Urogenital prolapse only 19 (29%) 
Urinary tract infection 6 (9%) 
Questionnaire not completed properly 5 (8%) 
Did not wish to complete questionnaire 2 (3%) 
Currently taking anticholinergic medication 2 (3%) 
Gender re-assignment 1 (2%) 
Urodynamics considered inappropriate 9 (14%) 
Table 9.1.: Reasons why women were excluded from the study. Number of women 
(Percentage of total number of women excluded). 
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9.5.1. Demographic details 
483 women were included in the study with a mean age of 50.4 years (SD 13.7) and 
median parity of 2 children (range 0-12). The age distribution is shown in Figure 9.1.. 
381 (78.9%) women were white, 33 (6.8%) black Afro-Caribbean, 27 (5.6%) Asian, 22 
(4.6%) black-African with the remaining 20 (4.1%) women from other races. 
154 (31.9%) women had previously undergone a hysterectomy of which 122 
(79.2%) had been performed abdominally. 190 (39.3%) patients were currently taking 
medication other than hormone replacement therapy. 
9.5.2. Previous treatment 
219 (45.3%) women had previously had treatment for their bladder complaint with 
some women having received multiple different therapies. This is shown in Table 9.2.. 
TREATMENT GIVEN NUMBER OF WOMEN (%) 
Pelvic floor exercises 138 (28.6%) 
Medication 121 (25.1%) 
An operation 76 (15.7%) 
Electrical stimulation 31(6.4%) 
Bladder retraining 29 (6.0%) 
Other 24 (5.0%) 
No treatment 264 (54.7%) 
Table 9.2.: Previous treatment given to the women in the study population. 

















Age group (years) 
Figure 9.1.: The age distribution of the 483 women referred for 
videocystourethrography who were included in the study. 
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9.5.3. Aetiology of urinary symptoms 
The patients were asked what they thought was the main cause of their bladder 
problems to try and determine how many women felt that the menopause was 
responsible for their urinary complaints. The responses are shown in Table 9.3.. 
Overall only 25 (5.2%) women felt that the menopause was the main cause of their 
urinary symptoms, although 21 (10.7%) of the postmenopausal women gave this 
response. 
CAUSE OF BLADDER PROBLEM NUMBER OF WOMEN (%) 
Having children 173 (35.8%) 
Hysterectomy 70 (14.5%) 
Menopause 25 (5.2%) 
Mental stress 23 (4.8%) 
An operation other than hysterectomy 21(4.4%) 
Cold weather 11(2.3%) 
Infection 8 (1.6%) 
Ageing 4 (0.8%) 
Other 35 (7.2%) 
Unsure 113(23.4%) 
Table 9.3.: The main reasons the women in the study considered to be the cause of 
their bladder problems. 
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9.5.4. Menopausal status of the study population 
On the basis of answers given in the questionnaire the women were categorised into the 
groups shown in Figure 9.2.. There was an almost identical number premenopausal 
women (n=194) and postmenopausal women (n=196) in the study group. There were 
only 6 (1.2%) women who were probably postmenopausal but could not be categorised 




































Figure 9.2.: The menopausal status of the 483 women referred for 
videocystourethrography who were included in the study. 
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9.5.5. The use of oestrogen and HRT 
281 (58.2%) women had taken the oral contraceptive pill in the past but only 20 (4.1 %) 
were currently using this medication. 190 (39.3%) patients had used HRT at some time 
with 124 (25.7%) women still using this treatment at the time of entry into the study. 


















Tablets Patches Implants Vaginal Topical 
cream 
Route of administration 
Figure 9.3.: Route of administration of Hormone Replacement Therapy being used 
by the women in the study. 
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9.5.6. The menstrual cycle and urinary symptoms 
194 (40.2%) women were premenopausal with a mean age of 38.4 years (SD 7.97). 45 
(23.2%) women had an irregular menstrual cycle. 149 (76.8%) premenopausal women 
had a regular menstrual cycle and formed the study group. However, 16 (10.7%) 
women with regular menses were taking the combined oral contraceptive pill (coc) and 
therefore excluded from further analysis [4 women with an irregular cycle were also 
taking the coc]. 
55/133 (41.4%) premenopausal women with a regular menstrual cycle (not on 
the coc or other hormonal therapy) complained that their urinary symptoms were 
cyclical with the worst times characteristically just before and during a period (Figure 
9.4. ). The time when the urinary symptoms were said to be most bothersome was 
distributed as follows: during a period 20 (36%), just after a period 4 (7%), middle of 












Time urinary symptoms most bothersome 
Figure 9.4: Time when urinary symptoms were most bothersome in relation to the 
menstrual cycle. 
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9.5.7. Videocystourethrography and the menstrual cycle 
The prevalence of abnormal detrusor activity diagnosed on videocystourethrography 
increased significantly with time from the last menstrual period and may reflect 
increases in the circulating level of progesterone following ovulation (Chi squared for 
trend=6.56, df=1, P=0.01) (Figure 9.5. ). The number of women with abnormal detrusor 
activity in each group was distributed as follows: day one-seven 7/31 (23%), day eight- 
fourteen 10/35 (29%), day fifteen-twenty one 12/35 (34%), day twenty two-twenty eight 
16/28 (57%). Data were not available for 4/133 (3%) women because of technical 
difficulties with the urodynamic equipment. 
Abnormal detrusor activity was not diagnosed more frequently in those women 
who complained of cyclical symptoms compared to the patients whose bladder 
complaint did not fluctuate with the menstrual cycle (Chi squared 1.71, dgl, P=0.19). 
In addition, the relationship. between increasing prevalence of abnormal detrusor 
activity and number of days from the last menstrual period was still present even in 
those women who did not complain that their symptoms were cyclical (Chi squared for 
trend=14.3, d3, P=0.003). 
Sub-analysis on the changing prevalence of the different types of detrusor 
overactivity with respect to the menstrual cycle was not performed as the numbers in 












Time from LMP (days) 
Figure 9.5.: Percentage of women with abnormal detrusor activity on 
videocystourethrography with respect to time from the last menstrual period. 
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9.6. DISCUSSION 
9.6.1. Study design and population investigated 
The primary objective of this study was to assess the menopausal status of women 
referred for urodynamic investigation. All patients attending the clinic were approached 
and asked to take part in the study. Questionnaires were completed while the women 
were waiting to be seen by medical staff and then handed back to the x-ray receptionist. 
Details of the patients' hormonal status and the nature of their urinary symptoms were 
therefore not seen before investigations were performed so as not to bias the results. 
Only five women who agreed to take part did not complete the questionnaire properly, 
suggesting that modification of the pilot versions had been successful. 
A large number of patients were studied in order to achieve a sample size large 
enough to draw meaningful conclusions. The multicultural population seen in the clinic 
appears to be a reasonable reflection of the surrounding community. The majority of 
women had received no treatment for their urinary symptoms, and in those who had, 
pelvic floor exercises were the most common therapy tried. Medication had been used 
by 25% of the population but as all were asked to stop taking any tablets which had 
been prescribed for their bladder seven days before investigation, only a very small 
number of women needed to be excluded because they were still taking anticholinergic 
therapy. 
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9.6.2. Hormonal characteristics of the population studied 
The mean age of the 483 women investigated was 50.4 years with approximately an 
equal proportion of women in the pre-menopausal and post-menopausal groups. These 
findings are similar to those of community based epidemiological surveys which also 
report the peak prevalence of incontinence to be almost identical to the average age of 
the menopause (Thomas et al 1980, Jolleys 1988). Also in common with these studies, 
the prevalence of incontinence appeared to rise many years before the menopause and 
fall in the period when oestrogen deficiency is most likely. 
Almost 60% of women had used the contraceptive pill at some point but only 20 
(4.1 %) were currently using this medication. In view of the small number of women in 
this group it was not really possible to comment on the influence of this therapy on 
urinary symptoms or the results of videocystourethrography. Using the contraceptive 
pill to treat women with cyclical urinary complaints is considered below. 
Although the largest number of women referred were in the perimenopausal age 
group, overall only 5.2% of patients felt that the menopause was the main cause of their 
urinary symptoms. Most women either thought that having children was the most likely 
cause of their problem or they were unsure why they had developed bladder symptoms. 
The use of hormone replacement therapy (HRT) in the study population was higher than 
the 15% previously reported in the UK (Barlow et al 1991, Wilkes & Meade 1991). 
There are several possible reasons why this may be the case. Firstly, these women had 
sought help from their family doctors and may therefore be more inclined to consider 
the health benefits of HRT than the general population who may not have a specific 
medical complaint. Secondly, some general practitioners may be aware of the possible 
use of HRT for urogenital disorders and start their patients on oestrogen before referral 
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to hospital. Thirdly, this fording may be a reflection of the increasing use of HRT over 
the last decade. 
9.6.3. Effect of the menstrual cycle on the prevalence of urinary symptoms and 
the results of urodynamic investigations 
Although it has long been recognised that some women report an increase in irritative 
bladder symptoms and their ability to maintain continence just prior to menstruation, 
prospective reports in this area are extremely limited. This study was therefore 
designed to clarify the impact of the menstrual cycle on the lower urinary tract. 
Analysis was restricted to patients with a regular menstrual cycle who were not taking 
hormonal therapy. It can therefore be assumed that at least 95% of these women will 
have had a hormonal pattern with a pre-ovulatory phase of oestrogen dominance and 
post-ovulatory phase of progesterone dominance (Baien & Jacobs 1997). This is 
outlined in detail in Chapter five. 
Approximately 40% of pre-menopausal women with a regular menstrual cycle 
(who were not taking hormonal therapy or anticholinergic medication) complained that 
their urinary symptoms occurred cyclically with the time just before a period 
characteristically found to be the most bothersome. The possible reasons for this are 
discussed below. It is uncertain why some women in this study found their bladder 
complaints particularly troublesome during a period. Although detrusor instability has 
been previously been described only during menstruation (Lewis & Warrell 1989) 
overall the prevalence of detrusor activity was at its lowest in the first few days of the 
menstrual cycle. This finding would therefore not support the hypothesis that cyclical 
prostaglandin release from the genital tract around the time of a period has a major 
influence on the bladder. A more likely explanation for the increase in problems at this 
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time is that women find it much more inconvenient to have urinary symptoms at the 
same time as they are menstruating. 
Attempts were made to try and determine which individual urinary symptoms 
changed during the menstrual cycle on early versions of the questionnaire. 
Unfortunately, almost all the women had more than one symptom and despite several 
modifications it proved impossible to reliably discriminate between the fluctuations of 
several different urinary complaints. To investigate this area in more detail, and 
validate the reported cyclical changes, further prospective studies could be performed to 
assess changes in the severity of different urinary symptoms over time using bladder 
diaries. Such a study would need to be done over a period of at least three months, but 
it would probably be the best way of assessing if any objective changes in patient 
symptomatology could be demonstrated. Measurement of progesterone levels on the 
21' day of the menstrual cycle could also be made although this would be time 
consuming (for both patient and doctor), expensive and unlikely to add significantly to 
the data in view of the hormonal changes which are already known to occur in women 
with regular cycles. 
The secondary objective of this study was to determine if the timing of 
videocystourethrography with respect to the menstrual cycle had an impact on the 
diagnosis of abnormal detrusor activity. When the study was being planned it was 
decided to only analyse this variable, rather than looking at all urodynamic parameters, 
because it was felt to be the most likely cause of the reported pre-menstrual increase in 
irritative bladder symptoms. Again the menstrual cycle appeared to have a significant 
influence on the prevalence of bladder dysfunction with an increase in the detection of 
abnormal detrusor activity occurring during the luteal phase. These data are important 
because they may have implications for the investigation and treatment of 
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premenopausal women whose initial urodynamics are normal. For example, 
urodynamic studies may need to be repeated during a different part of the menstrual 
cycle in such women, otherwise the diagnosis of detrusor instability may be missed and 
sub-optimal treatment given. 
The findings of this study are in contrast with two smaller previous reports 
which are discussed in Chapter six. Sorenson and colleagues (1988) were unable to 
detect any urodynamic changes attributable to the menstrual cycle in 10 women, 
although perhaps this was because they were all asymptomatic volunteers in whom 
there were no cases of detrusor instability. Shimonovitz and associates (1997) 
identified 57 women with regular periods on their urodynamic database. In this report 
more abnormal urodynamic diagnoses, including detrusor instability, were made during 
the follicular phase but only relatively few women were investigated during each stage 
of the menstrual cycle. In addition, also at variance with our findings was the 
observation that significantly more normal results were found in the women who felt 
their symptoms were influenced by the menstrual cycle compared to those who did not. 
In fact, in our study the relationship between increasing prevalence of abnormal 
detrusor activity and the number of days from the last period was still present even in 
those women who did not complain that their symptoms were cyclical. 
The changes in urinary symptoms and detrusor activity in our study provide 
further evidence that the female lower urinary tract is sensitive to the effects of sex 
steroids. There are several possible mechanisms to account for this. Oestrogen and 
progesterone are known to influence mood and cognitive function and it may be that a 
significant part of their effect on the lower urinary tract during the menstrual cycle is 
mediated via a central action on receptors in the brain and neurological pathways. 
Although progesterone does not appear to significantly change the urethral pressure 
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profile (Raz et al 1973, Rud 1980, Van Geelen et al 1981) increases in its level during 
pregnancy are thought to cause a rise in detrusor instability antenatally compared to that 
found postpartum (Cutner 1993, Chaliha et al 1998). It is unclear if this is secondary to 
a central action or a direct effect on the detrusor muscle itself. Therefore, during the 
menstrual cycle it is possible that the changes which appear to be induced by 
progesterone may be due to a combination of central and local effects although the exact 
mechanism of action remains to be determined. 
This study suggests that the timing of urodynamic investigation within the 
menstrual cycle may be important. However, it is uncertain if symptomatic women who 
have a normal study during the follicular phase of the menstrual cycle should have their 
study repeated during the luteal phase. It is also interesting to speculate that 
suppression of the normal menstrual cycle may improve the urinary symptoms of some 
women and possibly alter the detection of abnormal detrusor activity. However, as 
hormonal therapies have previously been shown to have a poor efficacy in the treatment 
of other urinary complaints the outcome of this type of therapy is far from clear. To 
answer these questions further appropriately designed studies will need to be performed. 
It is known that women with incontinence who are taking cyclical HRT may 
experience a deterioration in their symptoms during the progestogenic phase of 
treatment (Benness et al 1991). The effect of timing of urodynamic investigation in 
women on such preparations was not assessed in this study but could be the subject of 
further research. The effect of continuous combined therapy and the selective oestrogen 
receptor modulators (SERM) on the female lower urinary tract are also uncertain and 
considered further in Chapter 13. 
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CHAPTER 10 




The background to this study has been discussed in Chapter seven. Urinary symptoms 
occur commonly in women of all ages but epidemiological studies in postmenopausal 
women are complicated by the concurrent effects of the ageing process. Our aim 
therefore was to determine the effect of oestrogen deficiency on the prevalence of 
urinary symptoms in younger women. 
10.2. NULL HYPOTHESIS 
The following study was designed to test the null hypothesis that severe eating disorders 
and associated oestrogen deficiency had no impact on the prevalence of urinary 
symptoms in young women. 
10.3. OBJECTIVES 
10.3.1. Primary objective 
The primary objective was to measure the prevalence of urinary symptoms in women 
with severe eating disorders and a group of age matched controls. 
10.3.2. Secondary objectives 
The secondary objective was to determine if measures of oestrogen deficiency, 
including serum oestradiol level and presence of amenorrhoea, were directly related to 
the presence of the most predominant urinary symptoms in the women studied. 
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10.4. POWER CALCULATION 
Based on our earlier work showing an approximately 60% prevalence of irritative 
urinary symptoms in women with eating disorders (Boos et al 1999) and assuming a 
20% prevalence of irritative urinary symptoms in the general population (Bungay et al 
1980), 22 subjects were required in each group to show a difference with 80% power at 
the 5% significance level. 
10.5. PATIENTS AND METHODS 
10.5.1. Study population 
Women with severe eating disorders (anorexia nervosa or bulimia nervosa) were 
prospectively recruited to the study from a specialist resident In-patient unit at the Royal 
Bethlam Hospital. This is a tertiary referral centre run under the supervision of Dr Janet 
Treasure, Consultant Psychiatrist. During the study period I was assisted in identifying 
and enrolling eligible patients by Dr Sara Majid, Specialist Registrar in Psychiatry. 
Radiographers working in the x-ray department at King's College Hospital agreed to act 
as controls. This group was chosen because the women were likely to be of comparable 
age to those with eating disorders and also have similar socio-economic backgrounds. 
10.5.2 Inclusion criteria 
All English speaking women with an eating disorder who were In-patients at the Royal 
Bethlam Hospital, or radiographers working at King's College Hospital were eligible 
for inclusion in the study. 
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10.5.3 Exclusion criteria 
Women were not included in the study if they had one or more of the following 
exclusion criteria: 
1. Unwilling to give blood. 
2. Pregnant. 
3. Controls to have no history of an eating disorder. 
4. Did not wish to take part. 
10.5.4 Methods 
Women eligible to take part in the study were prospectively recruited. Permission to 
approach the radiographers was obtained from the superintendent radiographer Mr 
Richard Cannon, who announced that the study was taking place in a departmental 
meeting. All subjects were given a written information sheet (Appendix) and assured 
that any information they gave would be strictly confidential. 
To assess eating disorder severity all women completed the Eating Attitudes 
Test (EAT 26)(Appendix). A score of less than 20 for women in the control group was 
considered to indicate that the radiographer had no evidence of an eating disorder. The 
prevalence of urinary symptoms in each group was determined using the King's Health 
Questionnaire, which was completed in private (Appendix). Each bladder symptom 
was recorded as mild, moderate or severe by the subject, with absence of a response 
indicating that the woman did not have that urinary complaint. These answers were 
then converted into numerical scores of 0,1,2 or 3 allowing a mean score for each 
symptom and group to be calculated. 
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An assessment of each woman's menstrual pattern was made and the duration of 
amenorrhoea, if present, recorded. Details of any co-existent medical problems and 
medications were sought. 
Body Mass Index (BMI) was calculated and a mid-stream sample of urine 
(MSU) sent for microscopy and culture. As described in Chapter eight, urinary tract 
infection was diagnosed when there was a pure growth of >105organisms / ml. Serum 
was taken on the same day that the questionnaires were completed and analysed for 
oestradiol, luteinizing hormone, follicle stimulating hormone, thyroid stimulating 
hormone and prolactin levels. 
10.5.5 Statistical analysis 
The data were analysed using the statistical package SPSS (version 8.0 for windows). 
The prevalence of urinary symptoms in each group was compared using the Chi- 
squared test. As information was sought about the prevalence of nine different urinary 
symptoms, there was a high probability of fording a significant difference between the 
groups just by chance. In view of the multiple comparisons a correction in the level of 
significance was made using the Bonferroni method (P < 0.05 /9=0.006). 
The quality of life data was not normally distributed and therefore analysed 
using the non-parametric Mann-Whitney test. 
Logistic regression analysis is useful for trying to predict the presence or 
absence of a characteristic or outcome based on a set of predictor variables. This test 
was therefore used to assess the association between markers of oestrogen deficiency 
and the most common urinary symptoms. 
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10.6. RESULTS 
10.6.1 Demographic data 
A total of 55 women were recruited over a 4-month period. The study population 
comprised 30 women with eating disorders who were currently In-patients at the Royal 
Bethiam Hospital; 28 women had a diagnosis of severe anorexia nervosa and 2 women 
had severe bulimia nervosa. The median duration of time from diagnosis of an eating 
disorder was 7.4 years (IQR 3-9 years). 25 radiographers working at King's College 
Hospital agreed to act as controls. 
None of the women with eating disorders refused participation but two of the 
radiographers who were approached were unable to take part; one did not wish to have 
blood taken and the other was eight weeks pregnant. The demographic details of each 
group are shown in Table 10.1.. The distribution of EAT 26 scores is demonstrated in 
Figure 10.1. and BMI in Figure 10.2.. 
EATING DISORDERS CONTROLS 
(n = 30) (n = 25) 
Mean age (years) (SD) 26.6 (7.3) 26.8 (4.7) 
Number Parous 2 (6.6%) 2 (8%) 
Number using COC 0(00/0) 12 (48%) 
Median EAT 26 score (IQR) 52 (45-60) 3 (1-5) 
Median Body Mass Index (IQR) 15.6 (14.9-17.8) 23.0 (20.7-25.0) 
Table 10.1.: The baseline demographic details of the study population. 
194 












D Controls   Eating Disorders 













0 Controls   Eating Disorders 
195 
0-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 
EAT 26 score 
11-15 16-20 21-25 26-30 31-35 
BMI 
10.6.2 Hormonal Profile 
The menstrual pattern of each subject was determined and is shown in Table 10.2.. 
Women having periods every 35 days or more were classified as having 
oligomenorrhoea and women with absent menses for more than 6 months secondary 
amenorrhoea (none of the subjects studied had primary amenorrhoea). 24 (80%) 
women with eating disorders had secondary amenorrhoea with a median duration of 
absent menses of 3 years (IQR 1.1-5.9). 
MENSTRUAL PATTERN EATING DISORDERS CONTROLS 
Normal 4(13%) 21(841/o) 
Oligomenorrhoea 2 (7%) 4 (16%) 
Amenorrhoea 24 (80%) 0 (0%) 
Table 10.2.: The menstrual pattern of the study population. 
The results of the hormonal assays are shown in Table 10.3.. None of the 
patients with amenorrhoea had a hormonal abnormality which could account for their 
absent menses other than hypo-oestrogenism. Thyroid function was normal in all cases. 
HORMONE EATING DISORDERS CONTROLS 
LH (U/L) 1.35 (1.0-4.0) 4.7 (1.9-9.7) 
FSH (U/L) 5.10 (4.0-6.3) 4.2 (2.0-5.3) 
Prolactin (mU/L) 167 (130-240) 188 (149-294) 
Oestradiol (pmoVL) 67 (45-98) 165 (80-380) 
Table 10.3.: Hormonal characteristics of the women. Values given are medians 
(interquartile range). 
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10.6.3 Urinary tract infection 
1 (3%) woman in the eating disorder group had a positive urine culture and this grew E. 
Coli. 2 (8%) women in the control group had an infected MSU sample. In one there 
was a positive culture of E. Coli and in the other Klebsiella. 
10.6.4 Coexistent illnesses and Medication 
6 (20%) women with an eating disorder had been diagnosed as having osteoporosis but 
none had a history of associated fractures. 1 (3%) woman had a history of angina for 
which she took GTN spray but no other cardiac medications. None of the women in the 
control group had a history of significant illness or surgery. 
17 (57%) of the eating disorders group were using medication; 9 women were 
taking Fybogel for constipation, 1 women was using Ferrous sulphate for anaemia and 7 
women were prescribed antidepressants. Only 3 (12%) women in the control group 
were taking medication at the time of the study; one was using Mebeverine for irritable 
bowel syndrome and the other two used inhalers for mild asthma. 
10.6.5 Prevalence of urinary symptoms 
All women in the study completed the King's Health Questionnaire. There was a highly 
significant difference in the overall prevalence of urinary symptoms between the two 
populations. In the eating disorder group 28/30 (93%) women complained of one or 
more urinary symptom compared to only 9/25 (36%) women in the control group 
(P=0.0001). The prevalence of each urinary symptom is detailed in Table 10.4., with 








Frequency 26 (87) 6 (24) P=0.00002 
Nocturia 25 (83) 7 (28) P=0.00018 
Urgency 17 (57) 3 (12) P=0.00224 
Urge incontinence 13 (43) 1 (4) P=0.00317 
Stress incontinence 13 (43) 1(4) P=0.00317 
Nocturnal enuresis 6 (20) 1(4) P=0.189 
Intercourse incontinence 2 (7) 1(4) P=0.08713 
Recurrent infections 9 (30) 2 (8) P=0.08713 
Bladder pain 8 (27) 0(0) P=0.00633 
Table l04.: The prevalence of urinary symptoms in the control group and women 
with eating disorders. Values given are n (%). The difference in the prevalence of 
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10.6.6 Severity of urinary symptoms in women with severe eating disorders 
In the women with eating disorders the mean severity score for urinary frequency was 1.80 
(SD 1.06), nocturia 1.40 (SD 0.97), urgency 1.10 (SD 1.12), urge incontinence 0.70 (SD 0.95) 
and stress incontinence 0.57 (SD 0.73). The distribution of responses for these symptoms is 
shown in Figure 10.4.. Only 4 (13%) women had previously received treatment for their 
urinary symptoms (all had been prescribed antibiotics for a presumed urinary tract infection). 













Figure 10.4.: The severity of the most commonly reported urinary symptoms in the 
women with eating disorders. 
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Frequency Nocturia Urgency Urge Stress 
incontinence incontinence 
10.6.7. Impact of urinary symptoms on quality of life. 
The King's Health Questionnaire was used to assess the impact of the women's urinary 
symptoms on their quality of life. There was a significant difference in the scores 
between each study group in all of the domains except social limitations (possibly 
because the women with an eating disorder were hospital In-patients) and personal 
relationships (probably because few of the women with an eating disorder had a 
partner). The effect on quality of life is shown in Table 10.5. and Figure 10.5.. 
DOMAIN EATING CONTROLS SIGNIFICANCE 
DISORDERS 
General Health 50(25-50) 25 (0-25) P=0.001 
Incontinence Impact 33 (0-67) 0 (0-0) P=0.001 
Role Limitations 0 (0-17) 0 (0-0) P=0.001 
Physical Limitations 0 (0-33) 0 (0-0) P<0.001 
Social Limitations 0(0-21) 0 (0-0) P=0.192 
Personal Relationships 0 (0-13) 0 (0-0) P=0.571 
Emotions 11(0-22) 0 (0-0) P<0.001 
Sleep / Energy 33 (17-50) 0 (0-33) P<0.001 
Severity 25 (8-42) 0 (0-0) P<0.001 
Table 10.5.: Median (interquartile range) of scores in the domains of the King's 
Health Questionnaire. Differences in the groups analysed using the Mann- 
Whitney test. 
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10.6.8 Role of oestrogen deficiency in the aetiology of urinary symptoms 
Logistic regression analysis was used to assess if markers of oestrogen deficiency 
(serum oestradiol level, presence and duration of amenorrhoea), BMI and the time from 
diagnosis of the eating disorder were significant prognostic variables for the presence of 
the most commonly reported urinary symptoms. These variables were initially assessed 
independently and then in combination with their diagnostic group (eating disorder or 
control) as a covariable. 
10.6.8.1. Frequency 
Logistic regression analysis revealed the presence of amenorrhoea (P = 0.0047), 
duration of amenorrhoea (P = 0.0445), BMI (P = 0.0006) and time from diagnosis of an 
eating disorder (P = 0.0391) to be prognostic variables for the presence urinary 
frequency. Serum oestradiol was not a significant marker (P = 0.0527). However, 
when these factors were assessed with their diagnostic group as a covariable duration of 
amenorrhoea (P = 0.7225), BMI (P = 0.5960) and time from diagnosis (P = 0.7225) 
were no longer significant. It was not possible to tell which out of the presence of 
amenorrhoea or the diagnostic group was more directly related to urinary frequency 
because neither factor was significant after adjusting for the other (diagnostic group P= 
0.8104, presence of amenorrhoea P=0.8351). This is not surprising given the close 
association between the diagnosis of a severe eating disorder and the presence of 
amenorrhoea. 
10.6.8.2. Nocturia 
The presence of amenorrhoea (P = 0.0021) and BM (P = 0.0015) initially appeared to 
be prognostic factors for the symptom of nocturia while duration of amenorrhoea (P = 
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0.0559), time from diagnosis of an eating disorder (P = 0.730) and serum oestradiol 
level (P = 0.420) did not. However, when analysed in combination with the diagnostic 
groups neither of these markers was significant. It would therefore appear that 
amenorrhoea and low BMI are proxies for the presence of an eating disorder when 
predicting if a woman will have nocturia. 
10.6.8.3. Urgency 
The presence of amenorrhoea (P = 0.0095) and time from diagnosis of an eating 
disorder (P = 0.0149) both initially appeared to be prognostic factors for the presence of 
urgency while duration of amenorrhoea (P = 0.0635), BMI (P = 0.138) and serum 
oestradiol level (P = 0.2710) did not. However, when analysed in combination with 
diagnostic group neither of these markers was significant. As with nocturia, other 
variables were simply proxies for the presence of an eating disorder when predicting if a 
woman had urinary urgency. 
10.6.8.4. Urge incontinence 
The presence of amenorrhoea (P = 0.0277), duration of amenorrhoea (P = 0.0235), BMI 
(P = 0.0083) and time from diagnosis of an eating disorder (P = 0.0092) all initially 
appeared to be prognostic variables for the prediction of urinary urge incontinence while 
serum oestradiol level was not (P = 0.0924). However, when these markers were 
analysed in combination with the diagnostic group none remained significant. It would 
therefore appear again that these variables were proxies for the presence of an eating 
disorder when predicting if a woman had urge incontinence. 
204 
10.6.8.5. Stress incontinence 
Logistic regression analysis initially revealed only BMI to be a significant factor in 
predicting if a woman in the study complained of stress incontinence (P = 0.0209), but 
this was not independent of the diagnosis of an eating disorder (P = 0.6994). None of 
the other variables assessed, including parity, predicted if a woman would complain of 
this symptom. 
10.7. DISCUSSION 
10.7.1 Study design and recruitment of subjects 
A number of epidemiological studies have implicated the menopause in the 
pathophysiology of urinary symptoms. However, it is uncertain how much of this effect 
is secondary to the ageing process and how much is due to oestrogen deficiency. The 
primary objective of this study was therefore to evaluate the urinary complaints of a 
group of young oestrogen deficient women, in whom the effects of ageing were likely to 
be less significant. 
Several possible groups were considered when designing this study. Firstly, 
patients with premature ovarian failure. This is a relatively rare condition and most 
women are started on hormone replacement therapy almost immediately following 
diagnosis, malting recruitment of a large sample of patients difficult. Secondly, women 
undergoing down-regulation with gonadotrophin analogues for endometriosis or 
fibroids, or as part of infertility treatment. However, in this group the duration of 
oestrogen deficiency is usually relatively short and urogenital symptoms may be 
influenced by other pelvic pathology. Therefore, the third option of studying women 
with severe eating disorders was selected. As outlined in Chapter seven this condition 
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is associated with anovulation and, as a consequence, the effects of oestrogen deficiency 
including amenorrhoea and osteoporosis. 
After discussion with the colleagues in the eating disorders unit at the Royal 
Bethlam Hospital women with anorexia nervosa or bulimia nervosa, who were being 
treated as Inpatients, were recruited. These women certainly had evidence of 
prolonged, severe oestrogen deficiency. For example, the median serum oestradiol level 
at only 67 pmol/L was within the postmenopausal range, 87% had either 
oligomenorrhoea or amenorrhoea, and 20% had osteoporosis. The control group of 
radiographers was chosen as the women were likely to be of comparable age to the 
above study population; in fact both groups had a mean age of 26 years. However, they 
were shown different to the women with eating disorders in a number of important 
respects. Their median BMI was within the normal range, 84% had a regular menstrual 
cycle and none had evidence of an eating disorder on the EAT 26 questionnaire. The 
control subjects would therefore appear to represent a reasonable group for comparison. 
The study was designed to assess differences in the prevalence of urinary 
complaints between the two groups. The King's Health Questionnaire proved to be 
extremely useful for this as it allowed both an evaluation of the severity of different 
urinary symptoms and also their impact on the quality of life of the patient. It was 
hoped that women in the eating disorder group would be prepared to undergo 
urodynamic investigation to try an identify any underlying functional abnormalities. 
Unfortunately, the medical staff in the eating disorders unit were not in favour of this as 
there were concerns that it may upset the women and effect the psychotherapy that most 
were undergoing. In addition, without exception the women themselves were not 
prepared to have investigations performed even though sometimes their urinary 
symptoms were reported as being severe. 
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10.7.2 Urinary symptoms in women with an eating disorder and their impact on 
Quality of Life 
In common with our previous study (Boos et al 1999), women with eating disorders 
were shown to have a high prevalence of urinary symptoms. The small differences 
between the two studies were probably secondary to the different methods of collecting 
data - in the initial study a doctor administered questionnaire was used and this may 
account for the slightly lower prevalence of some of the symptoms. Following the 
menopause irritative urinary symptoms including frequency, urgency and urge 
incontinence occur commonly. This pattern was also found in our population of young 
women, providing further indirect evidence that the menopause and subsequent 
oestrogen deficiency are important in the pathogenesis of some urinary complaints. 
Interestingly, 43% of the women with an eating disorder admitted to having the 
symptom of stress incontinence, although only 2 (6.6%) were parous. It is possible that 
the underlying mechanism for this may be similar to that occurring in perimenopausal 
women. While the symptoms were mainly described as mild or moderate in their 
severity they were shown to have a significant impact on the quality of life of the 
women studied. However, despite this fording very few women had sought help or 
received treatment for their bladder problem in the past. 
The background prevalence of urinary symptoms in the control group was 
similar to that found in previous epidemiological studies (Bungay et al 1980). This was 
reassuring as there was some concern that the radiographers would feel embarrassed to 
admit to any bladder complaints if they were not entirely happy that the study would be 
completely confidential. Therefore, this does not appear to have been a problem. It is 
almost always possible to criticise the choice of a control group and the one chosen in 
this study is no exception. Eating disorders are essentially a psychiatric problem which 
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are associated with a degree of stress and anxiety. It may therefore have been better to 
have used a control group of women with an anxiety state for comparison, although this 
group of women could perhaps have formed a third arm of the study. An anxiety score 
could then be calculated for each group and related to the prevalence of the urinary 
symptoms. 
10.7.3 Is oestrogen deficiency the most likely cause of urinary symptoms in women 
with an eating disorder? 
Patients with eating disorders differ from normal women in a number of important 
psychological and metabolic respects, as outlined in Chapter seven. There are 
therefore a number of possible reasons why this group of women may develop urinary 
symptoms. Many women with anorexia nervosa have psychosexual problems, possibly 
leading to an increased perception of the urogenital area. It could be speculated that this 
may produce concerns about bladder and vaginal symptoms which are in fact variations 
of normal. Some women with eating disorders increase their fluid intake to stop 
themselves feeling hungry while others use diuretics and laxatives to prevent weight 
gain. Alone or in combination these actions may lead to urinary frequency and nocturia. 
However, this does not appear to have been the cause of the increased prevalence of 
urinary symptoms in this study because the women were all living in a controlled 
environment where their oral intake of food was strictly monitored and fluid restricted 
to 1500m1 / 24 hours. Although a number of women were taking antidepressants these 
were unlikely to be responsible for the high prevalence of irritative urinary complaints 
as these medications generally have an anticholinergic action, an effect which allows 
them to be used for treatment in women with abnormal detrusor activity. Their use may 
therefore have possibly reduced the prevalence of some symptoms. 
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The secondary objective of the study was to determine if measures of oestrogen 
deficiency were directly related to the presence of the most predominant urinary 
symptoms. Unfortunately, in this group of patients the diagnosis of an eating disorder 
and the presence of oestrogen deficiency were so closely linked that it was not possible 
to say which was the most important aetiological factor. The women assessed were all 
at the severe end of the disease spectrum and to investigate this question further it may 
be necessary to recruit women with a broader disease profile. An alternative approach 
would be to treat symptomatic women with oestrogen and see if they improved. The 
problem with this is that in general women with eating disorders do not like taking the 
combined oral contraceptive or other forms of oestrogen replacement as this treatment is 
associated with fluid retention and therefore mild weight gain. An alternative to limit 
this effect would be to give the oestrogen vaginally but overcoming the above concerns 
would probably still prove difficult. 
It is possible to speculate that urinary symptoms may improve as a patient with 
an eating disorder responds to treatment, puts on weight and starts to ovulate again. 
However, anorexia nervosa tends to run a chronic, relapsing course and many women 
remain resistant to successful long-term treatment. Therefore, few women may return 
to normal and if they did it would still be difficult to be sure if a change in bladder 
symptoms was due an improvement in the patient's oestrogen status rather than for 
other reasons. 
If the high prevalence of urinary symptoms in the women with eating disorders 
found in this study was secondary to oestrogen deficiency there are several possible 
underlying mechanisms (Chapter six). As well as a central action on oestrogen 
receptors in the brain, important peripheral changes in the urogenital tract itself may 
occur. For example, there may be a decrease in urethral pressure secondary to a 
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reduction in blood flow and cell cycle activity. Changes in connective tissues supports 
and pelvic floor muscle and collagen may also occur. Together these effects may be 
responsible for the unexpectedly high prevalence of stress incontinence found in the 
study. A fall in the sensory threshold of the bladder may also take place, making 
irritative symptoms of frequency and urgency more likely. Unfortunately, because this 
group of women are reluctant to undergo invasive testing identification of the exact 
underlying pathophysiological changes is likely to prove very difficult. 
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CHAPTER 11 
THE EFFECT OF AGEING AND THE 




Urinary tract infection occurs commonly in women following the menopause. 
However, it is uncertain if this effect is mainly due to the ageing process or secondary to 
changes in the urogenital tract which occur as a result of oestrogen deficiency. 
Following the menopause alterations in the vaginal flora are thought to place women at 
an increased risk of urinary tract infection. Unfortunately, randomised studies of 
oestrogen replacement therapy for prophylaxis against recurrent urinary tract infections 
have given conflicting results (Chapter 8). The true effect of oestrogen deficiency on 
the prevalence of bacteriuria is therefore uncertain. To investigate this area further 
changes in the incidence of bacteriuria, and the type of infecting organisms, with respect 
to age were studied with the aim of detecting if the menopause had a significant effect. 
11.2. NULL HYPOTHESIS 
The following study was designed to test the null hypothesis that the menopause has no 
impact on the incidence of bacteriuria in women. 
11.3. OBJECTIVES 
11.3.1 Primary objective 
The primary objective was to measure the incidence of bacteriuria in each age group 
with particular reference to changes occurring in the rate of infection at the time of the 
menopause and subsequent years. 
11.3.2 Secondary objectives 
The secondary objective was to document if changes occurred in the type of organisms 
infecting the urine with increasing age. 
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11.4. PATIENTS AND METHODS 
11.4.1 Study population 
All mid-stream urine (MSU) specimens sent to King's College Hospital from the 
community by General Practitioners (GP) in 1997 were assessed. Samples sent to the 
department of microbiology from the hospital wards, theatres or outpatient clinics were 
excluded. The study population therefore comprised the local population of community 
dwelling subjects. 
11.4.2 Methods 
On arrival at the King's College Hospital department of microbiology each MSU 
specimen was processed by Medical Laboratory Scientific Officers (MLSO). Analysis 
of the urine specimens was performed using an automated Mastascan system. 
The principle of the Mastascan system is that a colour video camera measures 
reflected light levels from colonies of bacteria on agar media. A microcomputer then 
compares these digitised light levels with those obtained from appropriate controls and 
interprets the results depending upon a defined threshold. Signals from the colour tube 
in the camera are received by the computer as red, green and blue analogue signals. 
Circuitry within the computer changes these analogue signals to digital values which are 
then used to determine whether colour changes indicate a positive or negative reaction. 
Provision is made in the computer software for the microbiologist to set the 
threshold level relating to the desired boundary between growth and no growth for a 
particular test. This threshold level is a percentage of the difference between the 
background (negative control) plate showing no growth and the control (positive) plate 
showing full growth. Differences in the colour reflected from colonies of bacteria are 
used to distinguish between different types of organism. Facilities are also available to 
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perform antibiotic susceptibility tests and antibiotic minimum inhibitory concentrations 
(MIC) determinants. 
In the King's College Hospital department of microbiology the threshold level 
for diagnosing an infected urine sample is set at a pure growth of 105 organisms / ml. 
Lower counts are not considered to be indicative of a proven urinary tract infection. 
Cultures of more than one organism are coded as mixed growth and are thought to be 
indicative of poor sampling technique, perhaps associated with contamination from 
organisms colonising the perineum. They are therefore not regarded as demonstrating a 
urinary tract infection regardless of the presence of pus cells or white blood cells on 
microscopy. This means that specimens with a positive culture are reported as infected 
even if the white cell count is low, and conversely MSU samples with a culture below 
the positive threshold are reported as not infected even if the number of white cells in 
the urine is increased. 
Following analysis of the MSU specimen by the Mastascan system each result is 
entered onto a computerised database and the information checked for accuracy by the 
MLSO. The database was set up in early 1996 and had therefore been running for over 
6 months before this study commenced. There is a full time data systems manager 
working within the department of microbiology to ensure that any technical problems 
can be remedied almost immediately with no loss of data. Information entered onto the 
database comprises the patient's name, date of birth, sex, the result of the MSU sample 
and any relevant antibiotic sensitivities. 
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11.4.3 Statistical analysis 
The data were analysed using the statistical package SPSS (version 8.0 for windows). I 
was assisted in the analysis of the results by Mr Richard Hooper, Lecturer in Medical 
Statistics at King's College Hospital. Logistic regression analysis was performed to 
investigate the relationship between age and the likelihood of having a positive 
(infected) MSU result. The results for men and women were compared. Changes in the 
rate of infection occurring around the time of the menopause were studied by looking 
for a non-linear (more specifically, a quadratic) relationship between age and the log 
odds of a positive result. Among positive MSU results from female subjects, the 
proportions due to particular infecting organisms were analysed in the same way to try 
and establish if the menopause led to a change in the bacterial flora of the infected 
urine. 
The age of the menopause was defined as 50 years for the study population. 
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11.5. RESULTS 
11.5.1 Number of MSU samples 
16 314 MSU samples were sent from the community between 1.1.97 and 31.12.97 
inclusive. Complete data was available for 15 392 (94%) of the specimens. Incomplete 
data was excluded from further analysis for the reasons outlined in Table 11.1.. 
TYPE OF DATA NUMBER OF MSU SAMPLES EXCLUDED 
Missing age 337 
Missing sex 561 
Missing age and sex 24 
Table 11.1.: Reasons MSU samples were excluded from analysis. 
Of the 15 392 MSU samples with complete data, 11 811 (77%) were from women and 
3 581 (23%) were from men. The age and sex distribution of the samples analysed is 
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11.5.2. Proportion of positive MSU samples 
To examine the effect of age and sex on the likelihood of having a positive MSU result, 
the proportion of positive MSU results was calculated in each age group for both men 
and women. The proportion was calculated as follows: 
Proportion of positive results = Number of positive (infected) MSU samples 
Total number of MSU samples 
Logistic regression analysis looking at the effects of age and sex found a 
significant linear effect of age (Chi-squared = 179.4, P<0.0001) which did not differ 
between males and females (interaction Chi-squared = 0.02, P=0.88). However, there 
was a significant main effect of sex (Chi squared = 170.9, P<0.0001): a specimen taken 
from a woman was more likely to be positive than one taken from a man of the same 
age (Figure 11.2. ). 
When non-linear effects of age were considered they were found to differ 
between men and women (interaction Chi-squared = 8.95, P=0.003). In women, there 
was no evidence of any non-linear relationship between age and the log odds of a 
positive result (Chi-squared = 0.79, P=0.37). A plot of the proportion of positive 
results did not suggest any departure from a linear relationship at or following the 
menopause. 
In men, there was a significant non-linear relationship between age and the log 
odds of a positive result (Chi-squared = 14.4, P=0.0001). Over the first 15-20 years of 








































































11.5.3. Infecting organisms in the MSU samples 
The organisms that led to positive MSU results in women were analysed. Escherichia 
coli was the most common organism overall accounting for 69.0% of infections, 
Enterococcus accounted for 8.5%, Proteus for 7.6% and Klebsiella for 6.1%. No other 
genus accounted for more than 2% of infections. 
The proportions of each of Escherichia coli, Enterococcus, Proteus and 
Klebsiella in positive results from women were analysed using logistic regression to fit 
a quadratic relationship between age and the log odds. If the quadratic term was not 
significant, a linear relationship was tried instead. The only organism for which the 
quadratic term approached significance was Klebsiella (Chi-squared=3.60, P=0.058), 
which appeared to accounted for a constant proportion of infections at ages below 50, 
and a steadily increasing proportion as age increased above 50 (Figure 11.3. ). The 
proportion of infections caused by Enterococcus decreased with increasing age (Chi- 
squared=28.0, P<0.0001), while Proteus was responsible for a steadily increasing 
proportion of infections (Chi-squared=6.89, P=0.009). The proportion of infections due 
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11.6. DISCUSSION 
11.6.1. Study design and population investigated 
This study was performed because it is uncertain if the increased risk of lower urinary 
tract infection which occurs in older women is secondary to the effects of ageing or the 
pathophysiological changes associated with the menopause and subsequent oestrogen 
deficiency. To longitudinally determine the changes occurring perimenopausally in the 
vaginal and urinary flora of community based women would require a large, expensive 
epidemiological study of probably at least 10 years duration. The microbiological 
database at King's College Hospital was therefore used as a model for the changes 
occurring in the population. There are of course some limitations to this approach 
which have been recognised. These data are cross sectional rather than longitudinal and 
the number of patients affected by urinary symptoms in each age group is impossible to 
determine. Although clinical details are added to the request form in the majority of 
cases, the information provided is very variable in its quality and nature. It is therefore 
not added to the database and is not available for analysis. Some patients may also have 
been represented more than once in the data set. Samples sent from hospital clinics and 
wards were not included because of the large number of specimens taken in specialist 
units (including intensive care, liver unit, urology and urogynaecology) which may have 
skewed the results. 
Ideally we would have liked to have been able to have determined whether each 
woman in the sample had reached the menopause, so that we could compare pre- and 
post-menopausal women after controlling for age and other relevant factors (such as 
treatment with hormone replacement therapy) using logistic regression. This 
information was not available in the present study, so the average age of the menopause 
(50 years) (Report of a WHO Scientific Group 1994) was used as a proxy for the onset 
222 
of oestrogen deficiency. The present uptake of hormone replacement therapy in the 
United Kingdom and elsewhere in Europe is probably less than 15% of women aged 40- 
65 (Barlow et al 1991, Wilkes & Meade 1991), with as many as 40% of women failing 
to complete 12 months of treatment even when there is a clear reason to do so (Ryan et 
al 1992). The use of oestrogen replacement in our study population is therefore unlikely 
to have had a significant effect on the results. 
It can be seen from Figure 11.1. that the actual number of urine samples sent 
from each age group varied, with the highest number originating from women of 
childbearing age. To overcome this problem the proportion of samples infected for each 
age group was calculated. It was then possible to achieve the primary objective of the 
study and measure the incidence of bacteriuria in each age group with particular 
reference to changes occurring in the rate of infection at the time of the menopause and 
in subsequent years. 
11.6.2. Role ageing and the menopause 
If changes in the vaginal flora at or following the menopause were really responsible for 
the increased risk of bacteriuria as women get older, an acceleration in the number of 
positive MSU results with increasing age would have been expected, starting at the 
earliest ages of menopause (and furthermore this pattern would not have been repeated 
in male subjects). Instead what we found was a steady rate of increase in positive MSU 
results from females (and indeed from males) from early adulthood onwards. No 
significant change in the linear rate of increase in bacteriuria occurred around the age 50 
years and in the subsequent postmenopausal years. This fording would suggest that 
while ageing is an important aetiological factor accounting for changes in the 
prevalence of bacteriuria (for reasons outlined in Chapter eight), in population terms 
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the menopause would appear to have little impact. This may in part explain the 
observation that while oestrogen has been shown to induce changes in vaginal flora 
which make urinary tract infection less likely, case controlled and randomised studies 
have not consistently shown this treatment to be better than placebo. 
11.6.3. Menopause and organisms causing bacteriuria 
The secondary objective of this study was to document if changes occurred in the type 
of organisms infecting the urine with increasing years. The most common infecting 
organism was E. Coli, which was present in 69% of infected samples from females and 
49% of infected samples from males. The prevalence of E. Coli and the other organisms 
shown in Figure 11.3. was similar to that previously reported by Grünberg (1994). 
Logistic regression analysis showed only the proportion of infections secondary 
to Klebsiella to increase following the menopause. However, overall this organism 
accounts for relatively few infections and the clinical significance of this fording is 
therefore debatable. There was in fact a fall in the proportion of positive results due to 
an Enterococcus with increasing age in our sample, suggesting that colonisation of the 
vagina with bowel flora was not the main underlying cause for the increase in the rate of 
infection as women get older. 
In summary, it can be concluded from this study that bacteriuria becomes more 
common in both men and women with increasing age. However, no significant changes 
appear to occur in the rate of infection or the infecting flora at the time of the 
menopause. It is therefore unlikely that pathophysio logical changes in the urogenital 
tract which occur as a result of oestrogen deficiency following the menopause have a 
significant impact on the prevalence of bacteriuria in community dwelling women. 
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CHAPTER 12 
A DOUBLE BLIND, PLACEBO 
CONTROLLED TRIAL ON THE EFFECTS OF 
25MG OESTRADIOL IMPLANTS ON THE 




The background to this study is discussed in Chapter five and Chapter six. Oestrogen 
deficiency in postmenopausal women is thought to be an important factor in the 
aetiology of a number of lower urinary tract complaints including the "urge syndrome. " 
This term is used to describe a clinical picture with a characteristic combination of 
urinary symptoms comprising frequency, nocturia, urgency and sometimes dysuria. 
Each urinary symptom may occur alone or in combination so the range of presentations 
of the "urge syndrome" and number of underlying diagnoses is large. 
In some studies oestrogen replacement has been shown to improve urinary 
symptoms in postmenopausal women. However, even though a number of reports have 
been published in this area few are randomised, placebo controlled trials with subjective 
and objective outcome measures. In addition, most investigators have examined the 
efficacy of oral or vaginal oestrogen for genuine stress incontinence or urinary urgency 
using the relatively inactive oestrogen oestriol over a short follow up period. Parenteral 
administration of oestrogen using hormone implants avoids first pass metabolism in the 
liver, thereby ensuring a relatively high and constant serum oestradiol level compared to 
medication given orally. In addition, compliance with treatment can be assured. This 
double blind, placebo controlled study assesses the effect of 25mg oestradiol implants 
on the "urge syndrome" in postmenopausal women. 
12.2. NULL HYPOTHESIS 
This study was designed to test the hypothesis that low dose oestradiol implants have no 
impact on the "urge syndrome" in postmenopausal women. 
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12.3. OBJECTIVES 
12.3.1. Primary objective 
The primary objective was to study the efficacy of 25mg oestradiol implants for 
postmenopausal women with the "urge syndrome. " 
12.3.2. Secondary objectives 
The secondary objective was to document the safety and tolerability of 25mg oestradiol 
implants used for treatment of the "urge syndrome" in postmenopausal women. 
12.4. STUDY DESIGN 
The study performed was a double blind, placebo controlled trial in one centre. The 
subjects were randomly allocated into one of two groups: 
1) 25mg pure crystalline 17ß-oestradiol implant. 
2) Placebo implant (implantation procedure performed but no implant 
given). 
This design was chosen because it provides the most appropriate method of assessment 
of this therapeutic regimen. Appropriate randomisation ensured that any differences in 
the characteristics of the patients in each arm of the trial occurred by chance alone. 
Blinding of myself and the patients to the treatment given ensured that all assessments 
were unbiased. 
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12.5. POWER CALCULATION 
Previous experience of recruitment to this type of study suggested we could not expect 
to recruit more than 60 subjects over a two and a half year period. With a cure rate in 
the placebo group of 25% this would give us 80% power at the 5% significance level to 
detect a group difference if the cure rate in the oestradiol group was 60% or more, 
though we recognised that at more realistic effect sizes the power would be reduced. 
12.6. PATIENTS AND METHODS 
12.6.1 Study population 
Women diagnosed with the "urge syndrome" were recruited from the urodynamic clinic 
and urogynaecology outpatient clinic at King's College Hospital. Information about the 
trial was provided orally and using a written information sheet (Appendix). Written 
informed consent was obtained prior to inclusion and signed by the patients and myself 
(Appendix). 
12.6.2. Inclusion criteria 
The women enrolled in the trial fulfilled the following inclusion criteria: 
1. Women had absent periods for at least 12 months, or if hysterectomised had a serum 
oestradiol level of less than 150 pmol/L. 
2. The patients had a clinical diagnosis of the "urge syndrome. " 
3. Informed consent was given in writing. 
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12.6.3. Exclusion criteria: 
The following exclusion criteria were used: 
1. The patients were not taking any other treatment for the "urge syndrome" and in 
particular were not using anticholinergic medication or prophylactic antibiotics. 
2. There was no history of diabetes mellitus or diabetes insipidus and the women 
were not taking diuretic therapy. 
3. The women did not have a condition for which oestrogen therapy was 
contraindicated. 
4. Patients had not received any hormone replacement therapy within 3 months of 
their enrolment into the trial, or had a previous implant or intramuscular 
hormone injection within the previous year. 
5. There was no evidence of endometrial pathology. The women had either an 
endometrial thickness of 4mm or less on ultrasound or normal endometrium on 
histological examination following curettage. 
6. The women did not have an infection or haematuria on an MSU sample. 
12.6.4. Trial medication 
The active medication used in the trial was a subcutaneous implant containing 25mg of 
pure crystalline 17ß-oestradiol. Randomisation was performed by Organon, who 
funded the study, on a 30 active: 30 placebo basis. A subject code was allocated to each 
implant and clearly labelled on the opaque box containing the trial medication. Women 
were assigned a code in numerical order of inclusion; the first subject received the first 
code, the second the next and so on. I did not have access to the randomisation codes, 




The implant was administered by infiltration of the skin in the lower abdomen or 
buttock with 5-10m1 of 1% lignocaine, and insertion of the implant into the 
subcutaneous tissue. A disposable fine bore trocar was used and no sutures were 
required. Women randomised to a placebo implant had identical packaging of the study 
medication but it did not contain an implant. They therefore had the same implantation 
procedure but no implant was given. 
All the implantation procedures were performed by my registrar colleagues 
working in the department of urogynaecology. I was therefore blind to the whether the 
patient had received active or placebo treatment. 
12.6.5 Subject assessment 
The women recruited to the study all underwent a pre-trial assessment to ensure they 
met the inclusion and exclusion criteria. Potential subjects were fully informed about 
the study and gave written informed consent. The implantation procedure was 
performed as described above and follow up arranged for one month, three months and 
six months. Assessments and investigations were performed as outlined in Table 12.1.. 
12.6.5.1. Medical history and physical examination 
A detailed history was taken to include details of the patient's current urinary symptoms 
and previous medical complaints. Physical examination was performed with particular 
emphasis on excluding any contraindications to oestrogen therapy. Hypertension was 
excluded and clinical examination of the breasts made. Pelvic masses and significant 
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12.6.5.2. Mid stream urine (MSU) specimen analysis 
Urinary tract infection was excluded using the methods and criteria outlined in Chapter 
eight. Antibiotics were prescribed on the basis of culture and sensitivity results. 
12.6.5.3. Serum oestradiol level 
Serum was taken and assayed for oestradiol at each visit using the methods described in 
Chapter five. 
12.6.5.4. Assessment of the endometrium 
Women who had not previously undergone a hysterectomy had an assessment of their 
endometrial thickness made at baseline and each follow up visit using ultrasound. The 
screening measurements were performed by myself, and if the endometrial thickness 
was more than 4mm either an endometrium pipelle sample was taken or the patient 
referred for dilatation and curettage. All subsequent assessments of endometrial 
thickness were performed by research registrars working in the gynaecology ultrasound 
department at King's College Hospital. The results were given to me in a sealed 
envelope to ensure that I was not unblinded to the treatment given by seeing an 
endometrial response to an active implant. It was decided that no action should be 
taken if an endometrial thickness of more than 4mm developed during the study unless 
the patient complained of vaginal bleeding. 
12.6.5.5. Questionnaires 
Subjective assessments included a doctor administrated urinary symptoms questionnaire 
(Appendix), visual analogue score of symptom severity (Appendix) and the King's 
Health questionnaire (Appendix). 
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12.6.5.6. Frequency volume charts 
A printed micturition chart in intervals of one hour (Appendix) was completed by the 
patient's at baseline and each follow up visit as described in Chapter four. The clinical 
efficacy evaluation was based on the following variables: 
1) The mean number of micturitions/24h, calculated from complete days of 
recording. 
2) The mean number of incontinence episodes/24h, calculated from complete days 
of recording. 
3) The mean volume per micturition as determined by the formula: 
Total volume voided during all complete days of recording 
Total number of volume measurements 
Only complete data for 24-hour days were included in the calculation of the number of 
micturitions, the number of incontinence episodes and the mean volume voided. Data 
were still included even if the result of an MSU sample taken at that visit was 
subsequently reported as showing a urinary tract infection. 
12.6.5.7. Urodynamic assessment 
I performed uroflowmetry, videocystourethrography and urethral pressure profilometry 
on each subject as described in Chapter four at baseline and after 3 months. 
12.6.5.8. Adverse events 
During each visit information on any adverse events experienced by the trial 
participants was sought. Upon entering the trial each subject was given a telephone 
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number which to use if they developed any problems. An adverse event was defined as 
any undesirable experience occurring to the subject during the trial period, whether or 
not it was related to the treatment given. A serious adverse event was defined as one 
which was life threatening, required hospitalisation or intervention to prevent permanent 
impairment. All other adverse events were regarded as non-serious. 
12.6.5.9. Case report forms 
All information about the trial participants was recorded in a case report form (CRF) 
which was available to representatives of Organon who monitored the visit every three 
months. Information was also recorded in the patient's hospital notes and the patient's 
general practitioner informed of entry into the study. 
12.6.5.10 Final visit 
At the end of the trial period all women with uterus were given a two-week course of 
norethisterone 5mg twice daily. If the patient had a withdrawal bleed this treatment was 
repeated on a monthly basis until the woman had two consecutive cycles without any 
vaginal loss. 
12.6.5.11. Statistical analysis 
All data collected in this study were recorded on or attached to the CRF's with the 
exception of the serum oestradiol results to ensure blinding was not compromised. 
Endometrial thickness results were kept in a sealed envelope as described earlier. 
The data were entered onto a Microsoft Excel spreadsheet, checked for accuracy 
and then analysed using the statistical package SPSS (version 8.0 
for windows). All 
data entry, processing and analysis was performed by myself. The change from 
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baseline of the urinary symptoms was analysed using the McNemar test with the Chi- 
squared test used for analysis between groups of categorical data. The numerical data 
were non-parametric data and therefore presented as medians (interquartile range) with 
comparisons from baseline made using the Wilcoxson signed rank sum test. The Mann- 
Whitney U test was used for comparisons between the groups. 
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12.7. RESULTS 
The results of the first 30 women completing the study are presented. The first patient 
was recruited to the study in November 1996 and it was recognised at an early stage that 
the recruitment rate was falling short of that expected. Letters were sent to all staff 
working in the urogynaecology and obstetrics and gynaecology departments at King's 
College Hospital reminding them about the study and encouraging referral for entry. 
Local general practitioners and geriatricians were also contacted and offered very early 
assessment of any women that they felt might be suitable for the trial. A prominent 
notice was placed in the urodynamics clinic. Unfortunately none of these measures had 
a significant impact on patient referral or entry into the study. I have therefore analysed 
the results of the women who had completed the study when I left my post as a research 
registrar at the end of February 1999. 
Eleven women who met the inclusion and exclusion criteria and were offered 
entry into the study indicated that they did not wish to take part. The main reasons 
given for this decision are shown in Table 12.2.. 
REASON DID NOT PARTICIPATE NUMBER OF WOMEN 
Concerned about side effects 4 (36.3%) 
Did not want a hormone implant 2 (18.2%) 
Not prepared to receive a placebo 2 (18.2%) 
Did not want HRT 1(9.1%) 
Did not want to take part in a study 1 (9.1%) 
Other (patient unwell with shingles) 1(9.1%) 
Table 12.2.: Main reasons given by the women who did not wish to participate. 
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12.7.1 Demographic details 
The demographic and baseline characteristics of the first 30 women completing the 
study are shown in Table 12.3.. 




Age at entry 66.3 (7.7) 66.6 (10.6) 
Median parity (range) 2.0 (0-6) 2.5 (0-6) 
Body Mass Index 26.5 (4.4) 29.4 (7.4) 
Previous hysterectomy 3(21%) 4 (25%) 
Age at menarche 13.2 (2.0) 13.1 (2.3) 
Age at menopause 48.9 (6.8) 49.4 (5.1) 
Median duration of symptoms (IQR) 3.25 (1.6-6.5) 3.0 (2.5-4.0) 
Symptoms began post-menopause 12 (86%) 15 (94%) 
Characterisation of disease 
Number with abnormal detrusor 4 (25%) 12 (75%) 
activity on cystometry 
Table 12.3.: Baseline demographic details of the women entered into the study. 
Values presented are means (SD) unless otherwise stated. Ages and duration of 
symptoms given in years. 
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12.7.2. Concurrent disease and concomitant therapy 
12.7.2.1. Concurrent disease 
28 (93%) women had at least one concurrent disease. The four most common 
concurrent diseases were arthritis (43%), polymyalgia rheumatica (7%), hypothyroidism 
(7%) and cataracts (7%). 1 (3%) woman had had a colposuspension seven years before 
entry to the study but none of the other women had undergone previous continence 
surgery. 
12.7.2.2. Concurrent medication 
As far as possible, concomitant medication was kept unchanged during the whole study 
period. Women with diabetes mellitus or diabetes insipidus and those taking 
anticholinergic therapy or diuretics were not included in the study. Concurrent 
medication was being taken by 15 (50%) women on entry to the study. The most 
commonly used medications were analgesics for arthritis (37%), prednisolone (10%), 
temazepam (10%), thyroxine (10%) and calcium channel blockers (7%). 
Women with a proven urinary tract infection were treated with antibiotics for 
five days based on urine culture and sensitivity results. 
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12.7.3. Compliance, dropouts and protocol violations. 
12.7.3.1. Compliance 
One of the main advantages of this study over others that have used oestrogen for 
treatment of the "urge syndrome" is that by using a hormone implant compliance with 
treatment was assured. The implantation procedure was performed successfully and 
without difficulty in each case. 
12.73.2. Dropouts 
Two women given an oestradiol implant did not attend their final assessment but there 
were no other dropouts from the study. One woman did not arrive despite being given 
an appointment which she said was suitable for her. She also did not reply to two letters 
and unfortunately was not on the telephone. The other patient had a hysterectomy 
between the three-month and final visit because of heavy vaginal bleeding. This is 
reported in the serious adverse events. 
12.7.3.3. Protocol violations 
One woman given an oestradiol implant did not complete any frequency volume charts, 
as her eyesight was so poor that she could not read the gradations on a measuring jug. 
She in fact also did not attend her final assessment. One other patient given an 
oestradiol implant dropped out of the study and did not attend the fmal visit as outlined 
above. Otherwise the data collected was complete. 
6 (43%) women given an oestradiol implant developed vaginal bleeding during 
the study (see adverse events) which unblinded me to the type of implant which had 
been given. In addition, they required treatment with progestogens which may have had 
some impact on their bladder function. 
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12.7.4. Mid stream urine specimens 
Urinary tract infection was excluded on entry to the study by MSU culture. The number 
of positive MSU cultures at each follow up visit and overall are shown in Table 12.4.. 
As outlined in Chapter eight, women with a mixed growth of organisms on urine 
culture were treated as not having an infection, regardless of the white cell count in the 
urine. 
There was no significant difference between the number of urinary tract 
infections found at each visit and overall between the two treatment groups. The use of 
antibiotics also did not differ significantly. 
VISIT OESTRADIOL PLACEBO 
1 MONTH 3/14 (21%) 5/16 (31%) 
3 MONTHS 3/14(21%) 0/16(0%) 
6 MONTHS 3/12 (25%) 8/16 (50%) 
TOTAL 9/40 (23%) 13/48 (27%) 
Comparison between the treatment groups using the Chi squared test. 
Table 12.4.: The number (percentage) of positive (infected) mid stream urine 
samples at each follow up visit. The total indicates the number of positive 
samples/number of samples analysed. 
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12.7.5. Serum oestradiol levels 
The serum oestradiol levels of the women in the study are shown below in Table 12.5.. 
At baseline the oestradiol levels in each treatment group were not statistically different. 
Following implantation, there was a highly significant increase in oestradiol level in the 
women given active treatment but not in those given placebo (P=0.001). The serum 
oestradiol level was therefore significantly higher in the active group at each assessment 
(P<0.0001). 
VISIT OESTRADIOL PLACEBO 
BASELINE 44 (37-54) 47 (30-55) 
1 MONTH 326 (245-382) 50 (30-74) 
3 MONTHS 247 (183-354) 46 (30-64) 
6 MONTHS 188 (143-253) 36 (30-65) 
Analysis of change in oestradiol levels from baseline using the Wilcoxson signed ranks 
test. Comparison of oestradiol levels between the groups at each visit using the Mann- 
Whitney U test. 
Table 12.5.: Serum oestradiol levels (pmol/L). Values are given as medians (IQR). 
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12.7.6. Ultrasound measurements of endometrial thickness 
The endometrial thickness measurements obtained using transvaginal ultrasound are 
presented below in Table 12.6.. At baseline all women had an endometrial thickness of 
less than 4mm. Following implantation, there was a highly significant increase in 
endometrial thickness in the women given active treatment but not in those given 
placebo (P<0.05). The endometrial thickness was therefore significantly greater in the 
active group at each assessment (P<0.0001). 
VISIT OESTRADIOL PLACEBO 
BASELINE 3.0 (3.0-3.0) 3.0 (2.0-3.0) 
1 MONTH 6.8 (5.0-8.3) 2.1 (1.4-3.0) 
3 MONTHS 11.5 (9.9-17.8) 2.7 (1.5-3.0) 
6 MONTHS 9.5 (7.0-13.8) 3.0 (2.1-3.0) 
Analysis of change in endometrial thickness from baseline using the Wilcoxson signed 
ranks test. Comparison of endometrial thickness between the groups at each visit using 
the Mann-Whitney U test. 
Table 12.6.: Endometrial thickness measurements (mm). Values are given as 
medians (IQR) 
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12.7.7. Efficacy of 25mg oestradiol implants for treatment of the "urge 
syndrome" 
12.7.7.1. Urinary symptom questionnaire 
Data regarding each symptom were obtained by direct questioning using the urinary 
symptoms questionnaire (Table 12.7. ). Cure was defined as the complete absence of a 
specific urinary symptom which was present on entry to the study. Two women from 
the oestradiol group did not attend the final assessment and this is represented by a 
change in the denominator. 
There was an improvement in the symptom of urge incontinence in the women 
given an oestradiol implant at the three and six month assessments (P<0.05). However, 
there were no other significant changes and no differences between the two groups. 
SYMPTOM ENTRY 1/12 3/12 6/12 % CURED 
Urgency 
Oestradiol 14/14 13/14 11/14 9/12 25% 
Placebo 16/16 14/16 15/16 15/16 6% 
Urge Incont 
Oestradiol 11/14 8/14 51141 4/121 44% 
Placebo 10/16 9/16 9/16 7/16 30% 
Stress Incont 
Oestradiol 8/14 7/14 5/14 5/12 29% 
Placebo 5/16 3/16 3/16 4/16 20% 
Dysu ria 
Oestradiol 5/14 3/14 2/14 1/12 80% 
Placebo 3/16 4/16 2/16 2/16 33% 
! P<0.05, McNemar test. Comparison of urinary symptoms from entry. 
Table 12.7.: Number of women complaining of different urinary symptoms at 
entry and each assessment visit. Cure applies to absence of a symptom at the end 
of the study. This figure takes account of the initial symptoms of the women who 
did not attend for their final assessment. 
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12.7.7.2. King's Health Questionnaire 
Quality of life was assessed at baseline and each follow up visit using the disease 
specific King's Health questionnaire. The results are presented in Table 12.8.. It can 
be seen there was virtually no change in the general health scores over the study period, 
providing further evidence of the validity and consistency of the questionnaire. 
There were no significant changes in the quality of life scores in any of the 
domains in either the oestrogen or placebo groups. In addition, there were no trends 
towards improvement in any of the areas measured. It is therefore unlikely that even 
when 60 patients have completed the study that oestrogen will be shown to improve the 
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12.7.7.3. Visual analogue scores 
There was a significant improvement in the symptoms of frequency, nocturia and 
urgency in both groups over the study period. Urge incontinence also improved in 
women given oestradiol. It can be seen that overall there was a trend for the 
improvement to have started by the first follow up visit at one month and then continue 
until the end of the trial period. However, at no time were the scores of any of the 
symptoms statistically different between the two treatment groups. These results are 
presented in Table 12.9.. 
VARIABLE BASELINE 1/12 3/12 6/12 
Frequency 
Oestradiol 64.2 (56.3-72.1) 47.8 (40.9-54.7) 48.1(38.7-57.5) 37.0(28.645.4)1 
Placebo 69.6 (63.7-75.5) 56.8 (50.3-63.3) 47.0 (40.8-53.2) 
b 54.0 (46.6-61.4) 
Nocturia 
Oestradiol 55.1 (47.1-63.1) 46.2 (38.1-54.1) 43.9 (34.3-53.5) 36.8 (28.245.4) A 
Placebo 70.3 (64.7-75.9) 63.3 (55.6-71.0) 47.8 (40.5-55.1) 1 47.0 (40.3-53.7) 1 
Urgency 
Oestradiol 79.6 (75.3-83.9) 54.6 (47.3-61.9) a 45.2 (35.6-54.8) a 34.4 (24.644.2) 
Placebo 75.2 (71.2-79.2) 52.3(45.7-58.9)1 34.6(28.041.2)h 47.5(40.5-54.5)b 
Urge Incontinence 
Oestradiol 50.1 (40.8-59.4) 29.2 (21.9-36.5) 26.0 (17.5-34.5) a 25.7 (16.7-34.7) 
Placebo 32.1 (25.0-39.2) 36.8 (28.5-45.1) 21.6 (15.2-28.0) 303 (21.9-39.1) 
a P<0.05, Comparison with baseline using Wilcoxson signed ranks test 
b P<0.01, Comparison with baseline using Wilcoxson signed ranks test 
Table 12.9.: Visual analogue scores (0-100mm). Results presented as medians 
(IQR). 
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12.7.7.4. Frequency volume charts 
Data obtained from the frequency volume charts is presented in Table 12.10. There 
were no significant differences between the treatment groups at baseline. After 3 
months the median volume voided per micturition was significantly greater in the 
women given an oestradiol implant. After 6 months there was a statistically significant 
reduction in the mean number of micturitions/24 hours in the women given an 
oestradiol implant. However, there were no other statistically significant changes from 
the baseline values. 










10.2 (9-11) 8.5 (8-10) 
8.3(7-10) 7.7(7-11) 
10.0(7-11) 8.0 (6-11) 1 
8.5(7-11) 7.9(7-10) 
165 (144-234) 205 (147-232) 217(160-250)b 186(157-218) 
147(134-175) 158(119-200) 170(124-200) 154(112-198) 
1.3 (0-1.6) 0.4 (0-1.9) 0(0-1.8) 
0(0-1.6) 0(0-1.8) 0(0-1.7) 
0(0-0.5) 
0(0-0.5) 
a P<0.05, Comparison with baseline using Wilcoxson signed ranks test. 
b P<0.05, Comparison between groups using Mann-Whitney U test. 
Table 12.10.: Data obtained from the frequency volume charts at baseline and each 
follow up visit. Median values (IQR) are given. 
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12.7.7.5. Uroflowmetry and videocystourethrography 
There were no significant differences in the urodynamic variables at baseline between 
each group and no statistically significant changes from baseline on follow-up 
assessment three months after entry (Table 12.11. ). However, the women given an 
oestradiol implant had a higher median first sensation to void and larger median 
cystometric capacity than those given a placebo after three months of treatment. 
ASSESSMENT BASELINE 3/12 
Uroflowmetry 
(a) Flow rate 
Oestradiol 23 (18-25) 20 (12-25) 
Placebo 15(12-16) 14(10-18) 
Vid eocvstou reth rog ra ah 
(b) 1 ý` sensation 
Oestradiol 175 (100-250) 220 (150-300) a 
Placebo 150 (100-160) 150 (102-150) 
(c) Maximum capacity 
Oestradiol 440 (350-500) 463 (363-495) A 
Placebo 350 (300-400) 320 (278-366) 
(d) Pressure rise on filling 
Oestradiol 10 (5-20) 5 (5-19) 
Placebo 19 (10-29) 19 (5-20) 
(e) Volume P>15cm H2O 
Oestradiol 275 (175-360) 250 (200-450) 
Placebo 290 (150-300) 250 (110-250) 
3 P<0.05, Comparison between groups using Mann-Whitney U test. 
Table 12.11.: Urodynamic variables at baseline and 3 months. Values given are 
medians (IQR). One woman given an oestradiol implant refused to have repeat 
urodynamics because of vaginal bleeding. 
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12.7.7.6. Urethral pressure profilometry 
The urethral pressure profile was measured at baseline and again three months after 
implantation (Figure 12.1. ). There were no significant changes in either the maximum 
urethral closure pressure (MUCP) or functional urethral length (FUL) in either group 
over the study period. 
The pressure transmission ratio was calculated for each quartile of the urethral 
pressure profile. There were no significant changes following implantation and no 
































Figure 12.1.: Urethral pressure profile parameters. Median values, interquartile 
range and ranges shown. Comparison between the groups using the Mann 
Whitney U test. 
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12.7.8. Adverse events 
12.7.8.1. Implantation procedure 
There were no adverse events associated with the implantation procedure itself other 
than minor bruising which settled spontaneously within a few days. 
12.7.8.2. Non-serious adverse events 
None of the women given a placebo complained of any non-serious adverse events 
during the study period other than a proven urinary tract infection, the frequency of 
which is presented earlier. Of the patients given an oestradiol implant, 3 (21%) women 
complained of mild breast tenderness which was most uncomfortable in the first 4 
weeks after implantation and then gradually settled. They were reassured and advised 
to wear a support bra. None felt that they required analgesia for this problem. 
6/11 (55%) women with a uterus who were given an oestradiol implant 
developed vaginal bleeding during the study. This started 9-18 weeks after implantation 
and in each case was associated with thickened endometrium on ultrasound (range 9- 
20mm). The histology of the endometrial pipelles taken was reported as showing 
evidence of exogenous oestrogen administration but not hyperplasia or malignancy. 
The women were started on oral progestogens, but despite taking increasing doses the 
bleeding tended to occur intermittently throughout the study period, although with the 
exception of one of the patients (reported in the serious adverse events) it was generally 
light in nature. 
12.7.8.3. Serious adverse events 
One women given an oestradiol implant was admitted to another hospital with angina 4 
months after implantation and underwent angioplasty. The team responsible for her 
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care apparently did not feel that her angina developed as a result of her treatment with 
oestrogen. She attended her final visit as planned. 
One (9%) woman with a uterus who was given an oestradiol implant developed 
very heavy vaginal bleeding 18 weeks after entry into the study. On ultrasound the 
endometrium was thickened and cystic with a measurement of 20mm. An endometrial 
pipelle sample showed blood and only a few fragments of endometrium, which were 
insufficient for histological analysis. In view of the significant loss she was started on 
provers 50mg daily with arrangements made for repeat assessment the following week. 
However, as she felt the bleeding was getting heavier she was admitted to the ward for 
observation earlier than her planned appointment. Her haemoglobin was 12.5g/dl. A 
dilatation and curettage was performed under general anaesthetic. The uterus was found 
to be enlarged to 12-week size, although it was normal in size on entry to the study. 
The histology of the curettings was reported as showing: "small inactive endometrial 
glands and decidualized stroma consistent with exogenous hormone treatment. A dense 
acute inflammatory infiltrate is present associated with focal degenerative changes and 
necrosis. The features are those of necrotic decidualized stroma with secondary 
inflammatory changes. There is no evidence of malignancy. " 
In view of the enlarged uterus and continuing heavy bleeding following 
curettage, the patient was offered a vaginal hysterectomy by the team continuing with 
her care. This was performed uneventfully and she made a good post-operative 
recovery. The endometrial cavity contained white polypoid tissue measuring 2.5 x 1.5 x 
0.6cm at maximum. The appearances on histology were identical to those of the 
endometrial curettings. There was again no evidence of hyperplasia or malignancy. 
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12.8. DISCUSSION 
12.8.1. Study design and recruitment of subjects 
Urogenital symptoms including those associated with the "urge syndrome" occur 
commonly following the menopause. It is therefore reasonable to assume that oestrogen 
supplementation may be useful for the treatment of postmenopausal urinary symptoms, 
particularly as the lower urinary tract has been shown to be sensitive to the effect of sex 
steroids. This study was designed to test the hypothesis that oestrogen replacement 
therapy given as an implant would be effective in the treatment of the "urge syndrome. " 
In view of the known large placebo effect which has been demonstrated in previous 
research into this condition a double blind, placebo controlled randomised study was 
considered to be the most appropriate design for this trial. Several steps were taken to 
ensure that the patients and myself remained blinded to the type of treatment given. 
Firstly, the study medication was kept in sealed and coded boxes before the 
implantation procedure, which was performed by colleagues in the department of 
urogynaecology. Secondly, the results of the serum oestradiol measurements and 
ultrasound scans were kept separately until the patients had completed the trial. 
Unfortunately, 6 women in the study developed vaginal bleeding which effectively 
revealed that these patients were in the active treatment group (as it was very unlikely 
that any of these women would have been in the placebo arm of the study). 
The rationale and safety of using unopposed oestradiol implants has been 
discussed in Chapter five. We chose to use 25mg oestradiol implants as this dose 
would hopefully provide an adequate therapeutic dose of oestrogen to treat the "arge 
syndrome" while keeping the effects on the endometrium to a minimum. By using an 
implant rather than other forms of oestrogen administration a relatively stable serum 
level of oestradiol was achieved and compliance was assured. The risk of a woman 
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developing endometrial carcinoma after six months of unopposed oestrogen therapy is 
extremely low with a relative risk of 0.6-1.4 (Grady et al 1995). Addition of a cyclical 
progestogen would have reduced the likelihood of the patients developing significant 
endometrial problems even further. However, this would have had the effect of 
inducing regular withdrawal bleeds, unblinding the study and reducing the acceptability 
of the treatment to the women. In addition, progestogens have been shown to have a 
largely detrimental effect on lower urinary tract symptoms and their use would have 
added a significant confounding factor which may have interfered with interpretation of 
the results of the study. 
Recruiting women to the trial was difficult and slower than anticipated. This 
problem was also found by Cardozo and colleagues (1993b), who only managed to 
assess 64 women from 10 centres over an 18 month period, and Jackson and associates 
(1999) who also failed to enrol as many women as planned. There are a number of 
reasons why this may be the case. Although there are few studies showing that 
oestrogen is efficacious for the treatment of postmenopausal urgency, it is widely held 
view amongst general practitioners and some gynaecologists that it can be of benefit in 
this situation. It may be therefore that a large number of women in the community will 
have presented with symptoms of the "urge syndrome" and have been successfully 
treated without the need for referral to hospital. This would reduce the number of 
women with this condition seen in a hospital setting and possibly mean that the majority 
of patients assessed in our clinic were at the more severe end of the disease spectrum. 
In addition, although overall less than 15% of women use HRT in the community 
(Barlow 1991, Wilkes 1991) surprisingly as many as 40% of the postmenopausal 
women referred with urinary symptoms had already used oestrogen replacement 
(Section 9.5.5. ). In contrast to some other studies only women who were definitely 
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oestrogen deficient and had not been taking HRT recently were sought, as it was felt 
that these women were most likely to respond to treatment. Perhaps the inclusion and 
exclusion criteria for entry into the study were also too rigid. However, it was 
important to make sure that the patients studied did not have other underlying 
conditions and were not taking medication which may have accounted for their 
symptoms. 
The other main obstacle to recruitment was the fact that approximately 50% of 
those patients who did not want to take part in the study indicated that this was because 
they were unwilling to take HRT, have an implant or were worried about the side effects 
of oestrogen. The risk of developing carcinoma of the breast associated with HRT does 
not start to increase until women have had 10 years of treatment. However, this disease 
is clearly of great concern to many women and therefore use of oestrogen replacement 
therapy may not be welcome, particularly if alternative treatments are available. 
12.8.2 Efficacy of 25mg oestradiol implants for the treatment of the "urge 
syndrome" 
The study population appear to represent a typical group of postmenopausal women 
with the "urge syndrome. " The mean age of the women was 66 years, with 90% of the 
patients developing symptoms following the menopause. In common with 
epidemiological studies of urogenital problems the symptoms were also 
characteristically of long duration (Thomas et al 1980, Barlow et al 1997). The 
concurrent illnesses and medications being taken were compatible with the age group of 
the study population. In addition, the incidence of bacteriuria was not unexpected in 
women of this age group complaining of urinary symptoms. 
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The serum oestradiol levels in the women given an active implant increased 
within one month of implantation and, although gradually decreasing, remained 
elevated throughout the study period. The levels obtained were sufficient to have an 
impact on the endometrium and it is therefore likely that they were also high enough to 
affect the female lower urinary tract. A number of different outcome measures were 
used to assess the efficacy of the treatment as there is at present no single "Gold 
Standard" tool which adequately highlights success or failure of a particular therapy. 
One of the problems in comparing studies of different types of treatment for 
urinary symptoms or incontinence is that different definitions of cure are used. For 
example, some authors only accept that a treatment has been successful when there is 
complete absence of a specific symptom while others may allow a greater than 50% 
improvement in its severity. To allow comparison with the previous largest study of 
oestrogen for the urge syndrome (Cardozo et al 1993b) the same strict definition of cure 
was used for analysis of the data from the urinary symptoms questionnaire. Cure was 
therefore defined as the complete absence of a specific urinary symptom which was 
present on entry to the study. 
The only significant change found using the urinary symptoms questionnaire 
was that 44% of women complaining of urge incontinence at the start of the study were 
cured of this problem. However, this was not statistically better than the control group 
because in common with other studies the placebo response rate was 30%. The cure 
rates for urgency and stress incontinence were disappointingly low and again not 
statistically better than placebo. The 80% cure rate of dysuria in the women given 
oestradiol needs to be interpreted with caution at this stage as there were only eight 
women complaining of this symptom at the start of the study. Assessment of quality of 
life using the King's Health questionnaire also indicated that the treatment was largely 
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unsuccessful with no significant changes occurring in any of the domains measured. 
Overall, the subjective results are very similar to those reported by Cardozo and 
colleagues (1993b) and certainly do not suggest that oestradiol implants are more 
efficacious for the treatment of the "arge syndrome" than oral oestriol. 
The largest changes were seen in the visual analogue scores, which provided an 
assessment of the severity of the urinary symptoms. Improvements tended to start soon 
after implantation and continue to the end of the study. However, again these changes 
were found in both the oestradiol and placebo groups for reasons which are discussed 
below. It can therefore be concluded that these preliminary results suggest that 
oestradiol does not produce an improvement in the symptoms of the "urge syndrome" 
greater than that found with placebo. 
Objective measurements of the changes in voiding pattern and bladder function 
were made using frequency volume charts and urodynamic studies. While there was a 
small reduction in the number of voids /24 hours in the women given oestradiol there 
were no statistical differences between the groups at the end of the study. In common 
with previous work (Fantl et al 1988) oestradiol was shown to increase the sensory 
threshold of the bladder and slightly increase the bladder capacity. There were no 
changes in the parameters of the women randomised to placebo. This may be because 
there were more women with underlying abnormal detrusor activity (75%) in this group 
compared to those patients treated with oestradiol (25%). It may be possible to say at 
the end of the study if the only women to respond to treatment are those without 
abnormal detrusor activity on cystometry. However, the numbers in each diagnostic 
C 
group (abnormal detrusor activity or no abnormal detrusor activity) at this stage are too 
small for meaningful analysis. There was a wide range in the urethral pressure 
profilometry measurements. As discussed in Chapter four this finding has been 
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reported by several authors and severely limits the value of this test both in a clinical 
and research setting. Probably for this reason there were no significant changes in any 
of the parameters of the urethral pressure profile three months after implantation. 
12.8.3 Safety and tolerability of 25mg oestradiol implants 
The secondary objective of this study was to assess the safety and tolerability of 25mg 
oestradiol implants as a treatment for the "urge syndrome. " Administration of 
oestrogen using subcutaneous implants has been in clinical practice for many years and 
the implantation procedure itself was found to be widely acceptable to the women. 
However, the onset of vaginal bleeding was a major cause of dissatisfaction and 
significantly reduced the acceptability of the treatment to the women affected. The high 
incidence of bleeding was greater than that reported with oral preparations (Sturdee et al 
1978, Jackson et al 1999) and was largely unexpected at the start of the study. It may 
be that the endometrium was more susceptible to the continuously elevated levels of 
oestrogen achieved when an implant is used compared to the fluctuations in serum 
oestradiol concentration found with other forms of HRT administration. 
Although the vaginal bleeding tended to be light and largely controlled by the 
addition of progestogens it was persistent in nature and unwanted by the women, 
several of whom had stopped their periods many years previously. The additional use 
of a progestogen may also have had an adverse effect on the urinary symptoms of some 
of the women and altered their response to the treatment given. The magnitude of this 
effect is difficult to assess and therefore all the subjects continued with their 
assessments and the results were analysed on an intention to treat 
basis. It is clearly of 
great concern that one patient had vaginal bleeding to the extent that she required a 
curettage and subsequent hysterectomy. Significant endometrial pathology 
had been 
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excluded by ultrasound on the baseline assessment and there was no evidence of 
hyperplasia or malignancy on either histological examination following her surgical 
procedures. The finding of an acute inflammatory infiltrate suggests that the patient 
developed a severe endometritis which may in part have accounted for her symptoms. 
However, the endometrium is clearly very sensitive to the effects of even low doses of 
oestrogen administered by implant and this severely impairs to possible use of this 
treatment in women with the "urge syndrome" who have not undergone a hysterectomy. 
12.8.4 Do 25mg oestradiol implants have a potential role in the treatment of the 
"urge syndrome? " 
These preliminary data suggest that when given alone 25mg oestradiol implants do not 
have a role in the treatment of the symptoms of the "urge syndrome. " This is for two 
main reasons. 
Firstly, even using a number of different outcome measures it was not possible 
to show any significant benefits of the active treatment, mainly because of the large 
placebo effect. This is a feature in common with other randomised studies of medical 
interventions, including previous controlled trials of oestrogen for the "urge syndrome" 
(Table 6.3. ). The word placebo ("I shall please") was first used in the 14th century 
(Shapiro 1964). Until the first half of the 20th century the use of placebos was 
widespread in medicine (Craen et al 1999). However, it was not until 1938 that the 
word placebo was first applied in reference to the treatment given to concurrent controls 
in a trial (Diehl et al 1938). While using placebos in research, clinicians began to 
realise the therapeutic value of administering inert preparations. In a review of 15 
placebo controlled trials it was concluded that, on average, the magnitude of the placebo 
effect was 32.5% (Beecher 1955). The placebo effect largely explains the fact that 
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while observational studies of oestrogen for urinary symptoms often show a subjective 
benefit, randomised trials have shown that when oestrogen is given alone there is 
virtually no additional improvement. 
The large placebo response found in this study may have occurred for a number 
of reasons. As a consequence of completing the frequency volume charts the women 
may have become more aware of their fluid intake and voiding pattern. In addition, 
although they were not instructed to do so they may in fact have been effectively 
undergoing a form of bladder retraining. Also, as with the treatment of a number of 
chronic conditions, the fact that I was seeing them personally on a regular basis, 
providing support and taking great interest in their progress may itself have produced an 
improvement. Regular urine culture and early treatment of urinary tract infection is also 
likely to have led to a symptomatic improvement in both treatment groups. 
Secondly, the use of 25mg oestradiol implants for this condition is also severely 
limited by the side effect of vaginal bleeding in patients who have not undergone a 
hysterectomy. At this stage of the study it is difficult to assess if those women who 
have had a hysterectomy, or do not have any vaginal bleeding, feel that their response to 
treatment is better than those who have had this side effect. However, it should be 
concluded that if oestrogen therapy is going to be used at all in this way for the "urge 
syndrome" then it should probably be restricted to women without a uterus. Treatment 
may also have to be limited to those women without underlying abnormal detrusor 
activity on urodynamics. The problem is that to further restrict this treatment would 
mean that very few women referred to a hospital department would be likely to benefit. 
Perhaps the best way forward would be to study the combined effect of oestrogen 





FINAL CONCLUSIONS AND 
FUTURE RESEARCH 
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13.1. Impact of sex steroids on the aetiology of urinary symptoms 
Detailed evidence has been presented which demonstrates that sex hormones have an 
important role in female lower urinary tract function throughout adult life. These 
effects probably occur through a number of mechanisms including a central effect on 
the brain and a local action on the bladder, urethra and pelvic floor. As the population 
of postmenopausal women in the community continues to grow an understanding of the 
effects of sex hormones on the bladder, and the possible benefits of oestrogen 
replacement therapy on urinary dysfunction, has become increasingly important. The 
studies reported in this thesis add significantly to our knowledge in this area. 
Hormonal fluctuations during the menstrual cycle may lead to both symptomatic 
and functional changes. It is now clear that as many as 40% of pre-menopausal women 
recognise a cyclical pattern to their bladder problems\ with the time just before 
menstruation appearing to be the most bothersome. The prevalence of abnormal 
detrusor activity detected on videocystourethrography also increases during the luteal 
phase of the menstrual cycle even in women who do not feel that their symptoms have a 
cyclical pattern. These observations are likely to be secondary to changes in the 
circulating level of progesterone following ovulation. Timing of urodynamic 
investigation within the menstrual cycle may, therefore, be important. However, it is at 
present unclear if symptomatic women who have a normal study during the follicular 
phase of the menstrual cycle should have their study repeated during the luteal phase. 
In addition, it is uncertain if suppression of the normal menstrual cycle may improve 
urinary symptoms in some women and also alter the detection of abnormal detrusor 
activity. Further research is needed to answer these questions. 
It is known that some incontinent women on HRT have an increase in urinary 
leakage during the progestogenic phase of their treatment (Benness et al 1991). At 
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present it is unknown if there is also an increase in the prevalence of abnormal detrusor 
activity at this time. Performing urodynamic studies at different times within a HRT 
cyclical (oestrogen only or oestrogen in combination with progestogen) may give 
further insight into the effect of progestogens on the female lower urinary tract. Indeed, 
it is possible that similar changes may occur to those found during the normal menstrual 
cycle. Further evaluation of the urinary symptoms of women with regular menstrual 
cycles or those on cyclical HRT could also be made using bladder diaries. Women 
could be asked to record the severity of different urinary symptoms daily, perhaps over 
a period of three months. It may then be possible to estimate the degree by which 
individual urinary symptoms change in relation to fluctuations in sex steroid levels, 
although other non-hormonal variables such as work and leisure activities would need 
to be taken into account. 
The mean age of women referred for urodynamic investigation coincides with 
the age of the natural menopause. However, relatively few patients feel that this is the 
main cause of their urinary problems. Although a number of epidemiological reports 
have implicated the menopause in the aetiology of urinary symptoms it has been 
difficult to separate this observation from the concurrent effects of ageing. It has now 
been shown that young women with eating disorders and associated oestrogen 
deficiency also have a high prevalence of urinary symptoms which have a significant 
impact on their quality of life. Unfortunately, it is difficult to be certain of the 
underlying changes that may account for these findings, as the women are usually very 
reluctant to undergo urodynamic investigation. Further work is necessary to establish if 
symptoms improve when oestrogen levels return to normal as weight is gained. 
However, as anorexia nervosa tends to run a chronic course lasting for many years, 
prospective studies may prove difficult to perform. 
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The recent fording that there is more than one type of oestrogen receptor has 
provided an exciting area for further research. It would be interesting to determine the 
distribution of ERa and ER/3 receptor subtypes in the lower urinary tract in more detail. 
It is possible that different rates of receptor expression may be found in premenopausal 
and postmenopausal women. In addition, the distribution and expression of different 
oestrogen receptor subtypes may vary between women with urogenital symptoms 
(including incontinence, the "urge syndrome" and prolapse) and normal controls. 
The menopause and oestrogen deficiency are thought to be important factors in 
the aetiology of recurrent urinary tract infection but their impact on this condition may 
have previously been overstated. Although oestrogen may change vaginal flora, the 
results of randomised studies of oestrogen for prophylaxis against recurrent urinary tract 
infections have given conflicting and largely disappointing results. Analysis in this 
thesis has shown that the proportion of infected urine samples increases with age but no 
significant changes occur at the time of or following the menopause. Therefore, the 
effects of ageing in community dwelling women appear to be more important than the 
changes in the female lower urinary tract induced by falling levels of oestrogen. 
13.2 Role of oestrogen replacement therapy in the treatment of the "urge 
syndrome" 
Symptoms of postmenopausal urogenital atrophy have been shown to respond to 
hormone replacement therapy, particularly when oestradiol is given by the vaginal route 
(Smith et al 1993). It is therefore surprising, given that the menopause has also been 
associated with the development of urinary symptoms, that oestrogen replacement 
therapy has been shown to be so ineffective in the treatment of a number of different 
lower urinary tract complaints. While improvements have been noted in observational 
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studies, none of the randomised controlled trials reported so far have shown an 
advantage over placebo. Although the study reported in this thesis is yet to be 
completed, at this stage it is difficult to justify the continued use of oestrogen alone to 
treat the "urge syndrome" in clinical practice. Even using oestradiol implants in a dose 
high enough to cause significant problems with the endometrium, no therapeutic 
benefits above those of placebo have been observed despite using multiple assessments. 
It is unlikely that further research using oestrogen alone, either in a higher dosage or by 
using an alternative route of administration, will lead to different conclusions. 
Oestrogen has been shown to be more effective when used in combination with 
alpha-adrenergic agents for the treatment of stress incontinence. It would be interesting 
to determine if other conservative treatments for stress incontinence (such as pelvic 
floor exercises) or surgical approaches (such as colposuspension or periurethral 
injections) are more effective when women are also given oestrogen replacement. 
Oestrogen may also have a role in the treatment of urgency and urge incontinence when 
used in combination with other therapies. As oestrogen has been shown to have a direct 
action on the bladder it is possible that it may be more efficacious in treating the "urge 
syndrome" when given in combination with other medications such as anticholinergics. 
This may form the basis of further work. For example, it would be possible to 
determine if agents such as oxybutynin or tolterodine are more effective in women who 
are taking hormone replacement therapy compared to those who are oestrogen deficient. 
Recruiting women into such a study would almost certainly be possible (and probably 
easier than for a trial of oestrogen alone) because a treatment of proven efficacy would 
also be offered. The community or general practice may be an ideal setting for such a 
study so as to include patients with a wider range of symptom severity than that which 
may be found in hospital practice. 
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Apart from its lack of efficacy, one of the biggest problems with using oestrogen 
therapy to treat urinary symptoms is the unwanted effect on the endometrium and 
associated vaginal bleeding. To overcome this problem several approaches could be 
considered in the future. 
Firstly, it may be possible to prevent vaginal bleeding in some women treated 
with oestrogen by inserting a progestogen directly into the uterus. One example of this 
is the Mirena intra-uterine system which releases levonorgestrel directly into the uterine 
cavity. The adverse effect of progesterone on the bladder may therefore be minimised 
(as relatively little is absorbed), and hopefully in most cases vaginal bleeding will be 
avoided. However, it is unlikely that many women, and in particular elderly patients 
who are most likely to complain of the "urge syndrome", would be willing to either try 
or take part in a study of this treatment when potentially more effective alternatives are 
available. 
Secondly, as dislike of vaginal bleeding is a major factor leading to non- 
compliance of sequential combined therapies, alternative types of HRT may be studied. 
With continuous combined HRT a progestogen is added to oestrogen to provide a 
continuous dose of both hormones. With this treatment progestogen counteracts the 
proliferative effect of oestrogen on the endometrium, so there is little or no shedding. 
The endometrium is therefore maintained in an atrophic state while the systemic 
benefits of oestrogen are maintained. Almost all women on continuous combined HRT 
stop bleeding within a year of starting therapy and a large proportion of women become 
amenorrhoeic immediately or after a few months of treatment (Ulrich et al 1997). In a 
recent study the effects of continuous combined HRT on the bladder have been reported 
for the first time. In a non-randomised, dose fording observational study of 102 women 
Kok and colleagues (1999) reported an improvement in urinary frequency, nocturia and 
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incontinence after 6 months of treatment. However, lack of baseline urodynamic 
studies, objective outcome measures and a control group indicate that further work is 
required to demonstrate if this effect is greater than that of a placebo. 
The third option, and another area for potential research, is the use of selective 
oestrogen receptor modulators (SERMs). Endogenous or therapeutically administered 
oestrogens mediate their biological effects mainly through oestrogen receptors which 
are found in a number of different tissues including breast, bone, liver and brain as well 
as the urogenital tract. SERMs bind to oestrogen receptors and show a mixed pattern of 
agonist and antagonist activity which is specific for a particular tissue. Increased 
interest in this area has coincided with the release of raloxifene, which is licensed for 
the prevention of non-vertebral fractures in postmenopausal women at increased risk of 
osteoporosis. This SERM has oestrogen like actions in bone and liver and blocks the 
effects of oestrogen on the breast. Raloxifene also appears to have little or no agonist 
activity on the endometrium. In a two-year placebo controlled study involving 601 
postmenopausal women, raloxifene did not increase endometrial thickness (assessed by 
transvaginal ultrasonography) or the frequency of vaginal bleeding (3% with raloxifene, 
2.2% with placebo) (Delmas et al 1997). There are at present no published data on the 
effects of raloxifene on the lower urinary tract and it would be very interesting to 
determine the action of this and other SERMs on this area. In the longer term, it is 
exciting to speculate that it may be possible to develop a SERM which acts principally 
on the female bladder and urethra, with minimal unwanted effects on other tissues. The 
therapeutic benefit for women with urogenital disorders may be considerable, and 
significantly greater than the disappointing effect of oestradiol implants on the "urge 
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King's College Hospital 
Frequency - Volume Chart 
KINGS COLLEGE HOSPITAL 
URODYNAMICS DEPARTMENT 
FREQUENCY VOLUME CHART 
IMPORTANT - PLEASE READ CAREFULLY 
It is imperative that you fill in the chart overleaf as carefully as possible during the five days before 
you come for your bladder test. It is designed to give us an idea of your fluid intake and urine 
output and leakage. This assists us greatly in the diagnosis of your condition. 
For each day record how much you drink (metric, ie - mis if possible) and when you drink it (put 
the volume in the square provided for that time). If you always drink from the same cup then you 
need only measure how much it holds once and put that value down every time you drink from it. 
When you go to the toilet, measure the urine you pass using a jug. If possible, record the volume 
in millilitres rather than fluid ounces, and again record it next to the right time. 
Every time you leak, put a 'W' for wet in the column provided. 
When you go to bed, put a line on the chart next to the right time so that we can tell how many 
times you have to get up at night to pass water. 
If you are unable to fill the chart in properly every day because of other commitments, please try to 
fill it in accurately for at least two days and record the frequency of passing water and leaking by 
ticking the correct box for the rest of the time. 
For example: 
Day One 








1.00 m 200 w 
2.00 m 300 
Urine passed = 400m1 at 7.00am 
Drank tea = 150mI at 8.00am 
Wet at 9.00am 
Urine passed = 150m1 at 9.30am 
Day 11 1 Day 21 1 Day 3 Day 4 Day 5 






















3 am II I 
4am 
yam 







VISUAL ANALOGUE SYMPTOM SCORE 
Number 0-3 Visit 4 
Date r-'o 
Frequency (Daytime) 




Normal, Very frequent 
Stress incontinence 
Not a problem ,, Very severe 
lirQency 
Not a problem i Very severe 
Urge incontinence 
Not a problem, iVery severe 
Bedwetting 
Not a problem L_ Very severe 
ate 
Normal Very slow 
Always L iNever 
L1J 
King's Health Questionnaire 
and Scoring System 




Todays date 199 
How would you describe your 






How much do you think your 
bladder problem affects your 
life ? 



















We would like to know what your bladder problems are and how much 
they affect you. From the list below choose ONLY THOSE PROBLEMS 
that you have at present. LEAVE OUT those that do not apply to you. 
How much do they affect you ? 
To choose please tick 
O A Little Moderately A lot 
FREQUENCY; going to the toilet 
ver often 
0 0 0 
y . 
NOCTURIA; getting up at night to 
pass urine - 
0 0 (1) 
., 
URGENCY; a strong and difficult 
to control desire to pass urine. 
O O O 
URGE INCONTINENCE; urinary 
leakage associated with a strong O 
O O 
desire to pass urine. 
STRESS INCONTINENCE; urinary 
l k ith h i l ti i 
0 0 O 
ea ys ca age w p ac v ty 
eg coughing, sneezing, running. 
NOCTURNAL ENURESIS; wetting O O O 
the bed at night. 
INTERCOURSE INCONTINENCE; 0 0 0 
urinary leakage With sexual 
intercourse. 
FREQUENT WATERWORKS O O O 
INFECTIONS; 
BLADDER PAIN; 0 O O 
Difficulty PASSING URINE 0 O 
O 
OTHER SPECIFY; 0 O 0 
Please turn the page 
office use 
+ F1 + 11 












Below are some daily activities that can be affected by bladder problems. How much 
does your bladder problem affect you ? 
We would like you to answer every question. Simply tick the circle that applies to you. 
ROLE LIMITATIONS 
To what extent does your bladder 
problem affect your household 
tasks (eg cleaning, shopping etc) 
Not at all Slightly Moderately A lot 
0000 
Does your bladder problem affect 
your job, or your normal daily act- 
ivities outside the home? 
PHYSICALISOCIAL LIMITATIONS 
Does your bladder problem affect 
your physical activities (eg going 
for a walk, run, sport, gymn etc)? 
Does your bladder problem affect 
your ability to travel? 
Does your bladder problem limit 
your social life ? 
Does your bladder problem limit 
your ability to seelvisit friends ? 
0000 
Not at all Slightly Moderately A lot 
0 o o o 
0 0 0 0 
o 0 o 0 
0 0 0 0 
Not Not at Slightly Moderately A lot 
PERSONAL RELATIONSHIPS 
applicable all 
Does your bladder problem affect 
O cII ID ID EI 
your relationship with your 
partner? 
Does your bladder problem affect 
OOO EI O 
your sex life? 
Does your bladder problem affect 
your family life? 
00000 
Please turn the page 
Office use QQQQQ F] Qn 
Kings's Health Questionnaire, Version 7 
EMOTIONS 
Does your bladder problem make 
you feel depressed? 
Not at all Slightly 
00 
Moderately Very much 
00 
Does your bladder problem make 
you feel anxious or nervous? 
(III) (II) O (ID 
Does your bladder problem make O EI EI EI 
you feel bad about yourself? 
SLEEP I ENERGY Never Sometimes 
Often All the time 
Does your bladder problem affect (I) 
(I) 
(II) 0 your sleep ? 
Do you feel worn out I tired? 
0 0 0 (II) 
Do you do any of the following?; If so how much ? 
Never Sometimes Often All the time 
Wear pads to keep dry? 
(I) (II) (I) (II) 
Be careful how much fluid you O 
O (II) (I) 
drink? 
Change your underclothes when 
0 EI EI O 
they get wet? 
Worry in case you smell? .O 
(I) O O 
Get embarassed because of 
your bladder problem ? 
O O O O 
Office use El n El El D n 
THANKYOU, NOW CHECK THAT YOU HAVE ANSWERED ALL THE QUESTIONS 
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PART III 
We would like to know what your bladder problems are and how much they 
affect you. From the list below choose only those problems that you have at 
present. Leave out those that do not apply to you. 
o Frequency : Going to the toilet very often. 
0 Nocturia : Getting up at night to pass urine. 
o Urgency :A strong and difficult to control desire to 
pass urine. 
o Urge incontinence : Urinary leakage associated with a strong 
desire to pass urine. 
o Stress incontinence : Urinary leakage with physical activity, eg 
coughing, sneezing, running. 
0 Nocturnal enuresis : Wetting the bed at night. 
0 Intercourse incontinence : Urinary leakage with sexual intercourse. 
0 Frequent waterworks infections 
0 Bladder pain 
o Difficulty passing urine 
0 Other (Please specify) 
Scale Score 
A little =1 
Moderately =2 
A lot =3 
Omitted =0 
To Calculate Scores 
1. General Health perceptions 
Score = ((Score to Qu1 - 1)/4) x 100 
2. Incontinence Impact 
Score = ((Score to Qu 2- 11/3) x 100 
3. Role Limhations 
Score = (((Scores to Qu 3a + 3b) -2) /6) x 100 
4. Physical limitations 
Score = (((Score to Qu 4a +4b) - 2) /6) x 100 
5. Social limitations 
Score = (((Score to Qu'4c +4d + 5c) - 3) /9) x 100 " 
If score to Qu 5c >=1, If 0 then .. -2) / 6) x 100 
6. Personal Relationships 
Score = (((Score to Qu5a + 5b) - 2) /6) x 100 
If score to Qu 5a+5b >=2, 
If Qu 5a+5b = 1; ..... -1) /3) x 100 If Qu 5a+5b = 0; .:... treat as missing value (Not applicable) 
7. Emotions 
Score = (((Score to Qu 6a+6b+6c) - 3) /9) x 100 
8. Steep/ Energy 
Score = (((Score to Qu 7a +7b) -2) /6) x 100 
9. Severity Measures 
Score = (((Score to Qu 8a + 8b + 8c + 8d + 8e) - 5) /15) x 100 
EAT 26 Questionnaire 




Please place an (X) under the column which applies best to each of the numbered 
statements. All of the results will be strictly confidential. Most of the 
questions directly relate to food or eating, although other types of questions 
ave been included. Please answer each question carefully. Thank you. 
W 





QOON cc: Z 
()( )( )( )( )( ) 1. Am terrified about being overweight 
( )( )( )( )( )( ) 2. Avoid eating when I am hungry 
( )( )( )( )( )( ) 3. Find myself preoccupied with food 
( )( )( )( )( )( ) 4. Have gone on eating binges where I feel that I mäy not 
be able to stop 
( )( )( ){ )( )( ) 5. Cut my food into small pieces 
' ýý 1( )( )( )( ) 6. Aware of the calorie content of foods that I eat 
( )( )( )( )( )( ) 7. Particularly avoid foods with a high carbohydrate 
content (e. g. bread. rice, potatoes, etc. ) 
( )( )( )( )( )( ) 8. Feel that others would prefer if I ate more 
( )( )( )( )(. )( ) 9. Vomit after I have eaten 
{ )( )( )( )( )() 10. Feel extremely guilty after eating 
( ){ )( )( )( )() 11. Am preoccupied with a desire to be thinner 
( )( )( )( )( )() 12. Think about burning up calories when I exercise 
( )( )( )( )( )() 13. Other people think that I am too thin 
( )( )( )( )( )() 14. Am preoccupied with the thought of having fat on my body 
( )( )( )( )( )() 15. Take longer than others to eat my meals 
( )( )( )( )( )( ) 16. Avoid foods with sugar in them 
( )( )( )( )E )( ) 17. Eat diet foods 
( )( )( )( )( )() 18. Feel that food controls my life 
( )( )( )( )( )(} 19. Display self-control around food 
( )( )( )( )( )( } 20. Feel that others pressure me to eat 
( )( )( )( )( )() 21. Give too much time and thought to food 
( )( )( )( )( )() 22. Feel uncomfortable after eating sweets 
( )( )( )( )( )() 23. Engage in dieting behaviour 
( )( )( )( )( )() 24. Like my stomach to be empty 
( )( )( )( )( )( ) 25. Enjoy trying new rich foods 
( )( )( )( )( )() 26. Have the impulse to vomit after meals 
Menstrual Status and Urinary Symptom 
Questionnaire used in Chapter 9 
THE DEPARTMENT OF UROGYNAECOLOGY 
KING'S COLLEGE HOSPITAL LONDON 
Professor Linda Cardozo 
THE EFFECT OF HORMONES ON THE BLADDER 
We are trying to find out what effect the female hormones oestrogen and progesterone have on 
the bladder. These hormones are found naturally in all women and are important in the 
control of fertility, periods and bone strength. After the menopause the level of oestrogen 
falls, unless Hormone Replacement Therapy (HRT) is being taken. We think that this fall may 
be important in the development of some bladder problems and urinary symptoms. 
We would be most grateful if you would complete the following questionnaire and 
return it to the X-ray receptionist. Thank you for your help which is much appreciated. 
YOUR NAME AGE 
TODAY'S DATE 
HOW MANY CHILDREN HAVE YOU HAD? 
PLEASE TICK THE BOX WHICH APPLIES TO YOU 
QUESTION 1 
What do you think is the main cause of your bladder problems? 
Please tick ONE box only 
" Having children Q 
" Menopause / stopping periods 
Q 
"A hysterectomy Q 
" An operation other than a hysterectomy Q 
" Medications / tablets Q 
" Cold weather Q 
" Mental stress Q 
" Another reason (please state) 
1 
QUESTION 2 
Which of the following treatments have you had in the past for your bladder problem? 
Please tick MORE THAN ONE box if you wish 
" An operation 
" Pelvic floor exercises 
" Electrical stimulation 
" Tablets 
" Bladder retraining 
" No treatment so far 




Are you taking any tablets or medications at the moment? Yes Q No Q 
If YES, what tablets or medications are you taking? 
. 
2 
QUESTION 4 Are you still having periods? 
If YES (A) When was your last period? 
(B) Are your periods regular? 
Yes Q No Q 
Yes Q No Q 
(C) Does your bladder problem change during the month? Yes Q 
If YES, at what time of the month do your bladder symptoms 
bother you the most? 
Please tick ONE box only 
" During a period Q 
" Just after a period Q 
" In the middle of the month Q 
" Just before a period Q 
" Other time (please state) 
If NO (A) When did your periods stop? 
(B) Why did you stop having periods? 
" Menopause 
" Hysterectomy 
" Contraceptive pill / injection 
" Another reason (please state) 
U 
0 
(C) If your periods stopped because you went through the menopause, 
how are your bladder problems now compared to the time when you were 
having periods? 
" Much better Q 
" Better Q 
" The same Q 
" Worse Q 




Have you had a hysterectomy (removal of your womb) 
If YES 1(A) How old were you when you had a hysterectomy? 
Yes Q No Q 
(B) How was the operation done? Through a cut in the tummy Q 
Through the vagina Q 
Key hole surgery Q 
(C) Were your ovaries removed at the same time? 
If YES, how many ovaries were removed? 




(D) Did you start Hormone Replacement Therapy (HRT) Yes Q No Q 
within 2 months of your hysterectomy? 
(E) Do you think your bladder problems were Yes Q No Q 
caused by your hysterectomy? 
4 
QUESTION 6 
Have you ever taken the contraceptive pill? 






Have you ever taken Hormone Replacement Therapy (HRT)? Yes Q No Q 
Are you taking HRT at the moment? 
If YES J what sort of HRT are you taking? " Tablets 
" Patches 
" Implants 
" Cream which goes into the vagina 
" Cream which is rubbed on the skin 
" Other (Please state) 
QUESTION 8 
Are you: 
" White Q 
" Black African Q 
" Black Afro-Caribbean Q 
" Asian Q 
" Chinese Q 
" Other (please state) 
Yes Q No Q 
Yes Q No Q 
Yes Q No Q 
5 
If you would like to make any further comments please write below. 
Thank you for your help. Please return this questionnaire to the X-ray receptionist. 
Eating Disorder Study 
Information Sheet and Consent Form 
used in Chapter 10 
URINARY SYMPTOMS AND EATING DISORDERS 
Information for Patients 
BACKGROUND 
Women start to ovulate (release an egg from the ovary) when their body reaches a certain 
weight; most women will then have periods. This normally occurs in the teenage years. If a 
person looses weight, perhaps because they are unwell or have not eaten enough, ovulation and 
periods may stop. At the same time the level of the female hormone oestrogen can fall to a 
very low level. 
Women who have gone through the menopause, and therefore have a low oestrogen level, 
have an increased risk of bladder symptoms. We are trying to find out if women with eating 
disorders, such as anorexia or bulimia, also have similar bladder problems. 
WHAT DOES THE STUDY INVOLVE 
If you agree to take part you will be asked to complete two questionnaires. The first asks 
about your view of your weight and how much you eat. The second asks about your bladder, 
any symptoms it may give you and what affect they have on your Quality of Life. You will be 
asked to give a sample of your urine and blood so that we can measure your hormone levels. 
Women will also be asked if they would be prepared to have a bladder test done at King's 
College Hospital but this is an optional part of the study. 
To make the research scientific, we are trying to compare the results from women who have an 
eating disorder with women who eat normally. We hope the results will help us to improve the 
treatment we offer to women with both bladder problems and eating problems. 
If you would like to ask any questions about the study please feel free to do so. 
Dr Sarah Majid 
Dr Janet Treasure 
Department of Psychiatry 
Mr Andrew Hextall 
Professor Linda Cardozo 
Department of Urogynaecology 
January 1998 
INFORMED CONSENT FORM 
Ii 
Urinary Symptoms and Eating Disorders 
Have you received enough information about the study? 
Who have you spoken to? 
Do you agree to take part in the study? 
Patient signature: 
Signed 




YES / NO 
YES / NO 
i 
Signed Date 
Name (in block capitals) 
Oestradiol Implant Study 
Information Sheet and Consent Form 
used in Chapter 12 
PATIENT INFORMATION LEAFLET 
Introduction 
You have been asked to take part in a clinical trial on a new treatment for the "urge syndrome" 
that is being conducted by the Urodynamics Department of King's College Hospital and 
sponsored by Organon Laboratories. To help you make an informed choice this leaflet is 
designed to provide you with information about the "urge syndrome", the treatment under 
investigation, the effects it may have on you, the risks and benefits it offers, what your rights 
are and what will be expected of you. 
The "Urge Syndrome" 
Your ovaries make a hormone called oestrogen which plays an important part controlling your 
fertility. Eventually the ovaries stop producing oestrogen. This may happen naturally at the 
menopause (the change) or may be the result of surgery (e. g. ) a hysterectomy. Either way the 
loss of oestrogen can have a number of effects on your body. Some women experience `hot 
flushes' and `night sweats. ' Some women can feel tired and loose their concentration. In 
addition, the lack of oestrogen can cause the lining of the bladder and urethra to become 
thinner. This can lead to urinary problems such as frequency, wanting to go to the toilet all of 
the time, having a sudden urge to go, leaking and a burning sensation on passing urine. This is 
called the "urge syndrome. " Treatment with oestrogen can help these symptoms by making 
the lining of the urethra and bladder stronger and healthier. It can also help with `hot flushes' 
and `night sweats' etc. 
This research is designed to find out whether Riselle, a subcutaneous oestradiol implant is 
effective in treating urinary problems. The oestradiol implant is a little pellet of pure 
oestrogen that is placed just beneath the skin, usually at the side of the stomach but sometimes 
in the buttock. It dissolves slowly and releases its oestrogen over a period of 4-6 months. 
If you agree to help in the study you will have a fifty-fifty chance of getting an implant. Half 
of the study patients will receive an implant and half will undergo the same procedure but no 
implant will be given. This is to compare the effect of having an implant and not having an 
implant. The study is designed so that neither you or your doctor will know whether you have 
been given an implant or not. That information will be held by your doctor in a sealed 
envelope which will be opened if any problems arise or at the end of the study. 
Each patient will be in the study for 6 months. We hope to enrol 60 people and the trial is 
likely to last for 2 V2 years from the first person entering to the last person leaving. 
What you have to do 
Before the implant is inserted some tests have to be done. This is normal for anyone coming 
to the clinic with these symptoms and will help the doctor decide the best way to treat you. 
Once the tests are done your doctor may think that it will be best for you not to continue in the 
study. 
These routine investigations include: 
A. A urine sample to detect any infection. 
B. Urodynamic assessment to assess the health of your bladder and urethra. 
C. A number of questionnaires to record how your general health is. 
D. An ultrasound scan of the bottom of your pelvis. 
E. A blood sample 
You will need to visit the clinic again after one, three and six months following the implant. 
At each visit a blood sample will be taken and an ultrasound scan will be performed. You will 
be asked to fill in the questionnaires again to monitor your symptoms. 
Insertion of the implant is a minor procedure with very little discomfort. The skin on the side 
of your stomach will be numbed with a local anaesthetic and the implant is inserted into the 
fatty tissue underneath. 
Risks and benefits 
Oestradiol implants have been used in the United Kingdom for over 30 years. Similar to other 
forms of HRT, Riselle is associated with common side effects. Some women have problems 
due to fluid retention such as a bloated feeling and breast tenderness. More serious problems 
are very rare and your doctor will be happy to discuss them further with you. The benefits 
derived of Riselle are that it should provide an effective treatment for some of your urinary 
problems, help to relieve any `hot flushes' you may experience and generally make you fell 
better. 
Your rights 
Your participation in the study is completely voluntary and if you decide that you do not want 
to be involved, your decision will not effect your medical care. You are also free to withdraw 
from the study at any time and again if you decide to do so your medical care will be 
unaffected. If you would like to withdraw from the study after the implant has been inserted 
we would strongly advise you to take progestogen tablets for 12 days every month for 6 
months. These tablets will give you a period every month. This is to ensure that the lining of 
the womb will not become thickened. 
Confidentiality 
The information that this study will produce may very well affect the care of many other 
patients and so it is very important that it is accurate. Because of this it will be necessary for 
suitably qualified representatives of the Sponsor Company and possibly the regulatory 
authorities (the government) to examine your medical records. Your confidentiality will be 
maintained at al times and you will not be identified in any report. 
Any questions 
If you have nay questions you wish to help you decide, or indeed any questions about your 
treatment whilst in the study, please contact Dr Andrew Hextall of the Urodynamics 
Department of King's College Hospital (Telephone: 0171 346 3568). 
Please keep this leaflet safe for your information. 
INFORMED CONSENT FORM 
A double blind, placebo controlled trial on the effects of 6 months treatment with 
Riselle (25mg oestradiol implant) on `urge syndrome' in 60 postmenopausal women. 
Have you read the Patient Information Sheet? 
Have you had an opportunity to ask questions and discuss this study? 
Have you received satisfactory answers to all of your questions ? 
I-lave you received enough information about the study? 
Who have you spoken to? Dr/Mr/Ms 
Do you understand that you are free to withdraw from the study: 
* at any time? 
* without having to give a reason9 








Do you understand and agree to authorised representatives of either the 
sponsor of the study or government regulatory authorities reviewing 
your medical records on the understanding that your confidentiality 
will be respected and you will not be identified in any report? YES/NO 
Do you agree to take part in the study? 
Patient signature: 
Signed ...................................... 
Name ( in block capitals) 
Physician signature: 
YES/NO 
Date (by subject) ................. 
Signed 
... . 
Date (by subject) ................. .......................................... 
Name ( in block capitals) ......... 
Doctor Administered Urinary Symptom 
Questionnaire used in Chapter 12 
SYMPTOM QUESTIONNAIRE 
VOIDS/24 HOURS 
LARGEST VOIDED VOLUME (ML) 
DAILY INCONTINENT EPISODES 
URGENCY Never / >2/52 / Weekly / Daily / Twice Daily / Worse 
URGE INCONTINENCE Never / >2/52 / Weekly / Daily / Twice Daily / Worse 
STRESS INCONTINENCE Never / >2/52 / Weekly / Daily / Twice Daily / Worse 
DYSURIA Never / >2/52 / Weekly / Daily / Twice Daily / Worse 
